Protocol : J4Z -MC-GIDA 
 
 
A randomized, double-blind, placebo- controlled multi-center study of intravenous bimagrumab, 
alone or in addition to open label subcutaneous semaglutide, to investigate the efficacy and 
safety in overweight or obese men and women  
 
 
[STUDY_ID_REMOVED]   
Approval Date: 09- Apr-2024 
 
   
 
CLINICAL STUDY PROTOCOL  
Bimagrumab  
VER201 -PH2-031 
A randomized, double -blind, placebo -controlled multi -center study 
of intravenous bimagrumab, alone or in addition to open label 
subcutaneous semaglutide, to investigate the efficacy and safety in 
overweight or obese men and women  
 
Confidentiality Statement  
This document is the sole property of Versanis Bio, Inc. This document and all information 
contained herein must be considered and treated as strictly confidential. This document shall be 
used only for the purpose of the disclosure herein provided. No disclosure or publication shall be 
made without the prior written consent of Versanis Bio, Inc.  
  IND Number:  161031  
EUDRA  CT number:  Not applicable  
Study phase  2 
Version number:  5.0 (Amendment 5) 
Sponsor:  
 Versanis Bio, Inc.  
A wholly owned  subsidiary of Eli Lilly and Co.  
1111 Broadway, Suite 1300  
Oakland, CA 94607  
United States  
Approval Date:  Protocol Electronically Signed and Approved 
by Lilly on date provided below.  
Document ID:  VV-CLIN -150100  
 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 2 of 112 
SPONSOR SIGNATURE PAGE   
The protocol has been approved by Versanis Bio, Inc.  
 
 
$876;7:J;=<07:1B-,!..1+-:  
 
 
  Date 
$SSURYHGRQ$SU*07PPD
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 3 of 112 
INVESTIGATOR â€™S AGREEMENT   
I agree, as an Investigator  conducting this study:  
ï‚· To assume responsibility for the proper conduct of the study at this site. 
ï‚· To conduct the study in compliance with this protocol, with any future amendments, 
and with any other written study conduct procedures provided, reviewed, and 
approved by the Sponsor.  
ï‚· Not to implement any deviations from or changes to this protocol w ithout agreement 
from the Sponsor, except where necessary to eliminate an immediate hazard to the 
participants or for administrative aspects of the study (where permitted by all 
applicable regulatory requirements).  
ï‚· That I am aware of, and will comply with,  Good Clinical Practice and all applicable 
regulatory requirements.  
ï‚· To ensure that all persons assisting me with the study are adequately informed about 
the investigational drug and that they are qualified to perform their study -related 
duties and function s, as described in this protocol.  
ï‚· That I have been informed that certain regulatory authorities require the Sponsor to 
obtain and supply details about the Qualified Investigator â€™s ownership interest in the 
Sponsor or the study drug and more generally about  his/her financial ties with the 
Sponsor. The Sponsor will obtain and disclose any relevant information in this regard 
solely for the purpose of complying with regulatory requirements.  
Hence, I  
ï‚· Agree to supply the Sponsor  with all information regarding own ership interest and 
financial ties with the Sponsor  (including those of my spouse and dependent 
children);  
ï‚· Agree to promptly update this information if any relevant changes occur during the 
study and for 1 year following completion of the study; and  
ï‚· Agree that the Sponsor may disclose this information about such ownership interests 
and financial ties to regulatory authorities.  
     
Printed Name of 
Investigator   Signature 
of 
Investigator   Date  
Site Name       
Site Address      
 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 4 of 112 
MEDICAL MONITOR NAME AND CONTACT INFORMATION   
Role in Study Name Email and Telephone Number 
 
   
 
 
   
 
 
   
 
        
        
DOCUMENT HISTORY   
DOCUMENT HISTORY 
Document Date 
Original (Ver 00) 14 June 2022 
Amendment 1 (Ver 1.0)  26 September 2022  
Amendment 1 (Ver 1.1) 10 October 2022 
Amendment 2 (Ver 2.0)   19 December 2022  
Amendment 3 (Ver 3.0)  08 May 2023  
Amendment 4 (Ver 4.0) 24 September 2023 
 
  
$SSURYHGRQ$SU*07PPD
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 5 of 112 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 5, PROTOCOL V. 5.0   
The amendment is considered to be substantial because it is likely to have a significant impact on 
the 
â— safety or the rights of the study participants,  and 
â— reliability and robustness of the data generated in the clinical study . 
Overall Rationale for the Amendment:  
The secondary endpoint has been adjusted to accommodate assessment at Week 72 , and n ew 
exploratory objecti ves/endpoints ha ve been added to align with the study design . This 
amendment also updates the pre-dose safety lab review at Week 64 to monito r safety . 
Additionally , this amendment provides  dosing guidance for management of participants with 
BMI â‰¤22  kg/m2 and those with perceived excessive body weight loss .  
Section # and Name  Description of Change  Brief Rationale  
Section 1.1. Synopsis  Revised the brie f title to read 
as: 
â€œSafety and efficacy of 
bimagrumab and semaglutide in 
adults who with are overweight 
or obese  obesity â€ Prioritizing person -first 
language and avoiding 
stigmatizing adjectives to 
describe individuals living 
with obesity  
Section 1.3. Schedule of 
Activities ( SoA)  Randomization and drug 
administration row:  
ï‚· Referenced Footnote â€œfâ€ for 
Week 64 
ï‚· Updated  Footnote â€œfâ€ to 
incorporate  pre-dose safety 
lab review  at Week 64   To observe and react  to 
potential enzyme elevations 
prior to the second dose of 
bimagrumab in Year 2  at 
Week 64  
Section 1.1. Synopsis  
Section 3. Objectives, 
Endpoints, and Estimands  ï‚· Secondary endpoint:  
Added Week 72 to assess 
treatment effect on waist 
circumference, fat mass, 
VAT, trunk fat mass, SAT, 
lean mass, self -reported 
health status and weight -
related quality of life  
ï‚· Secondary objective:  
Added â€œbody compositionâ€  Alignment with the study 
design to describe Year 2 
endpoints  
Section 3. Objectives, 
Endpoints, and Estimands  Exploratory objective:  
Added new objective to assess 
the treatment withdrawal effect 
of bimagrumab, semaglutide, 
and bimagrumab in addition to 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 6 of 112 
Section # and Name  Description of Change  Brief Rationale  
semaglutide on body weight, 
waist circumference, and body 
composition  
Section 3.1. Estimands  Added  information that  trial 
product or hypothetical 
estimand will be used to assess 
the primary estimand  For consistency with SAP  
Section 4.1. Overall Design  Core Treatment Period (Weeks 
1 to 48):  
ï‚· Replaced â€œparticipants will 
be required â€ to â€œparticipants  
should â€ follow 
recommendations  for the 
duration of the core 
treatment period  
ï‚· Added statement where 
occasional diary misses are 
permissible, provided there 
is no persistent non -
compliance  
Open -Label Extension 
Treatment Period (Weeks 49 to 
72): 
ï‚· Replaced â€œparticipants 
must â€ to â€œparticipants 
should â€ continue  to follow 
dietary and exercise  
recommendations for the 
duration of the extension 
treatment period  
ï‚· Added that participants 
must  self-administer weekly 
semaglutide as in the core 
treatment period  
Post-Treatment Follow -Up 
Period (Weeks 73 to 104):   
Replaced â€œparticipants must â€ to 
â€œparticipants should â€ continue 
to follow dietary and exercise 
recommendations  Clarification  
Section 5.31. Meals and 
Dietary Restrictions  Indicated  that participants must 
fast for at least 8 hours prior  to 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 7 of 112 
Section # and Name Description of Change Brief Rationale 
all visits that include blood 
sampling 
Section 5.3.4. Support 
During Treatment Withdrawal Period
 Newly added section: 
Added paragraph on 
accessibility to personnel and 
additional resources to aid in 
lifestyle management during the 
treatment withdrawal period To +4):1.A$876;7:J;
intentions regarding 
provision of these additional healthy
 lifestyle resources 
during the treatment 
withdrawal period  to 
promote participant 
retention 
Section 6.6.2. Semaglutide Updated section with 
management of participants 
with C

3/52 and those 
with perceived excessive body 
weight loss To be consistent with 
guidance for site 
participants who are losing excessive weight
 
Section 7.1.1. Liver, 
Pancreas, or Muscle Related Events Stopping Criteria Added a new timepoint G(--3
Hwhere the p ):<1+18)6<J;
safety labs will be reviewed at 
Week 64   Updated to align with the 
changes made in Section 1.3 on reviewing safety labs at Week 64 
Section 7.1.2. Temporary 
Discontinuation  Updated the section to reference 
Section 6.6.2 for  management 
of participants if they cannot 
tolerate current dose of 
semagl utide  Updated to align with the 
changes made in  Section 
6.6.2  
Section 8. Study 
Assessments and Procedures
 Added G  (Week 64)H as 
an ex ception to perform dosing  
within the corresponding 
window  To observe and react to 
potential enzyme elevations prior to the second dose of bimagrumab at Week 64   
Section 9.4. Treatment 
Extension and Post -
Treatment Follow -Up 
Period Analyses   Updated section to include 
analyse s and summaries of 
treatment effect at Week 72 
 Deleted language on 
treatment outcome comparisons To align with the changes 
made in Section 3 to describe year 2 endpoints 
Section 10.3.2. Definition 
of SAE  Other situations bullet: 
,,-,4)6/=)/-<0)<G44malignancies must be reported );$;H  For clarity 
Section 10.8. Appendix 8: 
Creatine Kinase Safety Edits made to Table 11 
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 8 of 112 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 4, PROTOCOL V. 4.0   
Section # and Name  Description of Change  Brief Rationale  
Medical Monitor Name and 
Contact Information  Replaced Drug Safety 
Physician contact information.  Eli Lilly Global Patient 
Safety has replaced Parexel  
for Drug Safety Physician 
services.  
Section 1.1 â€“ Synopsis  
Section 1.2 â€“ Study Schema  
Section 4.1 â€“ Overall 
Design  
 The extension t reatment period 
(Weeks 48 -72) changed from 
blinded to  open label  The study will be open label 
after Week 48  primary 
efficacy analysis, and 
unblinded after Week 48  
database lock .  Placebo 
injections will continue for 
Arms 2 and 3 until  after the 
Week 48  database lock and 
study unblinding .  
Section 1.1 â€“ Synopsis  
Section 3.1.1 â€“ Estimands 
of Secondary Objectives  Added appendicular lean mass 
by DXA  as secondary endpoints  Lean mass of the arms and 
legs has a higher proportion 
of skeletal muscle than total 
body lean mass.   
Section 1.1 â€“ Synopsis  
Section 3.1.1 â€“ Estimands 
of Secondary Objectives  
Section 9.1 â€“ Statistical 
Analyses  Removed language referring to 
adjustment for multiplicity.  Adjustment for multiplicity 
of primary or secondary 
endpoint analyses are no 
longer considered necessary 
by Sponsor , as study results 
will be used primarily  for 
further development 
planning purposes.  
Section 1.1 â€“ Synopsis  
 Allowed for the addition of  two 
non-voting members from  the 
Sponsor (who are not part of the 
study team ) to the DMC . The DMC has requested 
additio nal support from the 
Sponsor by adding  two non -
voting members with safety 
and statistical expertise.  
Section 1.3 â€“ Schedule of 
Activities (SoA)  Removed Week 104 blood 
draws for PD biomarkers and 
anti-drug antibodies . Follow up blood collection 
at Week 96  is sufficient  for 
these parameters.  
Section 3 â€“ Objectives, 
Endpoints, and Estimands  
Section 8.2.6.2  â€“ Glucose 
Metabolism Parameters: 
HbA1c, Fasting Insulin and 
Glucose  Replaced HOMA2 -IR with 
HOMA -IR . HOMA2 -IR is proprietary  
and unavailable; HOMR -IR 
is a suitable alternative.  
Section 5.3.1  â€“ Meals and 
Dietary Restrictions  Guidance  provided for cases 
where participant reache s a 
BMI â‰¤ 22 kg/m2. Guidance provided for 
safety of participants  losing 
excessive weight.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 9 of 112 
Section # and Name  Description of Change  Brief Rationale  
Section 9.3 â€“ Interim 
Analysis  Added interim analysis . A 24 -week interim analysis 
was added for internal 
decision -making  purposes  
Section 10.7 â€“ APPENDIX 
7: Lipase and Amylase 
Safety  Allowed for the addition of  an 
adjudication committee  for 
acute pancreatitis and other 
major adverse events.  The DMC has requested 
additional support for 
evaluating suspected cases 
of pancreatitis.  
Additional changes include grammatical corrections and cl arifying text.   
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 10 of 112 
SUMMARY OF CHANGES # FOR AMENDMENT 3, PROTOCOL V. 3.0  
Section # and Name Description of Change Brief Rationale 
Section 1.1 F Synopsis 
Table 1 F Table of 
Objectives and Endpoints 
Section 9.1 Statistical Analyses
 Rephrased primary endpoint, 
secondary objectives, and secondary endpoints to measure )I+0)6/-J:)<0-:<0)6 specify 
)6I)*;74=<-J7:I8-:+-6<Jchange. Allow the Statistical 
Analysis Plan to be the source of detail for all planned analyses.
 
Section 1.1 F Synopsis 
Table 1 F Table of 
Objectives and Endpoints 
Section 8.2.2 F DXA Scan Added assessment of treatment 
effects on subcutaneous adipose tissue
 to secondary objectives 
and secondary endpoints .  Also 
included an analysis of decrease 
in body weight >15%. More completely 
characterize treatment effects.
 
Section 1.1 F Synopsis 
Section 1.2 F Study Schema 
Section 1.3 F Schedule of 
Activities  
Section 4. 1 F Overall 
Design  
Section 4.2 F Scientific 
Rationale for Study Design 
Section 4.3 .1 F 
Bimagrumab Doses  
Section 6.1 F Study 
Intervention Administered 
Section 6.7 F Continued 
Access to Study 
Intervention after the End of Treatment
 
Section 7.1 F Participant 
Discontinuation of Study 
Intervention  
Section 7.2 F Participant 
Discontinuation/Withdrawal 
from the Study Revised study design to add a 
24-week treatment extension 
period and a 32-week post-
treatment follow-up period . 
During the  treatment exten sion, 
participant s in Arms 1 and 4  
will have blinded treatment 
modified  to 30 mg/kg 
bimagrumab . Compare the results of 
bimagrumab and/or 
semaglutide treatment for continued weight loss and fat mass reduction
 in the 2nd 
year of treatment, as well as 
in maintenance of weight loss and composition of weight regain
, if any. 
Allow  participants on 
placebo or low  dose 
bimagrumab in the 1st year 
to receive high dose 
bimagrumab during the 2nd 
year.  
Section 1.1 F Synopsis 
Section  4.1 - Overall 
Design  
Section 5 F Study 
Population  
Section 6.3  F Assignment to 
Study Intervention  
Section 6.4.2 F Semaglutide  
 
 
 Based on revised sample 
size calculation in 
accordance with revised 
endpoints; also, to account for the increased number of expected 
participant 
withdrawals due to the 
extended duration of study. 
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 11 of 112 
Section # and Name  Description of Change  Brief Rationale  
Section 9.5 â€“ Sample Size 
Determination  
Section 1.1 â€“ Synopsis  
Section 3.1 â€“ Estimands  
Section 9.1 Statistical 
Analyses  
Section 9.4 â€“ Treatment 
Extension and Post -
Treatment Follow -up Period 
Analyses  
Section 9.5 â€“ Sample Size 
Determination  Updated statistical analysis 
plans, including:  
ï‚· Revised the sample size 
determination ; 
ï‚· Identifying Week 48 as the 
point of p rimary efficacy 
analysis;  
ï‚· Adde d analyses for the 
treatment extension  and 
follow -up periods  Provide an o verview of the 
statistical plan for the 
revised study design . 
Section 1.1 â€“ Synopsis  
Section 3.1 â€“ Estimands  
Section 9.1 Statistical 
Analyses  â€˜Intention -to-treatâ€™ population 
redefined to include only 
randomized participants who 
receive d at least one dose of 
study medication . Remove from primary 
analysis participants who 
randomize into a treatment 
arm but did not  receive 
treatment.  
Section 1.3 â€“ Schedule of 
Activities  
Section 4.1 â€“ Overall 
Design  
Section 7.1 â€“ Participant 
Discontinuation of Study 
Intervention  
Section 7.2 â€“ Participant 
Discontinuation/Withdrawal 
from the Study  For participants permanently 
discontinuing study intervention 
early, c hange the required 
timeframe for conduct of an 
End of Study visit from 8 weeks 
to 12 weeks after last dose of 
bimagrumab/placebo . Evaluate the participant for 
safety after the 
bimagrumab/placebo is 
expected to  have been 
eliminated.  
Section 4.1 â€“ Overall 
Design  
Section 5.4 â€“ Screen 
Failures  
Section 8 â€“ Study 
Assessments and 
Procedures  
Section 8.5 â€“ 
Pharmacokinetics  Assessment windows added or 
clarified as follows:  
ï‚· Screening window revised 
to allow  1 repeat of any  
assessment that falls outside 
of Week  -6 to Day -1; 
ï‚· Added a window for Week 
4 dosing ; 
ï‚· Added a window for 
collection of post -dose 
bimagrumab PK samples.  Prevent the exclusion of 
otherwise eligible 
participants based solely on 
timing  of assessments in 
relation to dosing.  
 
Clarify allowable windows 
for select  assessments . 
Section 4.1 â€“ Overall 
Design  Specify the requirement for 
dietary intake evaluation  via 24-
hour recall assessments  at 
monthly dietician outreach.   Clarify the required 
assessments to be conducted 
and data collected during 
the dietary consultations.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 12 of 112 
Section # and Name  Description of Change  Brief Rationale  
Section 4.2 â€“ Scientific 
Rationale for Study Design  
Section 9.1 Statistical 
Analyses  FDA guidance for primary 
efficacy endpoints in phase 2 
trials  was added.  Clarify the FDAâ€™s 
recommendations  regarding  
the study â€™s primary 
endpoin t. 
Section 5.2 â€“ Exclusion 
Criteria  Exclusion Criteria refined : 
ï‚· #18 specifies medication 
associated with severe 
pancreatitis , such as 
valproate  
ï‚· #20 replac es BUN exclusion 
with s erum creatine >1.5x 
ULN  Prevent  concomitant 
medications from 
contributing to an increased 
risk o f on-study 
pancreatitis.  
 
More closely align the 
measure of impaired renal 
function with clinical 
practice.  
Section 5.3.1 â€“ Meals and 
Dietary Restrictions  Added provision for alteration 
of on-study dietary restrictions  
if healthy weight status is 
achieved . Allow standard clinical 
practice in dietary 
counseling for study 
participants who achieve a 
healthy weight.  
Section 5.4 â€“ Screen 
Failures  Clarification of screen failures 
to include participants who 
choose to not pro ceed to enroll . Account for the fact that 
participants  otherwise 
eligible may be categorized 
as screen failures if they 
chose to withdraw consent 
prior to dosing.  
Section 6.4 â€“ Blinding  Clarified that blinding will 
remain intact at least until 
database is  locked for the core 
and extension treatment 
periods.  Specify the duration of 
study blind as a result of the 
study extension.  T he 
primary analysis remains  at 
Week 48 , which is now 
mid-way through the study 
instead of at the conclusion.  
Section 6.6.1 â€“ 
Bimagrumab  Bimagrumab dosing 
modification may be allowed 
for safety reasons . Removed incongruity  
between this section and the 
guidance provided in 
Appendices 6, 7, and 8. 
Section 6.9.1 â€“ Prohibited 
Medicine  Prohibited medication s and 
recommended actions refined:  
ï‚· Hormone replacement therapy 
in women addressed;  
ï‚· Allow short term course s of 
glucocorticoid s; 
ï‚· Require Medical Monitor 
consultation for medications 
that may cause weight change ; Refine d the pro hibition of 
medications based on their 
situational potential to 
significantly impact safety 
or efficacy . 
 
Prevent valproate from 
contributing to the risk of 
on-study pancreatitis.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 13 of 112 
Section # and Name Description of Change Brief Rationale 
 Prohibit the use of valproate.  
Section 7.1.1 F Liver, 
Pancreas, or Muscle Related 
Events Stopping Criteria Section 7.1.2 
F Temporary 
Discontinuation  
Section 8.3.4 F Clinical 
Safety Laboratory Tests 
Section 10.7 F APPENDIX 
7: Lipase and Amylase 
Safety  
Section 10.8 F APPENDIX 
8: Creatine Kinase Safety Provided greater specificity in 
the guidance for study treatment interruption and/or discontinuation as a result of liver, pancreas, or muscle related events
, including a 
requirement to review lab 
results at Week 4 prior to administering bimagrumab/placebo dose
. Provide Investigators with 
more detailed guidance on how to assure the safety of participants experiencing one of these 
events. 
Section 7.4 F Treatment 
Arm and Study 
Stopping/Pausing Rules Specified that SAEs of a similar 
type must be related to blinded  
treatment  to qualify as part of 
the study stoppin g/pausing 
rules ; expected SAEs do not 
qualify . Ensure that SAEs related to 
semaglutide and those that are expected per the bimagrumab Reference Safety Information
 do not 
contribute to study stopping 
or pausing. 
Section 8.1 F Administrative 
Procedures  Specified data collection needs 
related to obesity history and obesity-related comorbidities. Provide additional detail 
regarding key obesity-
related data collection. 
Section 8.4.5 F Treatment 
Emergent Adverse Events 
of Special Interest  
Section 10.6 F Liver Safety 
Section 10.7 F Lipase and 
Amylase Safety  
Section 10.8 F Creatine 
Kinase Safety Revised the list of AESI s. Definition of AESIs was 
revised ; monitoring of 
laboratory test 
abnormalities is outlined in 
Appendices . 
Section 8.6.1 F PD 
Biomarkers  
Section 10.2 F APPENDIX 
2: Clinical Laboratory Tests  
 To allow further analysis of 
bone biomarkers.  
Section 10.2 F APPENDIX 
2: Clinical Laboratory Tests Clarified laboratory tests: 
 Screening only tests 
performed locally to include 
TSH and remove HBsAb and 
HBcAb 
 Added anti-drug antibodies  Clarify/align tests being 
performed at screening with the 
Schedule of 
Assessments  and Appendix 
2. 
Additional changes include grammat ical and clarifying text as well as revisions to reflect the 
extended treatment period.  
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 14 of 112 
SUMMARY OF CHANGES # FOR AMENDMENT 2, PROTOCOL V. 2.0   
Section # and Name Description of Change Brief Rationale 
Section 1.1 F Synopsis 
Section 2.1 F Study 
Rationale  
Section 2.3.2.1 - 
Bimagrumab  
Section 3.0 F Objectives, 
Section 9 F Statistical 
Considerations Revised primary endpoint from 
waist circumference to body weight and reordered secondary objectives and endpoints.
 Revised in response to FDA 
feedback.  
Section 1.1 F Synopsis 
Section 10.1.6 F Data Safety 
Committee  Revised timing of the first DMC 
meeting from 30 to days after 
the first % of participants have 
completed dosing.  The 2 week delay will allow 
for collection of safety data 
from the 0.5 mg semaglutide + bimagrumab treatment arms. 
Section 1.1 -  Synopsis 
 Added clarification on approved 
dosage substitution for semaglutide.
 Due to uncertain availability 
of semaglutide dosage forms, accepted dose levels for dose escalation are indicated. 
Section 1.1 - Synopsis 
Section 5.1 - Inclusion 
Criteria  
Section 5.3.3 - Other 
restrictions  
Section 10.4 - Appendix 4: 
Contraceptive Guidance Clarified the criterion to have an 
IUD in place from 3 months prior to the baseline visit and not the screening visit. Additionally, 
clarified the use of a barrier for 
these participants starts from the screening visit and last up to 4 months after the last dose of bimagrumab/placebo. The revised timeframe is 
deemed to be sufficient to ensure there are no safety issues with the placement of 
the IUD.
 
Section 1.1 F Synopsis 
Section 5.2 -  Exclusion 
Criteria  Key Exclusion Criteria F clarified 
exclusion of subjects with 
diabetes  Diabetic subjects on 
antidiabetic drug or with *	+D
?144*-excluded for this study of non-diabetic obesity. 
Section 3.1 FEstimands Estimand section revised based 
on the primary endpoint of body 
weight using the treatment policy 
strategy which include all subjects without relevance to intercurrent events. Section edited to match the 
revised primary endpoint. 
Section 1.3 - Schedule of 
Activities (SoA)  ,,-,):7?.7:G)A;H)6,
corrected the table header at week 36 to read P12. Editorial/clarification 
change.  
Section 1.3 - Schedule of 
Activities (SoA)  Added optional future use of 
samples informed consent as an 
assessment Added for clarity. 
$SSURYHGRQ$SU*07CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 15 of 112 
Section # and Name  Description of Change  Brief Rationale  
Section 2.3.1.1 - 
Investigational Intervention 
Bimagrumab  Added potential risk of disruption 
of menstrual cycles in 
premenopausal women with an 
IUD implant, due to decreased 
FSH levels.  Risk language in response to 
FDA feedback.  
Section 4.1 - Baseline  
Section 8.0 - Study 
Assessment and Procedures  Revised baseline window for 
DXA from 7 days prior to the 
baseline visit to 14 calendar days 
prior to the baseline visit. Non -
baseline DXA windows revised to 
be  -2 weeks to +1 week of the 
scheduled tim e for all other visits.  
The flexibility of the week 4 
dosing visit was removed.  Based on site feedback, DXA 
assessment window extended 
to allow sufficient time for 
DXA scans to be scheduled 
around study visits.  
Section 4.1 -Baseline  Clarified that baselin e 
assessments should be completed 
at least 15 minutes prior to 
dosing.  Editorial/clarification 
change.  
Section 8.4.1 â€“ Time Period 
for Collecting AEs  Non-serious AEs will be collected 
after first dose of study 
medication(s) instead of after 
screening.  To avoid incomplete entry of 
medical history, medical 
conditions identified during 
the screening period will be 
captured as medical history.  
Section 8.4.4 â€“ Pregnancy  Pregnancies in female partners of 
male participants will be reported.  Outcomes of pregnancies in 
female participants as well as 
female partners of male 
participants will be recorded.  
Section 9.3 â€“ Interim 
Analysis  Removed the plan for an interim 
analysis.  Due to the expected rate of 
recruitment, an interim 
analysis is no longer require d 
for development planning.  
Section 10.2 â€“ Clinical 
Laboratory Tests  HCV RNA removed from the 
screening tests  HCVAb will be used to 
detect hepatitis C infection; 
HCV RNA may be used to 
confirm active infection.  
Additional changes include grammatical and clarifying text as well as revisions to reflect the 
extended treatment period.  
SUMMARY OF CHANGES â€“ FOR AMENDMENT 1 .1, PROTOCOL V. 1.1   
Section # and Name  Description of Change  Brief Rationale  
Table of contents  Administrative  Table of Content s updated  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 16 of 112 
SUMMARY OF CHANGES  â€“ FOR AMENDMENT 1, PROTOCOL V. 1 .0  
Section # and Name  Description of Change  Brief Rationale  
1.0 Synopsis  
1.2 Study Schema  
1.3 Schedule of Activities  
1.4 Study Design  Study duration increased from 
28 weeks to 48 weeks . 
Corresponding additions  to 
assessments :  
ï‚· Phone calls at Weeks 32, 36 
and 44; on -site visits at Weeks 
40 and 48.  
ï‚· Dosing events at Weeks 28 
and 40.  
ï‚· DXA at Week 48  
ï‚· Safety/efficacy assessments at 
Weeks 40 and 48  Dosing through week 48 with 
placebo control will showcase 
greater effect of bima grumab  
and comb inations with  
semaglutide  across multiple 
measures of efficacy . 
1.0 Synopsis  
3.0 Objectives, Endpoints 
and Estimands  
9.0 Statistical 
Considerations  Changes in objectives and 
endpoints relate d to the 
increased duration of the study  
and the change in the lower dose 
of the semaglutide treatment 
arms.  Changes were r equired to 
harmonize with the study design.  
1.0 Synopsis  
4. Study Design  
5. Study Population  
2.2.2 Teratogenicity and 
Reproductive Toxicity Data  Age limit of 40+ years for 
females  lowered  to 18+ who are 
post-menopausal or post -
surgica lly sterilized  or have in 
place an IUD and are willing to 
use a form of  barrier  
contraception  Expanded age range m ay 
provide exposure, safety and 
efficacy data in the 18 -40 age 
range  for females , more 
reflective of the intended Phase 
3 study  population, as 
recommended b y FDA . 
4.2 Scientific Rationale for 
Study Design  
4.3 Justification for Dose  
6.1 Study interventions 
Administered  
6.6 Dose Modification  
9.1 Statistical Analysis  Semaglutide low dose increased 
from 0.5 mg to 1 mg  Longer dosing period (through 
week 48) allows for adequate 
titration and exploration of an 
approved dose of semaglutide 
(WegovyÂ®, OzempicÂ®) . 
1.0 Synopsis  
5.1 Inclusion Criteria  
5.2 Exclusion Criteria  
 Refined  inclusion criterion : 
ï‚· Stable body weight as +/-5 kg 
ï‚· Diagnosis of diabetes  includes  
HbA1c  â‰¥ 6.5%  Clarified information previously 
in both inclusion and exclusion 
criteria  
1.0 Synopsis  
9.4 Sample Size 
Determination  Modified sample size 
calculations  Longer duration of study allows 
for power calculation based on 
larger expected  treatment 
difference vs placeb o, 
anticipated dropout rate, and 
multiple endpoint testing.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 17 of 112 
9.3 Interim Analysis  Interim Analysis (group 
unblinding only) added at Week 
24 Provides limited, group 
unblinded data readout to 
facilitate clinical development 
program planning.  
 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 18 of 112 
TABLE  OF CONTENTS  
SPONSOR SIGNATURE PAGE  ................................ ................................ ................................ ....2 
INVESTIGATORâ€™S AGREEMENT  ................................ ................................ ............................... 3 
MEDICAL MONITOR NAME AND CONTACT INFORMATION  ................................ ............ 4 
DOCUMENT HISTORY ................................ ................................ ................................ ................. 4 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 5, PROTOCOL V. 5.0  ............................... 5 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 4, PROTOCOL V. 4.0  ............................... 8 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 3, PROTOCOL V. 3.0 ............................. 10 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 2, PROTOCOL V. 2.0  ............................. 14 
SUMMARY OF CHANG ES â€“ FOR AMENDMENT 1.1, PROTOCOL V. 1.1  .......................... 15 
SUMMARY OF CHANGES â€“ FOR AMENDMENT 1, PROTOCOL V. 1.0  ............................. 16 
TABLE OF CONTENTS  ................................ ................................ ................................ ............... 18 
LIST OF TABLES  ................................ ................................ ................................ ......................... 23 
LIST OF ABBREVIATIONS  ................................ ................................ ................................ ........ 24 
1. PROTOCOL SUMMARY  ................................ ................................ .......................... 28 
1.1. Synopsis  ................................ ................................ ................................ ...................... 28 
1.2. Study Schema  ................................ ................................ ................................ ............. 34 
1.3. Schedule of Activities (SoA)  ................................ ................................ ...................... 35 
2. INTRODUCTION  ................................ ................................ ................................ ......40 
2.1. Study Rationale  ................................ ................................ ................................ ........... 40 
2.2. Background  ................................ ................................ ................................ ................. 41 
2.2.1.  Preclinical Pharmacology  ................................ ................................ ........................... 42 
2.2.2.  Clinical Data  ................................ ................................ ................................ ............... 43 
2.3. Benefit/Risk Assessment  ................................ ................................ ............................ 44 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ......... 44 
2.3.1.1.  Investigational Intervention Bimagrumab  ................................ ................................ ..44 
2.3.1.2.  Semaglutide (WegovyÂ®, OzempicÂ®)  ................................ ................................ ......... 46 
2.3.1.3.  Study Procedures  ................................ ................................ ................................ ........ 48 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ .....49 
2.3.2.1.  Bimagrumab  ................................ ................................ ................................ ............... 49 
2.3.2.2.  Semaglutide  ................................ ................................ ................................ ................ 49 
2.3.3.  Overall Benefit Risk Conclusion  ................................ ................................ ................ 49 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 19 of 112 
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS  ................................ .................. 50 
3.1. Estimands  ................................ ................................ ................................ .................... 52 
3.1.1.  Estimands of Secondary Objectives  ................................ ................................ ........... 52 
4. STUDY DESIGN  ................................ ................................ ................................ .......54 
4.1. Overall Design  ................................ ................................ ................................ ............ 54 
4.2. Scientific Rationale for Study Design  ................................ ................................ ........ 57 
4.3. Justification for Dose  ................................ ................................ ................................ ..58 
4.3.1.  Bimagrumab Doses  ................................ ................................ ................................ .....58 
4.3.2.  Semaglutide Doses  ................................ ................................ ................................ ......59 
4.4. End-of-Study Definition  ................................ ................................ ............................. 59 
5. STUDY POPULATION  ................................ ................................ ............................. 59 
5.1. Inclusion Criteria  ................................ ................................ ................................ ........ 60 
5.2. Exclusion Criteria  ................................ ................................ ................................ .......60 
5.3. Lifestyle Considerations  ................................ ................................ ............................. 63 
5.3.1.  Meals and Dietary Restrictions  ................................ ................................ ................... 63 
5.3.2.  Activity  ................................ ................................ ................................ ....................... 64 
5.3.3.  Other Restrictions  ................................ ................................ ................................ .......64 
5.3.4.  Support During Treatment Withdrawal Period  ................................ ........................... 64 
5.4. Screen Failures  ................................ ................................ ................................ ............ 64 
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY  ........................ 64 
6.1. Study Interventions Administered  ................................ ................................ .............. 66 
6.2. Preparation, Handling, Storage, and Accountability  ................................ .................. 68 
6.3. Assignment to Study Intervention  ................................ ................................ .............. 68 
6.4. Blinding  ................................ ................................ ................................ ...................... 69 
6.4.1.  Bimagrumab and Placebo  ................................ ................................ ........................... 69 
6.4.2.  Semaglutide  ................................ ................................ ................................ ................ 69 
6.4.3.  SAE and Unblinding  ................................ ................................ ................................ ...69 
6.4.4. Unblinded Personnel  ................................ ................................ ................................ ...69 
6.5. Study Intervention Compliance  ................................ ................................ .................. 70 
6.6. Dose Modification  ................................ ................................ ................................ ......70 
6.6.1.  Bimagrumab  ................................ ................................ ................................ ............... 70 
6.6.2.  Semaglutide  ................................ ................................ ................................ ................ 70 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 20 of 112 
6.7. Continued Access to Study Intervention after the End of Treatment  ......................... 71 
6.8. Treatment of Over dose ................................ ................................ ............................... 71 
6.8.1.  Bimagrumab  ................................ ................................ ................................ ............... 71 
6.8.2.  Semaglutide  ................................ ................................ ................................ ................ 71 
6.9. Prior and Concomitant Therapy  ................................ ................................ .................. 71 
6.9.1.  Prohibited Medicine  ................................ ................................ ................................ ....72 
6.9.2.  Prohibited Non -Pharmacological Concomitant Treatments  ................................ .......73 
6.9.3.  Recommended Treatment of Adverse Events  ................................ ............................ 73 
7. DISCONTINUATION OF STUDY INTERVENTION, PARTICIPANT 
DISCONTINUATION / WITH DRAWAL AND STUDY STOPP ING / 
PAUSING  ................................ ................................ ................................ ................... 73 
7.1. Participant Discontinuation of Study Intervention  ................................ ..................... 73 
7.1.1.  Liver, Pancreas, or Muscle Related Events Stopping Criteria  ................................ ....74 
7.1.2.  Temporary Discontinuation  ................................ ................................ ........................ 74 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ........... 74 
7.3. Lost to Follow -up ................................ ................................ ................................ .......75 
7.4. Treatment Arm and Study Stopping/Pausing Rules  ................................ ................... 75 
8. STUDY ASSESSMENTS AND PROCEDURES  ................................ ...................... 76 
8.1. Administrative Procedures  ................................ ................................ .......................... 76 
8.2. Efficacy / Pharmacodynamics Assessments  ................................ ............................... 77 
8.2.1.  Anthropometric Measurements  ................................ ................................ .................. 77 
8.2.1.1.  Body Weight  ................................ ................................ ................................ ............... 77 
8.2.1.2.  Waist Circumference  ................................ ................................ ................................ ..77 
8.2.1.3.  Body Mass Index  ................................ ................................ ................................ ........ 77 
8.2.1.4.  Bioelectrical Impedance Analysis  ................................ ................................ .............. 77 
8.2.2.  DXA  Scan  ................................ ................................ ................................ ................... 78 
8.2.4.  Impact of Weight on Quality of Life -Lite Clinical Trials Version  ............................. 78 
8.2.5.  Short  Form (SF -36) Health Survey  ................................ ................................ ............. 78 
8.2.6.  Physical Activity Monitoring Via  ................................ ............................ 78 
8.2.6.1.  Lipid Profile  ................................ ................................ ................................ ................ 78 
8.2.6.2.  Glucose Metabolism Parameters: HbA1c, Fasting Insulin and Glucose  .................... 79 
8.3. Safety Assessments  ................................ ................................ ................................ .....79 
$SSURYHGRQ$SU*07CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 21 of 112 
8.3.1.  Physical Examinations  ................................ ................................ ................................ 79 
8.3.2.  Vital Signs  ................................ ................................ ................................ .................. 79 
8.3.3.  Electrocardiograms  ................................ ................................ ................................ .....80 
8.3.4.  Clinical Safety Laboratory Tests  ................................ ................................ ................ 80 
8.3.5.  Pregnancy Testing  ................................ ................................ ................................ ......81 
8.3.6. Hematology/Coagulation  ................................ ................................ ............................ 81 
8.3.7.  Blood Chemistry  ................................ ................................ ................................ ......... 81 
8.3.8.  Urinalysis and Urine Chemistry  ................................ ................................ ................. 81 
8.4. Adverse Events, Treatment Emergent Adverse Events, Serious Adverse 
Events, and Other Safety Reporting  ................................ ................................ ........... 81 
8.4.1.  Time Period and Frequency for Collecti ng AE, TEAE and SAE Information  .......... 82 
8.4.2.  Follow -up of AEs and SAEs  ................................ ................................ ....................... 82 
8.4.3.  Regulatory Reporting Requirements for SAEs  ................................ ........................... 82 
8.4.4.  Pregnancy  ................................ ................................ ................................ ................... 83 
8.4.5.  Treatment Emergent Adverse Events of Special Interest  ................................ ........... 83 
8.5. Pharmacokinetics  ................................ ................................ ................................ ........ 83 
8.6. Pharmacodynamics  ................................ ................................ ................................ .....84 
8.7. Genetics  ................................ ................................ ................................ ...................... 84 
8.8. Immunogenicity Assessments  ................................ ................................ .................... 85 
9. STATISTICAL CONSIDERATIONS  ................................ ................................ .......85 
9.1. Statistical Analyses  ................................ ................................ ................................ .....85 
9.1.1. Multiplicity Adjustment ................................ ................................ .............................. 86 
9.2. Analysis Sets  ................................ ................................ ................................ ............... 86 
9.3. Interim Analysis  ................................ ................................ ................................ .......... 87 
9.4. Treatment Extension and Post -Treatment Follow -Up Period Analyses  ..................... 87 
9.5. Sample Size Determination  ................................ ................................ ........................ 87 
10. SUPPORTING DOCUMENTATION AND OPERATIONAL 
CONSIDERATIONS  ................................ ................................ ................................ ..88 
10.1.  APPENDIX 1: Regulatory, Ethical, and Study Oversight Considerations  ................ 88 
10.1.1.  Regulatory and Ethical Considerations  ................................ ................................ ......88 
10.1.2.  Financial Disclosure  ................................ ................................ ................................ ...88 
10.1.3.  Informed Consent Process  ................................ ................................ .......................... 89 
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 22 of 112 
10.1.4.  Recruitment Strategy  ................................ ................................ ................................ ..89 
10.1.5.  Data Protection  ................................ ................................ ................................ ........... 89 
10.1.5.1.  Future Use of Stored Specimens and Data  ................................ ................................ .89 
10.1.6.  Data Safety Committee  ................................ ................................ ............................... 90 
10.1.7.  Site Monitoring  ................................ ................................ ................................ ........... 91 
10.1.8.  Clinical Monitoring  ................................ ................................ ................................ ....91 
10.1.9.  Audits and Inspections  ................................ ................................ ................................ 92 
10.1.10.  Data Quality Assurance  ................................ ................................ .............................. 92 
10.1.11.  Data Handling and Recordkeeping  ................................ ................................ ............. 94 
10.1.12.  Study and Site Start and Closure  ................................ ................................ ................ 95 
10.1.13.  Publication Policy  ................................ ................................ ................................ .......95 
10.2.  APPENDIX 2: Clinical Laboratory Tests  ................................ ................................ ...96 
10.3.  APPENDIX 3: AEs and SAEs: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  ................................ ................................ ......100 
10.3.1.  Definition of AE  ................................ ................................ ................................ .......100 
10.3.2.  Definition of SAE  ................................ ................................ ................................ .....101 
10.3.3.  Recording and Follow -Up of AE and/or SAE  ................................ .......................... 102 
10.3.4.  Reporting of SAEs  ................................ ................................ ................................ ....103 
10.4.  APPENDIX 4: Contracept ive Guidance  ................................ ................................ ...105 
10.5.  APPENDIX 5: Genetics  ................................ ................................ ........................... 106 
10.5.1.  Optional Consent  ................................ ................................ ................................ ......106 
10.5.2.  Use/Analysis of DNA  ................................ ................................ ............................... 106 
10.5.3.  Storage of Genetic Samples  ................................ ................................ ...................... 106 
10.6.  APPENDIX 6: Liver Safety: Suggested Actions and Follow -up Assessments  ........ 107 
10.7.  APPENDIX 7: Lipase and Amylase Safety  ................................ .............................. 109 
10.8.  APPENDIX 8: Creatine Kinase Safety  ................................ ................................ .....110 
11. REFERENCES  ................................ ................................ ................................ ......... 111 
 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 23 of 112 
LIST OF TABLES   
Table  1: Table of Objectives and Endpoints  ................................ ................................ ............. 50 
Table  2: Study Interventions Administered  ................................ ................................ .............. 66 
Table  3: Study Treatment Arms  ................................ ................................ ................................ 67 
Table  4: Prohibited Medications  ................................ ................................ ............................... 72 
Table  5: Safety Laboratory Tests  ................................ ................................ .............................. 96 
Table  6: Other Laboratory Tests (Central Lab)  ................................ ................................ ........ 98 
Table  7: Liver Event and Laboratory Trigger Definitions  ................................ ...................... 107 
Table  8: Actions Required for Liver Events and Laboratory Triggers  ................................ ...107 
Table  9: Follow Up Requirements for Liver Laboratory Triggers - Isolated 
Hyperbilirubinemia  ................................ ................................ ................................ ...108 
Table  10: Safety Monitoring Guidance for Amylase and Lipase Elevations  ........................... 109 
Table  11: Safety Monitor ing Guidance for Creatine Kinase Elevations  ................................ ..110 
 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 24 of 112 
LIST OF ABBREVIATIONS   
Abbreviation or Specialist Term  Explanation  
ActRII  Activin Receptor Type II 
ActRIIA  Activin Receptor Type II A 
ActRIIB  Activin Receptor Type II B  
ADA  Anti-Drug -Antibodies  
AE Adverse Event  
AESI  Adverse Events of Special Interest  
ALT  Alanine Aminotransferase  
ALP  Alkaline Phosphate  
AST  Aspartate Aminotransferase  
aPTT  Activated Partial Thromboplastin Time  
AUC  Area Under the Curve  
BIA Biomolecular Interaction Analysis  
BMD  Bone Mineral Density  
BMI  Body Mass Index  
bpm Beats Per Minute  
BSAP  Bone Specific Alkaline Phosphatase  
CBC  Complete Blood Count  
CIOMS  Council For International Organizations of Medical Sciences  
CCK18 Caspase -Cleaved K18 
CK Creatine Kinase  
CL Clearance  
Cmax  Maximum or Peak Concentration  
CRF  Case Report Form  
CRO  Contract Research Organization  
CTC(AE)  Common Terminology Criteria (For Adverse Events)  
CTX  C-terminal telopeptide  
DMC  Data Monitoring Committee  
DNA  Deoxyribonucleic Acid  
DXA  Dual -Energy X -Ray Absorptiometry  
ECG  Electrocardiogram  
EDC  Electronic Data Capture  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 25 of 112 
Abbreviation or Specialist Term  Explanation  
EOS  End of Study  
FAS Full Analysis Set  
FBM  Fat Body Mass  
FFM  Fat-Free Mass  
FSH Follicle Stimulating Hormone  
GDF11  Growth Differentiation Factor 11  
GCP  Good Clinical Practice  
GGT  Gamma -Glutamyl Transferase  
GLP1  Glucagon -Like Peptide -1 
HbA1c  Hemoglobin A1C  
HBV  Hepatitis B Virus  
HCV  Hepatitis C Virus  
HDL  High Density Lipoprotein  
HIV Human Immunodeficiency Virus  
HOMA2  Homeostasis Model Assessment , version 2  
hsCRP  High -sensitivity C -reactive protein  
IA Interim Analysis  
IB Investigator â€™s Brochure  
ICH International Conference on Harmonization  
ICE Intercurrent Event  
IEC Independent Ethics Committees  
IL-6 Interleukin 6  
IL-18 Interleukin 18  
IgG Immunoglobulin G  
IMP Investigational Medicinal Product  
INR International Normalized Ratio  
IRB Institutional Review Boards  
ITT Intention to Treat  
IUD Intrauterine Device  
i.v. Intravenous  
IWQOL -Lite-CT Impact of Weight on Quality of Life -Lite Clinical Trials  
IWRS  Interactive Web Response Systems  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 26 of 112 
Abbreviation or Specialist Term  Explanation  
LBM  Lean Body Mass  
LDH  Lactate Dehydrogenase  
LDL  Low Density Lipoprotein  
miR-122 Mirco RNA 122  
MRI  Magnetic Resonance Imaging  
MTC  Medullary Thyroid Carcinoma  
NGAL  Neutrophil gelatinase -associated lipocalin  
NOAEL  No Observed Adverse Event Level  
PD Pharmacodynamic(s)  
PI Package Insert  
PK Pharmacokinetic(s)  
PoC Proof of Concept  
PT Prothrombin Time  
QOL  Quality of Life  
QTc Corrected QT Interval  
QUICKI  Quantitative Insulin -Sensitivity Check Index  
SAE  Serious Adverse Event  
SAF Safety Analysis Set  
SAP Statistical Analysis Plan  
SAT  Subcutaneous Adipose Tissue  
SF-36 Short Form 36 Health Survey Questionnair e 
SGLT2  Sodium -glucose Cotransporter -2 
sIBM  Sporadic Inclusion Body Myositis  
s.c. Subcutaneous  
SD Standard Deviation  
SGOT  Serum Glutamic -Oxaloacetic Transaminase  
SGPT  Serum Glutamate Pyruvate Transaminase  
SoA Schedule of Activities  
SOM  Study Operations Manual  
SUSAR  Suspected Unexpected Serious Adverse Reactions  
T2DM Type 2 Diabetes  Mellitus  
TBW  Total Body Water  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 27 of 112 
Abbreviation or Specialist Term  Explanation  
TC Total Cholesterol  
TG Triglyceride  
TEAE  Treatment Emergent Adverse Event  
TGF -Î² Transforming Growth Factor Beta  
ULN  Upper Limit of Normal  
VAT  Visceral Adipose Tissue  
WC Waist Circumference  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 28 of 112 
1. PROTOCOL SUMMARY   
1.1. Synopsis   
Sponsor/Company  Versanis Bio, Inc.  
Investigational 
Product  Bimagrumab  
Protocol Number  VER201 -PH2-031 
Title  A randomized, double -blind, placebo -controlled study of intravenous  
bimagrumab, alone or in addition to open label subcutaneous semaglutide to 
investigate the efficacy and safety in overweight or obese men and women  
Brief Title  Safety and efficacy of bimagrumab and semaglutide in  adults with 
overweight or obesity  
Study Phase  2 
Study Type  Interventional  
Rationale  Most weight loss programs, including obesity pharmacotherapy , reduce body 
weight ; however , this often occurs at the expense of lean mass. Bimagrumab 
has been shown to reduce fat mass accompanied by an increase in muscle 
mass. This study investigates if bimagrumab , alone or  in addition to standard 
of care semaglutide , can preserve/increase muscl e mass in the presence of 
weight and fat mass loss.  
Primary Objective  1. To assess treatment effect of bimagrumab , semaglutide , and bimagrumab 
in addition to  semaglutide  vs placebo  on body weight  
Secondary Objectives  1. To assess  the treatment effect of bimagrumab, semaglutide, and 
bimagrumab in addition to semaglutide vs placebo on waist 
circumference  (WC, cm) 
2. To assess treatment effects on fat mass , visceral adipose tissue  (VAT) , 
trunk fat mass , subcutaneous adipose tissue  (SAT), and lean mass  (body 
composition)  
3. To assess the safety and tolerability of bimagrumab, semaglutide and 
bimagrumab in addition to semaglutide  
4. To assess the proportion of patients in each treatment group experiencing 
a change in the categorical classi fication of obesity based on BMI and 
waist -to-height ratio (WHtR) group  
5. To assess treatment effects on glucose metabolism  
6. To assess treatment effects on self -reported health status and weight -
related quality of life  
Primary Endpoint  1. Change  from baseline  in total body weight  at 48 weeks   
Secondary Endpoints  1. Change  from baseline in WC (cm) at 48 and 72 weeks 
2. a.  Change from baseline at 48 and 72 weeks in total body  fat mass (kg 
and % body fat ) by dual -energy x -ray absorptiometry  (DXA)  
b.  Change from baseline at 48 weeks in  VAT , SAT,  and trunk fat mass 
(kg) by DXA  
c.  Proportion of participants who achieve  a reduction  from baseline at 
48 weeks  in the following measures of obesity : 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 29 of 112 
i. WC â‰¥ 5 cm  
ii. Body weight â‰¥ 5%, â‰¥ 10% , and â‰¥ 15%  
iii. Fat mass  â‰¥ 5% , â‰¥ 10% , and â‰¥ 15%  by DXA  
iv. Fat mass â‰¥ 10% with <5% decrease (or an increase) in lean 
mass  by DXA  
d.  Percentage of weight loss due to fat mass or lean mass  at 48 weeks  by 
DXA  
e.  Change from baseline at 48  and 72  weeks in fat mass (kg and % body 
fat) by bioelectrical impedance analysis (BIA)  
f.  Change from baseline at 48  and 72  weeks in total body lean mass (kg 
and % body lean) by DXA and BIA and appendicular lean mass by 
DXA  
3. Safety and tolerability measur ements throughout 48 weeks:  
a. Incidence and severity of treatment emergent adverse events 
(TEAEs), treatment -related AEs, serious adverse events (SAEs) 
and evaluation of TEAEs of special interest (including significant 
muscle, skin, and gastrointestinal TEAEs, malignancy, and 
pancreatitis ) 
b. Clinical safety laboratory evaluation, including anti -drug 
antibodies (ADA)  
c. Vital signs (temperature, blood pressure, pulse rate)  
4. Proportion of patients with change from baseline in ca tegorical 
classification of obesity at any time up to  48 weeks:  
a. BMI categories:  
i. Healthy weight: 18.5 kg/m2 to 24.9  kg/m2 
ii. Overweight: 25 kg/m2 to 29.9 kg/m2 
iii. Obesity class 1: 30 kg/m2 to 34.9 kg/m2 
iv. Obesity class II: 35 kg/m2 to 39.9 kg/m2 
v. Obesity class III: â‰¥ 40 kg/m2 
b. WHtR ratio categories: <0.5; 0.5 -0.59; â‰¥0.6 [1] 
5. Change from baseline in HbA1c  at 48 weeks   
6. Change from baseline at 24 , 48, and 72  weeks in:  
ï‚· Quality  of Life Short Form 36 survey (SF -36) total score and 
physical functioning score  
ï‚· Impact of Weight on Quality of Life -Lite for Clinical Trials 
survey (IWQoL -Lite for CT) total score and physical function 
score  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 30 of 112 
Study Design This is a multicenter, randomized, double -blind, placebo -controlled (for 
bimagrumab)  study of i.v. bimagrumab, alone or in addition to open label s.c. 
semaglutide to investigate efficacy and safety in overweight or obese men 
and women.  
Participants will be randomize d to one of the following nine treatment arms  
(bima grumab or placebo by i.v. infusion, semaglutide by s.c. injection; exact 
doses of semaglutide , by subcutaneous injection, to be determined, not to 
exceed 2. 5 mg) for the 48-week core treatment period: 
1. Placebo  + no semaglutide 
2. Placebo + semaglutide 1.0 mg 
3. Placebo + semaglutide 2.4 mg 
4. Bimagrumab 10 mg/kg + no semaglutide 
5. Bimagrumab 10 mg/kg + semaglutide 1.0 mg 
6. Bimagrumab 10 mg/kg + semaglutide 2.4 mg 
7. Bimagrumab 30 mg/kg + no semaglutide 
8. Bimagrumab 30 mg/kg + semaglutide 1.0 mg 
9. Bimagrumab 30 mg/kg + semaglutide 2.4 mg 
The core treatment period is followed by a 24- week open-label treatment 
extension  period (which will remain blinded until after the 48 -week database 
lock and study unblinding) , during which 2 of the treatment arms will follow 
a modified treatment assignment:  
1. Switch from placebo to bimagrumab 30 mg/kg + no semaglutide  
2. No change; Placebo + semaglutide 1.0 mg; placebo replaced by no 
treatment after study unblinding 
3. No change; Placebo + semaglutide 2.4 mg ; placebo replaced by no 
treatment after study unblinding 
4. Switch from bimagrumab 10 mg/kg to 30 mg/kg + no semaglutide  
5. No change; bimagrumab 10 mg/kg + semaglutide 1.0 mg  
6. No change; bimagrumab 10 mg/kg + semaglutide 2.4 mg 
7. No change; bimagrumab 30 mg/kg + no semaglutide 
8. No change; bimagrumab 30 mg/kg + semaglutide 1.0 mg 
9. No change; bimagrumab 30 mg/kg + semaglutide 2.4 mg 
The extension period is then foll owed by a 32-week post-treatment follow -up 
period, during which all study treatments will be withdrawn for all arms. 
The study will consist of a screeni ng visit to assess eligibility, a baseline visit, 
followed by clinic visits/phone contacts every 4 weeks during the treatment 
and follow -up period s. 
Number of 
participants (planned) ;  participants per treatment group  
Investigational 
product, dosage and 
mode of administration
 1. Low dose bimagrumab F 10 mg/kg by i.v. infusion 
2. High dose bimagrumab F 30 mg/kg by i.v. infusion 
For both dose levels, loading doses at Weeks 1 (Day 1) and 4 , followed by 
q12 week  dosing (Weeks 16, 28, 40, 52, and 64) ; there will be no loading 
dose for Arm 1 during switch from placebo to bimagrumab. 
$SSURYHGRQ$SU*07CCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 31 of 112 
Reference therapy, 
dosage and mode of 
administration:  Bimagrumab placebo: Formulation buffer composed of histidine, trehalose 
and polysorbate  by i.v. infusion . 
Doses at Weeks 1 (Day 1) , 4, 16, 28, and 40 ; at Weeks 52 and 64, placebo 
infusion will be replaced by no treatment  after the 48 -week database lock and 
study unblinding . 
Comparator therapy, 
dosage and mode of 
administration  1. Low dose semaglutide  â€“ 1.0 mg s.c. weekly  
Dose escalation schedule listed below  
ï‚· Weeks 1 (Day 1)  to 4: 0.25 mg s.c. weekly  
ï‚· Weeks 5 to 8: 0.5 mg s.c. weekly  
ï‚· Weeks 9 to 71: 1.0 mg s.c. weekly  
2. High dose semaglutide  â€“ 2.4 mg s.c. weekly  
Dose escalation schedule listed below  (exact doses to be determined , 
not to exceed 2.5 mg) 
ï‚· Weeks 1 (Day  1) to 4: 0.25 mg s.c. weekly  
ï‚· Weeks 5 to 8:  0.5 mg s.c. weekly  
ï‚· Weeks 9 to 12:  1.0 mg s.c. weekly  
ï‚· Weeks 1 3 to 16: 1.7 mg s.c. weekly * 
ï‚· Weeks 1 7 to 71: 2.4 mg s.c. weekly * 
*Semaglutide doses of 1.7 mg and 2.4 mg may be substituted with 1.5 mg 
and 2.5 mg, respectively, based on availability of  semaglutide  pens. 
Duration of Study  Up to 110  weeks, which includes a n up to  6-week screening period , a 
baseline visit , a 72-week treatment period  (48 weeks core plus 24 weeks 
extension), and a 32 -week post-treatment follow -up period . 
Key Inclusion 
Criteria  ï‚· A written informed consent must be obtained before any study -related 
assessments are performed . 
ï‚· Men and women between 18 and 80 years, inclusive ; women of child -
bearing potential  (defined as  those who are not post -menopausal or post-
surgical sterilization)  must meet both of the following criteria:  
ï‚· Two negative pregnancy tests ( at screening and at randomization , 
prior to dosing ) 
ï‚· Use of intrauterine device, from at least 3 months before  the baseline 
visit through at least 4 months after th e last dose of 
bimagrumab/placebo  i.v., and an  additional contraceptive (barrier) 
method  from screening  through at least 4 months after the last dose 
of bimagrumab/placebo  i.v. 
ï‚· Body mass index (BMI) â‰¥ 30 kg/m2 or BMI â‰¥ 27 kg/m2 with one or more 
obesity -associated comorbidities (e.g., hypertension, insulin resistance, 
sleep apnea,  or dyslipidemia)  
ï‚· Stable body weight (Â± 5 kg) within 90 days  of screening , and body weight 
<150  kg 
ï‚· Have a history of at least one self -reported unsucces sful behavioral effort 
to lose body weight  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 32 of 112 
 Able to communicate well with the Investigator, comply with the study 
requirements and adhere to the diet and activity programs for the study 
duration 
Key Exclusion 
Criteria   History of, or known hypersensitivity to, monoclonal antibody drugs or a 
contraindication to semaglutide (OzempicÂ® or WegovyÂ®) 
 Use of other investigational drugs at the time of enrollment or within 30 
days or 5 half-lives of enrollment, whichever is longer, or longer if 
required by local regulations 
 Treatment with any medication for the indication of obesity within the 
past 30 days before screening 
 Diagnosis of diabetes, requiring current use of any antidiabetic drug or  
*	+D
  
 Note: Metabolic syndrom e is not an exclusion, even if managed with an 
anti- diabetic drug such as metformin or an SGLT2 inhibitor.  A diagnosis 
of prediabetes or impaired glucose tolerance managed exclusively with 
non-pharmacologic approaches (e.g., diet and exercise) is not an exclusion.  
 Any chronic infections likely to interfere with study conduct or 
interpretation such as hepatitis B (HBV), hepatitis C (HCV), or human 
immunodeficiency virus (HIV). History of hepatitis A or hepatitis C successfully treated is not exclusionary. Active COVID-19 infection. 
 Donation or loss of 400 mL or more of blood within 8 weeks prior to initial dosing, or longer if required by local regulation, or plasma donation (> 250 mL) within 14 days prior to the first dose 

 Any disorder, unwillingness, or i nability not covered by any of the other 
-@+4=;176+:1<-:1)?01+016<0-6>-;<1/)<7:J;781617651/0< 2-78):,1B-
the participant J;;).-<A7:+75841)6+-?1<0<0-8:7<7+74  
Sample Size 
Justification:   participants will be randomized to 1 o f 9 treatment 
groups. The sample size calculation is based on the primary efficacy estimand 
for weight .  Based on the FDA guidance on treatment for weight 
management, the minimum meaningful treatment effect for weight loss is 5% 
of baseline body weight over 1 year of treatment.   Assuming the  minimum 
treatment effect of % weight loss with a standard deviation (SD) of , for a 
minimum effect size of [2, 3] , a sample size of  participants per 
treatment arm will have approximately % statistical power to detect a 
treatment difference betwee n any active group and placebo /no treatment  
using a 2 -sided t-test at alpha= .   Assuming a % dropout rate, 
enrollment will target 55 participa nts per treatment arm.   
Sample size was estimated using a t-test for 2 means in NQuery Advisor V9.1 
(www.statsols.com ). [4, 5]  
$SSURYHGRQ$SU*07CCI
CC CC
CCI
CCICCI
CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 33 of 112 
Statistical Methods All randomized participants who received at least one dose of study 
medication  will be included in an Gintention-to-treat H population (treatment 
policy strategy) . Baseline and efficacy results will be summarized by 
randomized treatment arm  with active treatment arms compared to 
placebo /no treatment, and combination treatment arms to each monotherapy 
of the same dose.  
Safety and tolerability results will be summarized by actual treatment 
received.  
A detailed statistical analysis plan (SAP) will be finalized prior to database 
lock and will describe all planned analyses. 
Data 
Monitoring/Other 
Committee  A data monitoring committee (DMC) will be convened to review the 
available safety data after % of participant s have been treated for at least 
days, and periodically thereafter , with ad hoc meetings as necessary . The 
committee will consist of at least 2 independent clinicians, knowledgeable in 
obesity treatment, and 1  independent  biostatistician. Up to 2 additional non -
voting members from the Sponsor with relevant safety and statistical 
expertise may also be incl uded. Prior to convening the first DMC data review  
meeting , a DMC charter will be drafted and approved by the committee 
members. The primary role of the DMC is to advise on study conduct to 
ensure participant safety. This may include recommendations to dis continue a 
treatment arm or the study as a whole . 
 
 
$SSURYHGRQ$SU*07CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 4.0 
 
Confidential & Proprietary  
Page 34 of 112 
 
1.2. Study Schema   
 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 35 of 112 
1.3. Schedule of Activities (SoA)   
Core Treatment Period (Screening through Week 48)  
Study Phase SCR B/L Core Treatment 
Visit (V), Phone (P)           
Week b -                
Day                
 PARTICIPANT RELATED INFORMATION AND ASSESSMENTS  
Clinic Visit X X   X   X X   X X     X   X 
Phone Call     X   X     X     X X   X   
Informed consent X                             
Optional genetic and future use of 
samples informed consent c X                             
Demography X                             
Inclusion/Exclusion criteria S   Sd                           
Medical History X X                           
Con Meds/Therapies X X 
Drug screen S                             
Body height X                             
Hep B and C/HIV X                             
Lipid Panel X               
FSH e, HbA1c, TSH e S                             
RANDOMIZATION & DRUG ADMINISTRATION 
Randomization   X                           
Drug administration: 
bimagrumab/placebo IV   X   Xf     X     X     X     
Drug administration: semaglutide SC 
(self-administered) g   Weekly to week 71 
EFFICACY  
Body weight, including BIA h X X   X   X X   X X     X   X 
Waist circumference X X   X   X X   X X     X   X 
$SSURYHGRQ$SU*07CCI
CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 36 of 112 
Study Phase SCR B/L Core Treatment 
Visit (V), Phone (P)           
Week b                
Day                
DXA Scan   Xb       X     X           X 
   X       X     X           X 
QoL Questionnaires i   X       X     X           X 
  X 
SAFETY 
Adverse Events   X 
Physical Examination j X X   X   X     X       X   X 
Vital signs k X X   X   X X   X X     X   X 
ECG X         X                 X 
Hematology l (CBC) X X   X   X     X       X   X 
Clinical chemistry l X X   X   X     X       X   X 
Coagulation l X X   X   X     X       X   X 
Urine chemistry l   X       X     X       X   X 
Urinalysis X X       X     X       X   X 
Pregnancy test n X X   X   X X   X X     X   X 
Blood draw: Safety Biomarkers l, o   X o   X o   X o     X o       X o   X o 
Blood draw:    X       X     X           X 
Blood draw: Anti-drug antibodies   X   X   X     X           X 
Blood draw:    
X   X   X X   X X         X 
Training: eDiary, exercise program, 
semaglutide self-administration   X                           
Dietary/physical activity counselling   X   X X X X X X X X X X X X 
Exercise program r   X 
eDiary completion s   X 
 
  
$SSURYHGRQ$SU*07CCI
CCI
CCI
CCICCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 37 of 112 
Extension and Post-Treatment Follow -Up Period s (Wee k 52 through End of Study ) 
Study Phase Extension Treatment EOTa Post-Treatment Follow-Up EOSa 
Visit (V), Phone (P)               
Week b               
Day               
 PARTICIPANTS RELATED INF ORMATION AND ASSESSMENTS 
Clinic Visit X     X   X     X     X   X 
Phone Call   X X   X   X X   X X   X   
Con Meds/Therapies X 
RANDOMIZATION & DRUG ADMINISTRATION 
Drug administration: 
bimagrumab/placebo IV X     Xf                     
Drug administration: semaglutide SC 
(self-administered) g Weekly to Week 71         
EFFICACY 
Body weight, including BIA h X     X   X     X     X   X 
Waist circumference X     X   X     X     X   X 
DXA Scan           X           X     
           X           X     
QoL Questionnaires i           X           X     
 X 
SAFETY 
Adverse Events X 
Physical Examination j       X   X     X     X     
Vital signs k X     X   X     X     X   X 
ECG                             
Hematology l (CBC)       X   X     X     X     
Clinical chemistry l       X   X     X     X     
Coagulation l       X   X     X     X     
Urine chemistry l       X   X     X     X     
Urinalysis       X   X     X     X     
$SSURYHGRQ$SU*07CCI
CCICCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 38 of 112 
Study Phase Extension Treatment EOTa Post-Treatment Follow-Up EOSa 
Visit (V), Phone (P)               
Week b               
Day               
Pregnancy test n X     X   X                 
Blood draw: Safety Biomarkers l, o           X o           X o     
SAFETY 
Blood draw:             X           X    
Blood draw: Anti-drug antibodies           X                 
Blood draw:             X                 
OTHER ASSESSMENTS 
Dietary/physical activity counselling X X X X X X X X X X X X X   
Exercise program r X 
eDiary completion s X 
Abbreviations : SCR, screening; B/L=baseline; D=day; EOS=end of study; V=visit; P=phone; BIA=bioimpedance analysis;  DXA=  dual-energy X -ray absorptiometry; 
HbA1C=hemoglobin A1C; PD=pharmacodynamic; ECG=  electrocardiogram; Hep=hepatitis; HIV=human immunodeficiency virus; CBC=complete blood count ; aPTT =activated 
partial thromboplastin time ; PT/INR=prothrombin time/ international normalized ratio ; IUD=intrauterine device ; DNA=deoxyribonucleic acid; eDiary=el ectronic diary ; S=remains 
as source data at site  and is not collected in the eCRF.  
a. EARLY TREATMENT DISCONTINUATION: At the time of discontinuing treatment early , the End of Treatment  (EOT)  visit should be conducted as 
b/placebo . 
 OPTIONAL GENETIC INFORMED CONSENT:
d. INCLUSION/EXCLUSION : Eligibility to be confirmed prior to dosing.  
e. SCREENING  FSH, HbA1c  and TSH : Follicle -stimulating hormone testing to be conducted for post -menopausal women at screening  (see footnote o for 
other timepoints ). HbA1c required for all participants at screening.  Thyroid -stimulating hormone testing to be conducted at screening unless a n ormal value 
is documented within 6 months prior to screening.  
f. WEEK S 4 AND 64 PRE -DOSE SAFETY LABS : Prior to administering the Week 4 and Week 64 doses of bimagrumab/placebo, Investigators must obtain 
and review results of safety labs against the safety gui dance present ed in Sections  10.6, 10.7, and  10.8, Appendices 6, 7, and 8 . 
g. SEMAGLUTIDE ADMINISTRATION : Semaglutide is to be administered s. c. weekly by the participant at home. On study visit days, participants will 
take their dose on site, in the presence of study personnel, after study assessments.  The last dose of semaglutide is taken  at the beginning of week of 71, on 
Day 498. 
h. BODY WEIGHT, INCLUDING BIA: Bioelectrical impedance scale to be used to measure weight , body fat, and lean (muscle)  mass.  
i. QOL QUESTIONNAIRES: Questionnaires include IWQoL -Lite for CT and SF -36. 
$SSURYHGRQ$SU*07CCI
CCI
CCICCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 39 of 112 
j. PHYSICAL EXAMINATION: A complete physical examination is required, including skin assess ment for acne or lesions an d, for males, assessment of 
gynecomastia.  
k. VITAL SIGNS : Includes body temperature, blood pressure, pulse rate.  
l. CLINICAL LABORATORY TESTS : Refer to Appendix 2 for a complete list of all analytes included in each panel.  
m. BLOOD DRAWS : Blood draws should be collected in th e fasted state (approximately 8 hours ), except for the screening visit, where fa sting is not required. 
Time of last meal should be noted.  
n. PREGNANCY TEST : Serum pregnancy test is required for all female participants at screening. Urine pregnancy test can be used at all other vi sits for pre -
menopausal female par ticipants, unless serum is required  based on local requirements.  
o. SAFETY BIOMARKERS : A sample for safety biomarkers will be collected for all par ticipants but will only be analyze d for participants with abnor mal 
liver or pancreatic test results per safety l abs. 
r. EXERCISE PROGRAM : Participants will be encouraged to exercise for at least 150 minutes per week.  
s. eDIARY : Exercise and dosing information collected.    
$SSURYHGRQ$SU*07CCICCI
Protocol No. VER201 -PH2-031 
Version No. .0 
 
Confidential & Proprietary  
Page 40 of 112 
2. INTRODUCTION   
2.1. Study Rationale   
Obesity is one of the greatest public health challenges of the 21st century. Its pr evalence has 
tripled in many countries since the 1980s, and the numbers of those affected continue to rise at 
an alarming rate. In 2016, globally more than 1.9 billion adults (39%) were overweight ; of these , 
650 million (13%) were obese. In addition to cau sing various physical disabilities and 
psychological problems, excess weight drastically increases a personâ€™s risk of developing a 
number of comorbidities, including cardiovascular disease, cancer, insulin resistance and type 2 
diabetes mellitus (T2D M) [6]. The Global Burden of Disease study reported that 4.7 million 
people died prematurely in 2017 as a result of obesity [7]. 
A body weight reduction of 5 -10% has been associated with significant and clinically 
meaningful improvem ents in insulin sensitivity, glycemic control, hypertension, and 
dyslipidemia. Combining lifestyle management with pharmacotherapy is increasingly recognized 
as an effective and safe treatment option for many patients with obesity [8]. Currently, 5 
medications are on the market for long term us e in the US, the latest is once weekly s.c. 
semaglutide  (a GLP 1-receptor agonist) , approved in 2021  for chronic weight management in 
adults with obesity (BMI >30 kg/m2) or overweight with at least one weight -related condition 
(BMI >27 kg/m2). 
Adipose tissu e, in particular , visceral adipose tissue ( VAT ), is involved in energy storage and is 
considered an endocrine and paracrine organ that affects several metabolic processes, through 
the release of cytokines and bioactive mediators. Cytokines and mediators can influence body 
weight, as well as insulin resi stance and pathogenesis of diabetes mellitus, lipid metabolism  and 
inflammation, thus explaining premature atherosclerosis in people with obesity  [9-11]. VAT 
rather than body mass index ( BMI ) determines metabolic risk and  is associated  with metabolic 
syndrome even in participant s with normal BMI, defined as normal weight obese  [12-14]. 
Therefore, loss of VAT might be of great importance to prevent cardiovascular disease.  
Most weight loss programs are able to reduce body weight within the first few weeks; however, a 
significant amount of the weight loss includes loss of LBM. Also, obesity pharmacotherapy 
results in loss of LBM in connection with loss of FM [15], so it is important to focus on body 
composition i n an effort to maintain LBM. The loss of LBM is problematic for several reasons, 
including impacts on health, ability to conduct activities of daily living and potential effects on 
emotion and psychological states. The loss of LBM impedes sustainability  of successful obesity 
therapy  by causing lowered resting energy expenditure/metabolism, fatigue, decline in 
neuromuscular function, and increased risk for injury [16-18]. In an e ffort to offset LBM loss, 
studies have incorporated exercise in conjunction with a weight loss program; however, this has 
only provided modest benefit , most likely due to the modest caloric expenditure experienced 
with moderate exercise [19, 20] . In general, it is recognized that for every 1 kg of FM lost, 
approximately 0.26 kg of lean tissue is lost in post -menopausal women [21]. Importantly, the 
lean mass lost is only partiall y regained with weight gain. There are no approved obesity 
interventions that preserve or build lean mass while promoting fat mass loss.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 41 of 112 
Bimagrumab is a recombinant human monoclonal antibody binding to the activin receptor type II 
(ActRII). Bimagrumab prev iously has been studied in muscle wasting indications and has been 
shown to increase  skeletal muscle mass in healthy volunteers, in patients with sporadic inclusion 
body myositis (sIBM), and in patients with sarcopenia.  
In a recent randomized double -blind,  placebo -controlled study including 75 overweight or obese 
patients with type 2 diabetes mellitus (T2DM), bimagrumab 10 mg/kg i.v. every 4 weeks for 48 
weeks in addition to lifestyle intervention, resulted in a marked loss in FM, an increase in LBM, 
and im provement in a range of metabolic biomarkers [5]. Participants lost 5.1 kg (p<0.001) body 
weight in the bimagrumab group vs. the placebo group with a decrease in placebo -adjusted WC 
of 9.5 cm (p<0.001). Patients lost 20.5% of FM, had a 3.6% increase in LBM, and had a decrease 
of 0.76 percentage points in their HbA1c levels, whereas placebo patients only had a decrease in 
total body FM of 0.5%, LBM reduction of 0.8%, and an increase of 0.04 percentage points in 
HbA1c levels. The loss in total body FM and gain in LBM led to net weight losses of 6.5% and 
0.8%  in patients receiving bimagrumab or placebo , respectively . Addition ally, greater reduction s 
in VAT  and hepatic fat fraction were observed in the bimagrumab group versus placebo  group . 
The expansion of the lean mass (i.e., skeletal muscle) compartment in t he presence of negative 
energy balance and weight loss is a novel feature in weight loss pharmacotherapy. Overall, 
adverse effects  (AEs) were balanced between the bimagrumab and placebo groups . Participants  
on bimagrumab vs. placebo reported more muscle sy mptoms, diarrhea and nausea. The 
frequency of gastrointestinal A Es was highest during the first dosing period with bimagrumab 
and diminished with repeat dosing. More patients in the bimagrumab group experienced transient 
elevations of pancreatic and liver enzymes, which tended to subside after the first dose of 
bimagrumab . The etiology of these elevations is unclear but could be related to mobilization of 
adipocyte triglycerides and amino acids as a new metabolic equilibrium is reached during early 
bimagrum ab dosing.  
The planned study is designed to evaluate the effect of bimagrumab alone or in addition to the 
approved obesity therapeutic semaglutide in obese or overweight participants with at least one 
obesity related co -morbidity, without T2DM. The main endpoint in the study is body weight . 
Other endpoints include waist circumference, body composition, and evaluation of the impact of 
treatment on metabolic parameters and safety.  
2.2. Background   
The activin type 2 receptors ActRIIA and ActRIIB, abbreviated as ActRII, modulate signals for 
ligands belonging to the transforming growth factor beta (TGF -Î²) superfamily . These included  
growth differentiation factor 8 (GDF8, myostat in), GDF11, and activin s, which are all negative 
regulators of skeletal muscle growth, acting via the ActRII receptor signaling pathway to inhibit 
muscle protein synthesis and myocyte differentiation and proliferation. A pharmacological way 
to block these ligandsâ€™ action to increase muscle mass and hence exercise capacity is through 
inhibition of ActRII [22]. Blockade  of ActRII resul ts in hypertrophy of skeletal muscle through 
an increase in size of existing myofibers [23-25], which in turn is hypothesized to improve 
peripheral insulin sensitivity, since skeletal muscle is one of the major glucose -utilizing tissues in 
the body [22]. 
Activin receptor signaling is also active in adipose tissue and contributes to the regulation of 
adipose tissue mass.  Adipocytes express the highest levels of the type 1  receptor ALK7 and are 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 42 of 112 
the major tissue source of activin B. In rodents, knockout of the ALK7 receptor decreases total 
fat mass and confers resistance to diet -induced obesity.  In humans, single nucleotide 
polymorphism s in the ALK7 gene are associated with lower BMI and resistance to obesity [26, 
27]. 
Bimagrumab, a recombinant human, monoclonal antibody (modified IgG, Î»2) binds 
competitively to the ActRII with a greater affinity than its natural ligands.  
Information currently available on pharmacology, toxicology, pharmacok inetics, and 
pharmacodynamics are reported in the Investigator  Brochure ( please refer to most recent edition ) 
and has been obtained from in vitro experiments, animal studies, toxicology studies, and human 
trials.  
2.2.1.  Preclinical Pharmacology   
The co -administration of CDD866, a murinized version of bimagrumab , with semaglutide was 
studied in obese C57Bl/6J mice . Animals were fed a high fat diet (60% of total caloric input as 
fat) for 20 weeks  and reached body weights of approximately 50 g rams ( twice normal ) at the 
time the therapeutic interventions were initiated.  The high fat diet was continued throughout the 
experimental period  and the two drugs were evaluated individually  and when co -administered , 
along with vehicle -alone groups . The primary  efficacy assessment was total body fat  mass  
determined  weekly by magnetic resonance spectroscop y. Each drug alone exhibited the expected 
effect on body  fat mass and lean mass and when administered together, the decrease in body fat 
mass was at least additive . Greater than  30% body fat mass loss was observed over 3 weeks with 
the co -administration of the two highest dose levels of bimagrumab and semaglutide. Other than 
the expected decrease in food intake in the semaglutide arms of the study, there were no safety or 
tolerability issues observed. Specifically, a quantitative open field test of behavior showed no 
significant differences between the drug -treated groups and vehicle -treated groups.  
Teratogenicity and Reproductive Toxicity Data  
In embryo -fetal development studies, bimagrumab was seen to be developmentally toxic in the 
rat and rabbit and teratogenic in the rat (NOAEL of 1 mg/kg). The exact mechanism, direct or 
indirect, underlying the reproductive organ changes observed with bimagrumab is unclear. A 
pre- and postnatal development (dose range -finding) study in the rat was terminated at the end of 
the weaning phase of pup development bec ause of a high incidence of litter death in the control 
animals (reason unknown). In rats dosed at 1 or 10 mg/kg there was an increase in the number of 
females unable to complete the process of parturition and an increase in the number of stillborn 
pups. T his observation was not seen in the control animals.  
Women of child -bearing potential , who are not post -menopausal or post -surgical sterilization , 
must use highly effective contraception during treatment and for 4 months after their last dose of 
bimagrumab due to the risk of teratogenicity and embryo -fetal death observed with bimagrumab 
in animals.  
Clinical studies evaluating single and multiple dos es of bimagrumab showed no difference in 
changes in testicular volume or sperm count or quality between male participant s receiving 
bimagrumab and those receiving placebo. Furthermore, m onoclonal antibodies are large 
molecules that do not readily (< 1%) pa ss the blood -testis barrier and are not readily excreted in 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 43 of 112 
seminal fluid. As  a result of this data, no contraception is required for male participant s 
participating in bimagrumab trials.  
2.2.2.  Clinical Data   
Human safety and tolerability  
Bimagrumab has been studied in Phase 2/3 clinical studies that have evaluated  the safety , 
tolerability, PK and efficacy of bimagrumab in different  populations, including  5 phase 2a/proof 
of concept studies (recovery from disuse, sporadic inclusion body myositis (sIBM), sarcopenia 
with mobility limitations, and cancer cachexia and chronic obstructive pulmonary disease 
cachexia ), two phase 2b studies (sarcopenia and hip fracture reco very) and one phase 2b/3 study 
in sIBM  patients . Study results to date indicate bimagrumab has a good safety profile; is 
generally well tolerated; has predictable nonlinear kinetics caused by target -mediated drug 
disposition; and reliably increases muscle volume and decreases adipose tissue levels. Body 
composition changes begin within 2 weeks of administration and continue throughout exposure 
in both healthy volunteers and patients regardless of age.  
Transient cases of episodic, involuntary muscle contract ions (referred to as â€œcramps or spasmsâ€), 
acne and diarrhea of mostly mild intensity have been observed in study participants  with 
symptoms occurring more frequently in participants receiving the highest doses of drug 
(30 mg/kg). Several participants have discontinued treatment in  earlier studies because of an AE 
(exacerbation of acne, muscle cramps or diarrhea). Data from a dedicated hormonal  study  
showed no effect on the hormonal axis except for a decrease in FSH levels in postmenopausal 
women with comple te resolution after bimagrumab  clearance. Data from a dedicated 24-week  
cardiac safety study indicated no effect of bimagrumab on multiple cardiac parameters  in the 
context of the expected skeletal muscle hypertrophy . 
Human pharmacokinetic data  
Bimagrumab exhibits a non -linear kinetic profile following single and repeat i.v. administrations , 
very likely caused by target -mediated drug disposition . The total clearance (CL) of bimagrumab 
is concentration -dependent and is the sum of linear CL and non -linear CL. The half -life is also 
concentration dependent. The half -life ranges from 19 days in the linear portion of the profile 
(high bimagrumab concentrations) to 5 days when the maximum CL is achieved. Based on 
graphical exploration, the nonlinear CL s aturation seems to occur below a threshold serum 
concentration of approximately 10 Î¼g/mL.  
Bimagrumab, like any human IgG antibody, is expected to be eliminated via intracellular 
catabolism, following fluid -phase or receptor mediated endocytosis. Since the majority of 
immunoglobulins undergo proteolytic degradation, bimagrumab is not expected to yield active 
metabolites.  Since bimagrumab is a human IgG with large molecular size (~150 kDa), little 
intact immunoglobulin can be filtered by the kidney, hence lit tle/no antibody is expected to be 
excreted in the urine.  
There was only limited evidence of an effect of the dietary protein intake on the PK of 
bimagrumab. PK profiles of b imagrumab in healthy volunteers of Japanese descent, older adults 
up to 83 years of  age, obese adults , and patients with sIBM were similar to those of healthy 
younger adults.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 44 of 112 
Human pharmacodynamic data  
Consistent, measurable increases in muscle size  have been observed in clinical studies. In 
healthy volunteers, single doses of 3, 10 and 30 mg/kg i.v. and repeat doses of 3 and 10 mg/kg 
resulted in gains in thigh muscle volume of +2.7 -

.:75*);-416-7>-:8 4)+-*7)<L	
?--3;
post dose. The increase in muscle volume was associated with improvements in physical 
function in patients with sIBM (+6.0%) in an early PoC study. The muscle increase was also 
seen in a recent Phase 3 study, but the improved function was not repeated. Patients with 
sarcopenia saw 8% increases in muscle volume 8 weeks after a single dose of 30 mg/kg, which 
resulted in clinically relevant improvements in muscle strength and mobility performance.   
Consistent, dose -dependent, linear decreases in total body fat measured by DXA have also been 
observed in clinical studies with bimagrumab. Reductions in fat mass of between 2.5 and 3.5 kg 
over 6 months occurred in participant s with sarcopenia , hip fracture , sporadic inclusion body 
myositis and in healthy volunteers participating in a cardiac safety study  and in elderly healthy 
participant s.  Efficac y results  in obese and overweight patients with T2D M are reported in 
Section  2.1. 
For more information on bimagrumab, please refer to the  most recent version of the  Investigator s 
Brochure .  For information on semaglutide, refer to the current Wegovy Â® or Ozempic Â® package 
insert.  
2.3. Benefit/Risk Assessment   
More detailed information about the know n and expected benefits and risks and reasonably 
expected adverse events (A Es) of bimagrumab can be found in the  Investigators Brochure  and in 
the Package Insert  for semaglutide.  
2.3.1.  Risk Assessment   
2.3.1.1.  Investigational Intervention Bimagrumab   
A total of 21 clinical studies including 3 extension studies have been conducted with 
bimagrumab, including  adults, with  receiving the bimagrumab. Dose levels ranged 
from 0.01 mg/kg to 30 mg/kg, with larger studies using 1 mg, 3 mg, and 10 mg/kg as i.v. 
infusion, s.c. injections of 2 mg/kg and fixed doses of  mg,  mg,  mg,  mg, and 
 mg; th e majority of  most  studies assessed i.v. infusions of 10 mg/kg and 30 mg/kg. 
Treatment durations ranged from single to multiple doses over 6 to 12 months. The longest 
continuous exposure  in obese adults with T 2DM was 12 months with doses of 10 mg/kg body 
weight (  mg maximum) and 12 -26 months in patients with sIBM.  
Muscle symptoms  
In a recent bimagrumab study in obese or overweight patients with T2D M, an increased AE 
incidence of muscle spasms (usually described as muscle cramps)  of  ( %), all mild 
( %) or moderate ( %)  in intensity  was observed  in the bimagrumab group .  ( %) 
participant reported muscle fatigue  and  ( %) reported muscle stiffness ; both were mild. 
The majority of the A Es were judged to be related to study drug by t he Investigator . In the 
placebo group there were 2 muscle events,  ( %) of muscle spasms and  ( %) of 
muscle twitching. In previous stud ies, in different indications, muscle symptoms were also seen 
$SSURYHGRQ$SU*07CCI CCI
CCI CCI CCI CCI
CCI
CCI
CCICCI CCI CCI
CCI CCI
CCI CCI CCI CCICCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 45 of 112 
in the form of muscle spasms, tightness and twitching . In general, m uscle symptoms are mostly 
mild or moderate, transient, painless, and of short duration . For the details of previous individual 
studies please refer to the Investigators Brochure . 
The etiology and clinical meaning of these observations a re not known. Similar symptoms  have 
been reported with at least one other anabolic molecule, a beta -2 adrenergic agonist [28] and are 
commonly reported by adults performing muscle buildin g exercise.  
Skin symptoms  
In the obesity study, in the bimagrumab group there w ere  ( %) participants with at least one 
AE of skin symptoms, while there were  ( % in the placebo group). All skin symptoms were 
mild. The re were   participants in the bimagrumab group who reported AEs of acne (1), blister 
(1), and rash (2).  
In previous studies, in different indications, skin symptoms were seen mostly in the form of acne 
and rash. In general, skin symptoms are mostly mild or moderate, transient, painless , and of short 
duration. For the details of previous individual studies please refer to the current edition of the  
Investigators Brochure . 
Acne has been confirmed in these studies by dermatology consult and biopsy. Treatment has 
been successful with good skin hygiene using a 4 -10% benzoyl peroxide wash and over the 
counter topical treatments. On occasion, a  prescription, topical or oral antib iotic (i.e., 
minocycline 100 mg bid), was recommended. However, early standard of care intervention is 
recommended in participants when acne pr esents. A possible mechanistic link between 
bimagrumab and skin reactions remains unclear.  
Diarrhea  
In the obesit y study, diarrhea was reported in  participants ( %, % mild, % 
moderate) in the bimagrumab group  versus  ( %, % mild, % moderate) participants in 
the placebo group. Diarrhea has also been observe d more frequently in other studies in d ifferent 
indications.  
Reproductive organs  
Data from a dedicated hormonal study demonstra ted no clinically or statistically significant 
effect of  bimagrumab  on circulating  testosterone  levels  and no effect  on pituitary -adrenal axes in 
either gender and minimal effect on the pituitary -gonadal axes in men. Suppression of FSH 
levels in postmenopausal women  and premenopausal  women  of non-childbearing  potential  has 
been  observed  with no associated safety risk identified. However, in p remenopausal  women  
with an IUD  there is an associated  risk of disruption  of menstrual cycle s. All effects were 
transient and resolved after bimagrumab  exposure ended. Semen analysis  data from the multiple 
dose study suggest that three doses of  10 mg/kg have no effect on spe rm count or quality  in 
males.  
Women of childbearing potential must us e highly efficacious contraception (see study eligibility 
criteria , Section  5). 
  
$SSURYHGRQ$SU*07CCICCI
CCICCI
CCI
CCICCI CCICCI
CCICCICCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 46 of 112 
Immunogenicity  
A treatment  related  anti-drug antibody (ADA) response has been observed  infrequently  in 
participant s treated with bimagrumab. Nevertheless, there was no evidence of an infu sion or 
hypersensitivity  reaction that could be related to immunogenicity or any sign of immune 
complex formation in the clinical trials performed so far. No positive signal in the 
immunogenicity assay was  accompanied  by a change  in the bimagrumab  PK profile.  
Lipase and amylase elevations, and pancreatitis  
Observations of dose -dependent, transient, elevations of lipase and/or amylase  have been 
identified in several studies in the bimagrumab clinical program. The biological  explanation for  
this temporal rise in pancreatic enzymes seen in some individuals is not yet  fully  understood.  
As of 1 March 2022, 4 participants in 3 studies have experienced acute pancreatitis among  
participants administered bimagrumab. All 4 participants recover ed from the acute pancreatitis, 2 
discontinued study drug and 2 were considered to be related to study treatment. One participant 
on placebo experienced pancreatitis. To reduce the potential  risk of elevated  pancreatic  
enzymes and pancreatitis, study  participants with acute or chronic pancreatitis or with elevated 
amylase and/or lipase will be excluded as per Section  5.2. 
2.3.1.2.  Semaglutide ( WegovyÂ® , Ozempic Â®)  
Risk of Thyroid C -Cell Tumors  
In mice and rats, semaglutide caused a dose -depend ent and treatment -duration -dependent 
increase in the incidence of thyroid C -cell tumors (adenomas and carcinomas) after lifetime 
exposure at clinically relevant plasma exposures . It is unknown whether semaglutide  causes 
thyroid C -cell tumors, including med ullary thyroid carcinoma (MTC), in humans, as human 
relevance of semaglutide -induced rodent thyroid C -cell tumors has not be en determined. Cases 
of MTC in patients treated with liraglutide, another GLP -1 receptor agonist, have been reported 
in the post  marketing period; the data in these reports are insufficient to establish or exclude a 
causal relationship between MTC and GLP -1 receptor agonist use in humans.  
Acute pancreatitis  
Acute pancreatitis, including fatal and non -fatal hemorrhagic or necrotizing pa ncreatitis, has 
been observed in patients treated with GLP -1 receptor agonists, including semaglutide. Acute 
pancreatitis was observed in patients treated with semaglutide  in clinical trials . After initiation of 
semaglutide , observe patients carefully for signs and symptoms of acute pancreatitis (including 
persistent severe abdominal pai n, sometimes radiating to the back, and which may or may not be 
accompanied by vomiting). If acute pancreatitis is suspected, semaglutide  should promptly be 
discontinued, an d appropriate management should be initiated. If acute pancreatitis is confirmed, 
semaglutide  should not be restarted.  
Acute Gallbladder Disease  
In WegovyÂ®  randomized clinical trials, cholelithiasis was reported by % of semaglutide  -
treated patients and % of placebo -treated patients. Cholecystitis was reported by % of 
semaglutide  -treated patients and % of placebo -treated patients. Substantial or  rapid weight 
loss can increase the risk of cholelithiasis; how ever, the incidence of acute gallbladder disease 
$SSURYHGRQ$SU*07CCI
CCI
CCI CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 47 of 112 
was greater in semaglutide  -treated patients than in placebo -treated patients, even after 
accounting for the degree of weight loss. If cholelith iasis is suspected, gallbladder investigations  
and appropriate clinical follow -up are indicated.  
Hypoglycemia  
Semaglutide  lowers blood glucose and can cause hypoglycemia . In a trial of patients with type 2 
diabetes and BMI greater than or equal to 27 kg/m2, hypoglycemia (defined as a plasma glucose 
less than 54 mg/dL) was reported in % of semaglutide -treated patients vers us % of 
placebo -treated patients. One episode of severe hy poglycemia (requiring the assistance of 
another person) was reported in one semaglutide -treated patient versus no placebo -treated 
patients.  
Inform patients of the risk of hypoglycemia and educate  them on the signs and symptoms of 
hypoglycemia.  
Acute Kidney Injury  
There have been post marketing  reports of acute kidney injury and worsening of chronic renal 
failure, which have in some cases required hemod ialysis, in patients treated with semaglutide.  
Patients with renal impairment may be at greater risk of acute kidney injury, but some of these 
events have been reported in patients without known underlying renal disease. Most  of the 
reported events occurred in patients who had experienced nausea, vomi ting, or diarrhea, leading 
to volume depletion . 
Monitor renal function when in itiating or escalating doses of semaglutide  in patients reporting 
severe adverse gastrointestina l reactions. Monitor renal function in patients with renal 
impairment reporting an y adverse reactions that could lead to volume depletion.  
Hypersensitivity  
Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported with 
semaglutide. If hypersensitivity re actions occur, discontinue use of semaglutide , treat promptly 
per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a 
previous hypersensitivity to semaglutide or any of the excipients in semaglutide . Anaphylaxis 
and angioedema have been reported with other GL P-1 receptor agonists.  
Use caution in a patient with a history of anaphylaxis or angioedema with another GLP -1 
receptor agonist because it is unknown whether su ch patients will be predisposed to these 
reactions with semaglutide . 
Diabetic Retinopathy Compli cations in Patients with Type 2 Diabetes  
In a trial of patients with T2DM and BMI greater than or equal to 27 kg/m2, diabetic retinopathy 
was reported by % of semaglutide -treated patients and % placebo -treated patients.  
In a 2 -year trial with semaglu tide 0.5 mg and 1 mg once -weekly injection in patients with type 2 
diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in patients 
treated with semaglutide injection ( %) co mpared to placebo ( %). The absolute risk 
increa se for diabetic retinopathy complications was larger among patients with a history of 
diabetic retinopathy at baseline (semaglutide  injection %, placebo %) than among patients 
without a known history of diabetic retinopathy (semaglutide injection %, placebo %).  
$SSURYHGRQ$SU*07CCI CCI
CCI CCI
CCI CCI
CCI CCI
CCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 48 of 112 
Rapid improvement in glucose control has been  associated with a temporary worsening of 
diabetic retinopathy. The effect of long -term glycemic control with  semaglutide on diabetic 
retinopathy complications has not been studied. Patients wi th a history of diabetic retinopathy 
should be monitored for progre ssion of diabetic retinopathy.  
Heart Rate Increase  
Mean increases in resting heart rate of 1 to  4 beats per minute (bpm) were observed in 
semaglutide -treated patients compared to placebo in  clinical trials. More patients treated with 
semaglutide  compared with placebo had maximum changes from baseline at any visit of 10 to 19 
bpm ( % versus %, respectively) and 20 bpm or more ( % versus %, respectively).   
Instruct patients to inform the ir healthcare providers of palpitations or feelings of a racing 
heartbeat while at rest during semaglutide  treatment. If patients experience a sustained increase 
in resting heart rate, discontinue semaglutide . 
Suicidal Behavior and Ideation  
Suicidal behavi or and ideation have been reported in clinical trials with other weight 
management products. Monitor patients treated with semaglutide  for the emergence or worsening 
of depression, suicidal thoughts or behavior, and/ or any unusual changes in mood or behavi or. 
Discontinue semaglutide  in patients who experience suicidal thoughts or behaviors. Avoid 
semaglutide  in patients with a history of suicidal attempts or active suicidal ideation.  
Adverse reactions  
Semaglutide  was evaluated for safety in 3 randomized, do uble-blind, placebo -controlled trials 
that included  patients with overweight or obesity treated with semaglutide  for up to 68 
weeks and a 7 week off drug follow -up period. In clinical trials, % of patients treated with 
semaglutide  and % of patie nts treated with placebo permanently discontinued treatment as a 
result of adverse reactions. The most common adve rse reactions leading to discontinuation were 
nausea ( % versus %), vomiting ( % versus %), and diarrhea ( % versus %) for 
semaglutide  and placebo, respectively. The most frequent adverse events reported as AEs were 
nausea/vomiting reported in % / % respectively of patients on semaglutide  versus  % / 
% of patients on patients treated with placebo. Diarrhea/constipation was reported in % / % 
respectively of patients on semaglutide  and % / % of patients on placebo. Abdominal pain 
was reported in % of patients on semaglutide  and % on placebo.  
2.3.1.3.  Study Procedures   
Infusion risks  
Infusion -related reactions can occur with monoclonal antibodies. Hypersensitivity reactions can 
manifest as fever, chills, urticaria, dyspnea, headaches, myalgia and/or hypotension. No serious 
infusion reaction (anaph ylaxis ) has been seen in patients treated with bimagrumab . If a severe 
hypersensitivity reaction occurs, administrati on of bimagrumab should be discontinued and 
appropriate therapy initiated.  
Dual -Energy  X-ray Absorptiometry  (DXA)  
DXA scans in this study will be used to assess  bone mineral density and body composition  (i.e., 
fat and lean mass) . The effective radiation  dose of a DXA whole body scan on an adult is 2.1 
$SSURYHGRQ$SU*07CCI CCI CCI CCI
CCI
CCI
CCI
CCI CCI CCICCICCI CCI
CCI CCI CCI
CCICCI CCI
CCI CCI
CCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 49 of 112 
ÂµSv. Therefore, the total  amount of radiation exposure per participant  from 6 DXA scans will be 
about 12.6 ÂµSv over a period of  96 weeks . This amount of radiation is less than 14 days of 
background exposure  (approximately 0 .03 ÂµSv per hour at sea level).  For effective  radiation  
doses  under  3 ÂµSv (300 mrem),  the risk is considered  to be minimal [29]. Therefore,  the    
radiation exposure in this study involves minimal risk.  
2.3.2.  Benefit Assessment   
All participant s enrolled in the study may benefit from lifestyle  interventions including diet and 
physical activity, and regular monthly contact with the site staff. Potential benefits associated 
with bimagrumab and semaglutide are described below . 
2.3.2.1.  Bimagrumab   
Based on  recent  clinical data  in overweight and obese diabetic participants , treatment with 
bimagrumab in non -diabetic obesity is expected to result in decrease d body weight and  waist 
circumference, with improved body composition resultin g from loss of fat mass and increase of 
lean mass . In the diabetic  participant  study , bimagrumab also result ed in reduction in visceral fat 
mass, reduction in hepatic fat fraction, and improved insulin sensitivity and glucose control .  
Bimagrumab in combination with semaglutide may mitigate the loss of lean mass.  
2.3.2.2.  Semaglutide   
Semaglutide is approved in the USA  and the EU as a chronic weight management treatmen t in 
obese or overweight adults . Once weekly  s.c. semaglutide result s in substantial percentage 
change and absolute change in body weight as reported in a recent meta -analysis  [4]. Compared 
with placebo, once weekly  semaglutide also led to superior reductions in  body weight,  waist 
circumference and BMI compared with placebo ; however, losses in lean mass (approximately 
10%) were also observed  [30]. Furthermore, the effect on improving other cardiometabolic risk 
factors and health -related quality of life was more pronounced for once -weekly semaglutide 
relative to placebo.  
2.3.3.  Overall Benefit Risk Conclusion   
Considering  the measures take n to minimize risk to participants participating in this study, the 
potential risks identified in association with bimagrumab are justified by the anticipated benefits 
that may be afforded to participants who are obese or overweight.  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 50 of 112 
3. OBJECTIVES, ENDPOINTS, AND ESTIMANDS   
Table  1: Table of Objectives and Endpoints  
OBJECTIVE S ENDPOINTS  
Primary Objective  
1. To assess the treatment effect of 
bimagrumab , semaglutide,  and 
bimagrumab  in addition to 
semaglutide vs placebo on body 
weight  1. Change  from baseline in total body weight  at 48 weeks  
 
OBJECTIVE S ENDPOINTS  
Secondary Objectives  
1. To assess the treatment effect of 
bimagrumab, semaglutide, and 
bimagrumab in addition to 
semaglutide vs placebo on waist 
circumference (WC ) 1. Change from baseline in WC (cm) at 48 and 72 weeks  
2. To assess treatment effects on  fat 
mass , visceral adipose tissue  (VAT) , 
trunk  fat mass , subcutaneous 
adipose tissue (SAT), and lean mass  
(body composition)  2.    a. Change from baseline at 48 and 72 weeks in total 
body fat mass (kg and % body fat) by DXA  
b.  Change from baseline at 48 and 72 weeks in  VAT , 
SAT, and trunk fat mass (kg) by DXA  
c.  Proportion of participants who achieve a reduction 
from baseline at 48 weeks in the following measures of 
obesity : 
i. WC â‰¥ 5 cm  
ii. Body weight â‰¥ 5% , â‰¥ 10% , and â‰¥ 15% 
iii. Fat mass â‰¥ 5% , â‰¥ 10% , and 15%  by DXA  
iv. Fat mass â‰¥ 10% with <5% decrease (or 
an increase) in lean mass  by DXA  
d.  Percentage of weight loss due to fat mass or lean 
mass  at 48 weeks  by DXA  
e.  Change from baseline at 48 and 72 weeks in fat 
mass (kg and %  body fat ) by bioelectrical impedance 
analy sis (BIA)  
f.  Change from baseline at 48 and 72 weeks in total 
body lean mass (kg and % body lean) by DXA and 
BIA and appendicular lean mass by DXA  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 51 of 112 
3. To assess the safety and tolerability 
of bimagrumab, semaglutide and 
bimagrumab in addition to 
semaglutide  3. Safety and tolerability measurements throughout 48 
weeks : 
a. Incidence and severity of treatment emergent 
adverse events (TEAEs), treatment -related AEs, 
serious adverse events (SAEs) and evaluation of 
TEAEs of special interest (including significant 
muscle , skin, and gastrointestinal  TEAEs, 
malignancy, and pancreatitis)  
b. Clinical safety laboratory evaluation , including 
anti-drug antibodies  (ADA ) 
c. Vital signs (temperature, blood pressure, pulse rate) 
4. To assess the proportion of patients in 
each treatment group experiencing a change in the categorical classification of obesity based on 
BMI and waist -to-height  ratio 
(WHt R) group  4. Proportion of patients with change from baseline in 
categorical classification of obesity at any time up to 
48 weeks : 
a. BMI categories:  
i. Healthy weight:   18.5 kg/m2 to 24.9  kg/m2 
ii. Overweight:         25 kg/m2 to 29.9 kg/m2 
iii. Obesity class 1:    30 kg/m2 to 34.9 kg/m2 
iv. Obesity class II:   35 kg/m2 to 39.9 kg/m2 
v. !*-;1<A+4);;D kg/m2 
b.     WHtR ratio categories: <0.5; 0.5- 
D [1] 
5. To assess treatment effects on 
glucose metabolism  5. Change from baseline in HbA1c at 48 weeks 
6. To assess treatment effects on self-
reported health status and weight-
related quality of life  6. Change from baseline at 24,48, and 72 weeks in: 
a. Quality of Life Short Form 36 survey (SF -36) total 
score and physical functioning score  
b. Impact of Weight on Quality of Life -Lite for 
Clinical Trials survey (IWQoL -Lite for CT)  total 
score and physical function score 
  
 
 
 

  
 
  
 
$SSURYHGRQ$SU*07CCI
CCICCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 52 of 112 
3.1. Estimands   
The primary estimand will quantify the average tr eatment effect of bimagrumab, semaglutide or 
a combination of bimagrumab with semaglutide relative to placebo after 48 weeks, in  all 
randomized participants  who received at least one dose of study treatment , regardless of 
adherence to treatment and regardless of intercurrent events %01;.7447?;<0-G<:-)<5-6<8741+AH
strategy which closely adheres to full analysis set (FAS) with an intention -to-treat (ITT) 
population.  
The following expansion of the primary estimand w ill quantify the averag e treatment effect of 
combination treatment of semaglutide with bimagrumab relative to each monotherapy of the 
same dosage strength after 48 wee ks, in all randomized participants regardless of adherence to 
treatment and regardless of intercurrent events (ICE) . 
As a sensitivity analysis, t he primary estimand will also be assessed using the Gtrial product  or 
hypothetical -;<15)6,H  to quantify the average treatment effect  in all participants  who adhered to 
treatment and  did not experience any ICEs . Intercurrent events will be detailed in the SAP.  
3.1.1.  Estimands of Secondary Objectives   
The estimands of the secondary objectives will follow the treatment policy strategies outline d for 
the primary estimand.  Details of the secondary es timands and the ICEs that are relevant will be 
provided in the SAP.  
Statistical an alyses for the treatment extension and post -treatment follow -up periods will be 
detailed in the SAP.   
  
 
 
  
 
 
  
 
 
  
 
 
  
 
 
 
 
 
  
  
 
 
  
 
 
 
$SSURYHGRQ$SU*07CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 53 of 112 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 54 of 112 
4. STUDY DESIGN   
4.1. Overall Design   
This is a non-confirmatory, randomized, double -blind, placebo -controlled (for bimagrumab) 
multi -center study of i.v. bimagrumab, alone or in addition to open label s.c. semaglutide , to 
investigate the efficacy and safety in  adult men and women  between the ages of 18 and 80, 
inclusive, who are ob ese or who are overweight with at least one obesity related co -morbidity.  
Women  must be post-menopausal , post-surgical ly sterilized  or using an intrauterine device.  
 participants  are planned to be enrolled and randomized to 1 of 9 treatm ent 
arms (see Section  6.1). 
The total study duration will be approximately 104 weeks and will consist of an up to 6 -week 
screening period, a 72-week treatment period  (48 weeks core followed by 24 weeks of 
extension), and a 32 -week post-treatment follow -up period . Overview of the study design can be 
found in the study schema in Section  1.2. 
Screening (Week -6 to day -1) 
Potential participants will undergo the screening activities listed in the Schedule of Activities  
(SoA)  Section  1.3 to determine their eligibility for the study (see enrollment criteria Section  5).  
Screening assessments that a re outside of the Week -6 to Day -1 window may be repeated once . 
The Investigator  must recommend a li festyle intervention [31] that includes dietary counseling 
for weight loss with a daily caloric deficit of approximately 500  kcal and with protein intake of 
at least 1.2 g/kg/day to support muscle anabolism.  Participants will also be encouraged to 
exercise for at least 150 minute s per week . 
These lifestyle interventions will be explained during the screening visit and initiated at the 
baseline visit.  
Baseline  (Day 1, up to 15 minutes prior to dosing ) 
Eligible participants will return to clinic to undergo baseline assessments as defined  in the SoA 
Section  1.3. Baseline assessments must be completed  prior to dosing.  DXA scans may be 
performed up to 14 calendar days prior to dosing.  
During this visit, participants will be provided with an  device in the form of a  wrist  
band . Participants will be advised to wear the band at all times for the entire course of the study.  
The band  should be removed during showering and  may be removed during sleep if desired . 
Site staff will assist participants with downloading study  application s on their mobile phone  that 
will send visit reminders, collect patient reported outcomes and provid e gene ral study 
information to the participant . 
Randomization and Dosing (Day 1)  
Upon completion of all baseline activities, e ligible participants  will be randomized to one of the 
9 treatment arms listed in Section  6.1. 
Bimagrumab or placebo will be administered  i.v. over a period of ~ 30 minutes, followed by 
flushing for ~15 minutes and a  15-minute  post-flush  observation period that will include  safety 
$SSURYHGRQ$SU*07CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 55 of 112 
and tolerability observations and PK  sampling.  Bimagrumab will be dosed based on the previous 
visit body weight at 10 mg/kg  or 30 mg/kg depending on the assigned treatment arm . 
Participants assigned to semaglutide treatment arms will receive their first dose o f semaglutide in 
clinic, along with training on how to store semaglutide pens and self -administer injections at 
home.  
Following all assessments, participants  may be discharged from the Investigator  site when the 
Investigator  judges them to be medically sta ble, in good general health , and not needing further 
observation.  
Participants assigned to semaglutide treatment arms will be sent home with a semaglutide pen  (to 
be self -administered, once weekly) , disposal containers and inst ructions to return  any unused  
pens to clinic at their next scheduled visit.  
Core Treatment Period (Weeks 1 to 48) 
For the duration of the core treatment period, participants should : 
 Follow the dietary and exercise  recommendations prescribed  by the Investigator . 
 Wear the band.  
 Complete weekly eDiaries.  Occasional missed diaries are permissible in the absence 
of persistent non -compliance.  
For participants assigned to semaglutide arms, self -administer weekly semaglutide injections and 
return all used and unused pens at their next clinic visit.  
Participants will return to clinic : 
 at Weeks 4 , 16, 28 and 40  for i.v. bimagrumab or placebo dosing . Additional 
assessments will be performed as detailed in the SoA  Section  1.3. 
 at Weeks 12, 24, and 48 for DXA scan ning and other assessments detailed in the SoA 
Section  1.3. 
Site staff will call participants at Weeks 2, 8, 20 , 32, 36, and 44  to ensure  there are no safety 
issues and to address any questions the participant  may have.  
Qualified dieticians will reac h out to participants on a monthly basis to provide dietary and 
exercise counseling , and to calculate participant J; dietary  intake via 24 -hour recall assessment  
(see study operation s manual  for detailed description) . If desired, t hese touchpoints may be 
combined with the in -clinic  visits or safety calls.  
Should participants report any adverse events over the phone, these will be recorded in the 
eCRF.  
Open Label Extension Treatment Period (Weeks 49 to 72)  
The open label extension tr eatment period will be conducted similarly to the  core treatment 
period described above , however , participants randomized to study treatment arms 1 
(bimagrumab placebo) and 4 ( bimagrumab 10 mg/kg)  will switch treatment to bimagrumab 30 
mg/kg  at Week 52.  Dispensing of drug product  in a manner that maintains the blind is described 
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 56 of 112 
in Section  6.4.4 . Note, the extension treatment period will be made open labe l after the 48-week 
database lock and study unblinding.  
For the duration of the extension treatment period, participants should continue to follow dietary 
and exercise recommendations, wear t he  band, complete the weekly eDiaries, and 
must self-administer weekly semaglutide (for participan ts assigned to semaglutide arms) as in the 
core treatment period.  
Participants will return to clinic  at Weeks 52 and 64 for i.v. bimagrumab or placebo dosing. 
Additional assessments will be perform ed as detailed in the SoA Section  1.3. Note : no placebo 
infusions will be adminis tered to treatment arms 2 and 3 after the study is made open label , e.g., 
after the Week 48  database lock and study unblinding.  
Site staff will call participants at Weeks 56, 60, and 68 as described above.  Should participants 
report any adverse events ove r the phone, these will continue to be recorded in the eCRF.  
Qualified dieticians will continue to counsel  participants on a monthly basis as described above.  
End of Treatment Visit (End of Week 72)  
Participants will return for the End of Treatment (EOT) Visit  at the end of Week 72 or at the 
time of early termination  to perform DXA scan and other assessments as detailed in the SoA 
Section  1.3.  If study intervention is permanently discontinued  early , the EOT  visit should be 
conducted as soon as possible, per Section  7.1. 
Post-Treatment Follow -Up Period (Weeks 73 to 104) 
Upon completion of the EOT  visit, all study treatment will be  withdrawn (bimagrumab/placebo 
and semaglutide) and participants will be followed for an additional 32 weeks.  
For the duration of the post-treatment follow -up period , participants should follow dietary and 
exercise recomm endations, wear the  band, a nd complete the weekly eDiaries.   
Participants will return to clinic at Weeks 84 and 96 for efficacy and safety assessments to be 
performed as detailed in the SoA Section  1.3. 
Site staff will call participants at Weeks 76, 80, 88, 92 , and 100, as described above.  Should 
participants report any adverse events over the phone, these will continue to be recorded in the 
eCRF.  
Qualified dieticians will continue to counsel  participants on a monthly basis as described above.  
Participants will return f or their end of treatment follow up visit at the end of Week 96 for DXA 
scan and other assessments detailed in the SoA Section  1.3. 
End of Study Vis it (End of Week 104) 
Participants will return for their final  end of study (EOS) visit at the end of Week 104 for vital 
sign and BIA measurements .  During this visit , site staff should assist participants in removing 
study -specific applications from their personal devices.  
If study intervention is permanently discontinued early  during one of the treatment periods , the 
EOT  visit should be conducted  at that time , followed by an EOS visit at least 12 weeks after the 
last dose of bimagrumab or placebo.  
$SSURYHGRQ$SU*07CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 57 of 112 
If study participation is permanently discontinued early during the post -treatment follow -up 
period, the EOS  visit should be c onducted at least 12 weeks after the last dose or bimagrumab or 
placebo . 
4.2. Scientific Rationale for Study Design   
The design of this Phase 2 study addresses the primary and the key secondary objectives of 
assessing if the efficacy of bimagrumab i.v. admini stered in addition to semaglutide s.c. is 
superior to either drug administered alone or to placebo and if the efficacy of bimagrumab i.v. is 
superior to s.c. semaglutide.  
The ra tionale for key  elements of the study  design include:  
 Randomization : To provide equal access to any of the treatment arms regar dless of 
gender, age, or baseline characteristics . 
 Stratification : To decrease the chance of an imbalance in gender across treatm ent 
arms  
 Triple -blind with regards to bimagrumab : The participant , Investigator  and 
Sponsor  will be blinded to bimagrumab dose and placebo -bimagrumab to avoid bias 
in adverse event and efficacy reporting, and to avoid any potential confounding effect 
of intentional and unintentional behavioral changes by participants.  
 Open  label with regard s to semaglutide:  Commercially available sem aglutide will 
be used in the study.  Because it is delivered in a pre -filled syringe, package d and 
labeled by the manufacturer , it is not possible to blind semaglutide.  The inclusion of 
two doses: a very low dose 1.0 mg and the registered dose of 2.4 mg , as well as the 
addition of the double -blinded bimagrumab treatment to all semaglutide doses, should 
mitigate the risk of bias. 
 Placebo arm : Inclusion of a placebo group will allow the analysis of whether or not 
bimagrumab treatment is more effective th an a standard treatment approach based on 
lifestyle intervention.  
 Primary endpoint : The FDA guidance for phase 3 clinical tri als in weight 
management recommends that in general, a product can be considered effective for 
weight management if after 1 year of treatment either of the following occurs:  
 The difference in mean weight loss between the active -product and placebo -
treated groups is at least  percent and the difference is statistically significant  
or 
 The proportion of participant s who lose greater than or equal to  percent of 
baseline body weight in the active -product group is at least  percent, is 
approximately t he proportion in the placebo -treated group, and the 
difference between groups is  statistically significant . 
For phase 2  clinical trials, the FDA guidance states that primary efficacy endpoint s 
should include a comparison of the mean absolute or percent change in body weight 
between the ac tive-produc t and placebo -treate d groups.  
$SSURYHGRQ$SU*07CCI
CCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 58 of 112 
ï‚· Population: Men and women, fulfilling the criteria with regards to overweight and 
obesity from the FDA Draft Guidance [32] of being at significant risk for weight -
related morbidity and mortality, and who have already tried and failed lifestyle 
modifications. Bimagrumab is teratogenic in animal studies, therefore women who 
are not post -menopausal or post -surgical ly steriliz ed must meet  the relevant  eligibility  
criteria  to minimize the risk that women  of child -bearing potential  experience a 
contraceptive failure or should wish to become pregnant.  
ï‚· Treatment e xtension : Continued weight loss  may not be observed during the 2nd 
year of w eight loss treatment, as demonstrated in the STEP  5 study [33].  The 
extension treatment period in the current study will compare the results of 
bimagrumab and/or semaglutide treatment for continued weight loss and fat mass 
reduction in the 2nd year of treatment.  
ï‚· Post-treatment follow -up:  Prevention of weight regain following successful weight 
loss is a key challenge for obesity management .  After withdrawal of treatment, 
weight regain is common  for method s of weight loss  dependent on reduced caloric 
intake . One year after withdrawal of semaglutide, for example, participants in the 
STEP 1 trial regained two -thirds of their  prior weight loss ( Wilding  2022).   The post -
treatment follow -up period in the current study will compare the results of 
bimagrumab and/or  semaglutide  in maintenance of weight loss and composition of 
weight regain . 
4.3. Justification for Dose   
4.3.1.  Bimagrumab Doses   
This study will evaluate two doses of bimagrumab 10 mg /kg and 30 mg/kg  i.v., administered at 
baseline, Week s 4, 16, 28, 40, 52, and 64 . 
The dose of bimagrumab , 10 mg/kg  i.v., administered to healthy volunteers and  to obese/  
overweight  participant s provide d exposure levels above 10 Î¼g/mL , at which the anabolic effect is 
observed , with levels maintained over the dosing interval of 4 weeks . PK/PD modelling has 
predicted that with dosing  of 10 mg/kg  at baseline , 4 weeks  and 16 weeks , exposures will drop 
below 10 ug/mL for approximately half the time through 24 weeks and result in  fat mass loss es 
intermediate between those expected in the placebo group and the 30 mg/kg group.  The 
10 mg/kg dose group has been included to help determine  whether a lower dose of bimagrum ab, 
when added to semaglutide, might result in near -maximal efficacy, superior tolerability, or both.  
The 30 mg/kg i.v. dose was administered  as 2 doses 8 weeks apart  in healthy volunteers and in 
patients with chronic obstructive lung disease with cachexia . A 30 mg/kg dose of  bimagrumab is 
expected to achieve circulating levels sufficient to block the ActRIIB receptor (greater than 
~10 Î¼g/ml) over nearly all dosing intervals. A serum  level of bimagrumab above this threshold 
resulted in an increase in thigh muscle volume in  healthy volunteers.  
The loading doses of bimagrumab  4 weeks apart  is supported from a safety perspective by the 
findings from both the 13 -week  and 26-week toxicity studies with maximum exposure of 14 
weekly doses of 100  mg/kg. AUC  and C max values of the 100 mg/kg i.v. dose level in the 
cynomolgus monkey toxicity studies  are approximately 3 and 6 times greater than that expected 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 59 of 112 
in humans from a secon d i.v.  dose of 30 mg/kg of bimagrumab 8 weeks apart (14,710 Pg/day/mL 
vs. 5340  Pg/day/mL and  4480  Pg/mL vs. 726 Pg/mL). While this is the first time bimagrumab 
will be administered as seven 30 mg/kg doses, it is considered safe based on the 13- and 26 -week  
toxicity study results  and the clinical data noted previously .  The PK/PD modeling predicts the 
30 mg/kg doses at baseline, and Weeks 4, 16, 28, 40, 52, and 64  will maintain exposures above 
10 Pg/mL over nearly the entire 12-week interval between doses  and yield a near-maximal 
treatment effect on fat mass loss.  
Participants in  core treatment  arms 1 (placebo; no semaglutide)  and 4 (bimagrumab 10 mg/kg; no 
semaglutide) will be switched to the higher dose of bimagrumab (30 mg/kg) during the 24 -week 
extension period in order to allow  these  participants to receive a dose of bimagrumab predicted 
to achieve maximal treatment effect  during the 2nd year. 
4.3.2.  Semaglutide Doses   
Semaglutide is a glucagon -like peptide -1 (GLP -1) receptor agonist  indicated as an adjunct to a 
reduced calorie diet and increased physical  activity for chronic weight management  in adult 
patients with an initial  BMI of 30 kg/m2 or greater (obesity) or 27  kg/m2 or greater (overweight) 
in the presence of at least  one weight -related comorbid condition (e.g.,  hypertension,  type 2 
diabetes mellitus, or dyslipidemia) . 
Semaglutide is administered  s.c. once weekly, on the same day each week, at  any time of day, 
with or without meals . Treatment is i nitiate d at 0.25 mg once weekly for 4 weeks. In 4-week  
intervals,  the dose unit is increased until a dose of 2.4 mg is reached . The maintenance dose of 
WegovyÂ®  is 2.4 mg once weekly . In this study the higher  dose of semaglutide is the approved 
dose for obesity , while th e lower dose of 1.0 mg s.c. per week  is an approved dose for diabetes , 
and is  predicted to yield body weight loss intermediate between no semaglutide an d the 2.4 mg 
dose. The  1.0 mg dose group has been included to help determine whether a lower dose of 
semaglutide,  when added to bimagrumab , might result in near-maximal efficacy, superior 
tolerability, or both.  
4.4. End-of-Study Definition   
The end of the study is defined as the date of the last scheduled procedure shown in the schedule 
of activities for the last participant in the study , globally . 
A participant is considered to have completed the study if the participant has completed all 
periods of the study including the last scheduled procedure shown in the SoA  Section  1.3. 
5. STUDY POPULATION   
 overweight/obese men  and women  aged 18 F 80 years (inclusive) will be 
enrolled in the study.  
The Investigator  must ensure that all participants  being considered for the study satisfy  the 
inclusion/exclusion  criteria. No additional criteria should be applied by the Investigator , in order 
that the study population will be representative of all eligible participant s. 
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 60 of 112 
Participant  selection is to be established by checking through all eligibility criteria at screening 
and baseline. A relevant record (e.g., checklist) of the eligibility criteria must be stored with the 
source documentation at the study site.  
Deviation from any entry criterion  (inclusion and exclusion)  excludes a participant  from 
enrollment into the study.  
Prospective approval of protocol deviations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not pe rmitted.  
5.1. Inclusion Criteria   
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. A written informed consent must be obtained before any study -related assessment s are 
performed . 
2. Men and women between 18 and 80 years, inclusive; women of child -bearing potential 
(defined as those who are not post -menopausal or post -surgical sterilization ; see 
Section  10.4 Appendix 4 ) must meet both of the following criteria:  
ï‚· Two negative pregnancy tests (at screening and at randomization , prior to dosing ) 
ï‚· Use of intrauterine device, from at least 3 months before the baseline visit through at 
least 4 months after the last dose of bimagrumab/placebo i.v. , and an  additional  
contraceptive (barrier) method  from screening  through at least 4 months after the last 
dose of  bimagrumab/placebo  i.v. 
3. Body mass index (B MI) â‰¥ 30 kg/m2 or â‰¥ 27  kg/m2 with one or more obesity -associated 
comorbidities (e.g., hypertension, insulin resistance, sleep apnea,  or dyslipidemia).  
4. Stable body weight (Â± 5 kg) within 90 days  of screening , and body weight <150  kg. 
5. Have a history of at least one self-reported unsuccessful behavioral effort to lose body 
weight.  
6. Capable of using common software applications on a mobile device (smartphone) . 
7. Access to an internet -enabled smartphone, tablet,  or computer for the duration of the 
study, meeting minimal op erations systems (OS) requirements.  
8. Able to communicate well with the Investigator , comply with the study requirements and 
adhere to the diet and activity programs for the study duration . 
 
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
1. History of, or known hypersensitivity to, monoclonal antibody drugs or a 
contraindication to semaglutide ( OzempicÂ® or WegovyÂ® ). 
2. Use of other inve stigational drugs at the time of enrollment or within 30 days or 5 half -
lives of enrollment, whichever is longer, or longer if required by local regulations.  
3. Lack of peripheral venous access.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 61 of 112 
4. Are not  able or willing  to comply with protocol requirements including  lifestyle  
interventions , for example : 
a. History of clinically significant condition that precludes regular walking for exercise 
e.g., cardiovascular or pulmonary disease or osteoarthritis . 
b. Contraindication to following a 500 -calorie da ily deficit, high protein diet . 
5. Women  who are  pregnant  or intend to become preg nant or are nursing . 
6. Disease s known to cause cachexia or muscle atrophy,  or disease s known to cause GI 
malabsorption (e.g., inflammatory bowel disease, celiac disease, short bowel syndrome, 
pancreatic insufficiency) . 
7. Use of any prescription drugs known to adversely affect muscle mass or body weight , 
including anti -androgens ( e.g., gonadotropin hormone  releasing hormone agonist s, 
androgen receptor antagonists , glucocorticoids administered systemically for >2 weeks if 
dose is â‰¥10 mg of prednisone or equivalent within 12 weeks prior to Day 1 to EoS ). Low 
dose estrogen replacement therapy in post -menopausal women is acceptable and 5 -alpha 
reductase inhibitors in men are acceptable.  Spironolactone and related drugs are 
acceptable in men and women . 
8. Treatment with any medication for the indication of obesity within the past 30 days 
before screening.  
9. Previous or planned ( during the trial period) obesity treatment with surgery or a weight -
loss device. However, the following are allowed: (1) liposuction and/or abdominoplasty, 
if performed >1 year before screening; (2) lap banding, if the band has been removed >1 
year before screening; (3) intragastric balloon, if the balloon has been removed >1 year 
before screening; (4) duodenal -jejunal bypass sleeve, if the sleeve has been removed >1 
year before screening  or Ple nityÂ®, if discontinued at least 1 week prior to screening . 
10. Unco ntrolled thyroid  disease , defined as thyroid stimulating hormone  above or below the 
normal range , at screening or within 6 months prior to screening . Hypothyroid patients 
treated with thyroid hormone replacement therapy must be on a stable dose for at least 6 
weeks prior  to screenin g. 
11. Diagnosis of diabetes , requiring  current use of any antidiabetic drug  or HbA1c â‰¥ 6.5% . 
Note: Metabolic syndrome is not an exclusion, even if managed with an anti -diabetic 
drug such as metformin or an SGLT2 inhibitor.   A diagnosis of prediabetes  or impaired 
glucose tolerance  managed exclusively with non -pharmacologic approaches (e.g. , diet 
and exercise) is not an exclusion.  
12. History of malignancy of any organ system, treated or untreated within the past five years, 
regardless of whether there was evidence of local recurrence or metastases, except non -
melanoma skin cancer treated only with local therapy.  Specifically exclude d are 
participant s with multiple endocrine neoplasia type  2 (MEN2) or a personal or family 
history of medullary thyroid cancer (MTC)  or known elevation of blood calcitonin  >50 
ng/L.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 62 of 112 
13. Known heart failure classified as New York Heart Association Class III and IV or a 
history of chronic hypotension , defined as systolic blood pressure <100 mmHg  or 
diastolic blood pressure <50 mmHg . Uncontrolled hypertension, defined as systolic blood 
pressure >180 or diastolic blood pressure >100 mmHg at screening /baseline . 
14. ECG showing clinically significant abnormalities including any current supra -ventricular 
arrhythmia with an uncontrolled ventricular response (mean heart rate >100 beats per 
minute [bpm]) at rest despite medical or device therapy, or any history of spontaneous or 
induced sustained ventricular tachycardia (heart rate >100 bpm for 30 sec) despite 
medical or device therapy, or any history of resuscitated cardiac arrest or presence of an 
automated internal cardioverter -defibrillator.  Prolonged QT syndrome or QTcF > 
450 msec (Fridericia Correction) for males and >470  msec for females at screening.  
15. Histo ry of unstable angina, myocardial infarction, coronary artery bypass graft surgery, 
or percutaneous coronary intervention (such as angioplasty or stent placement) within 
180 days of screening . 
16. History or presence of significant coagulopathy  e.g., PT/INR >1 .5. 
17. History of familial hypertriglyceridemia or history of fasting triglyceride > 500 mg/d L 
(5.65 mmol/L).  
18. Known history or presence of severe acute or chronic liver disease (compensated or 
decompensated), known cholelithiasis or  cholecystitis or bile duct  disease, acute or 
chronic pancreatitis (or medication associated with  severe pancreatitis, such as valproate) , 
or severe  GI dysmotility syndrome including functional disorders such as severe irritable 
bowel syndrome . Serum lipase >2x  upper limit of normal ( ULN ) or serum amylase  > 2x 
ULN  at screening.  
19. Liver injury as indicated by abnormal liver function tests such as AST , ALT , GGT,  
alkaline phosphatase, or serum bilirubin ; 
ï‚· Any single transaminase >3x ULN . 
ï‚· Total bilirubin concentration increased above 1.5x ULN  (except for cases of known 
Gilbert syndrome ). 
20. History or presence of substantially impaired renal function as indicated by eGFR < 
45 mL/min/1.73 m2 or serum creatinine > 1.5x ULN  or proteinuria > 2+ by urine dipstick 
or equivalent . 
21. Total WBC <3000/Î¼ L, neutrophils <1500/Î¼L, hemoglobin <8.5 g/dL, or platelet count 
<100,000/Î¼L at screening.  
22. Any chronic  infections  likely to interfere with study  conduct or interpretation such as 
hepatitis B (HBV), hepatitis C (HCV), or human i mmunodeficiency virus (HIV ). History 
of hepatitis A or hepatitis C successfully treated is not exclusionary.  Active COVID -19 
infection.  
23. Donation or loss of 400 mL or more of blood within eight weeks prior to initial dosing, or 
longer if required by local r egulation, or plasma donation (> 250 mL) within 14 days 
prior to the first dose.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 63 of 112 
24. Acute illness within the 30 days prior to screening  that, in the opinion of the Investigator , 
affects the patientâ€™s ability to participate in the study.  
25. Known  or suspected  abuse of alcohol  or other substances including , but not limited to:  
a. Smoking more than one pack of cigarettes daily.  
b. Drinking 5 or more alcoholic beverages on each of 5 or more days in the past 30 days.  
c. Using cannabis more than twice weekly.  
d. Any use of heroin, cocaine, etc.  
26. Any disorder, unwillingness, or inability not covered by any of the other exclusion 
criteria, which in the Investigator â€™s opinion , might jeopardize the participant â€™s safety or 
compliance with the protocol.  
5.3. Lifestyle Considerations   
5.3.1.  Meals and Dietary Restrictions   
Study participants  will be counseled to follow a modest calorie restrict ed diet with a daily deficit 
of approximately 500 kcal . The following is a recommended, but not required, breakdown  of 
daily calories: approximately 45 -50% from carbohydrate, 20 -25% from protein and 30% from fat 
intake throughout the study . Participants wi ll be advised to consume  at least 1.2 g/kg/body 
weight of protein as per guidelines for daily  recommended protein intake  for anabolism (WHO 
guidelines 2015).  
Counselling will be conducted by a dietician or a similar qualified healthcare professional every 
4 week s during the study  via visits/phone contacts  to encourage dietary intake that will promote 
weight loss  and document any change in dietary habits . During these dietician contacts , 
participants  will be asked to re call all food and dr ink they have consumed in the previous 24 
hours . 
If BMI â‰¤ 22 kg/m2 is reached during the study, the recommended daily energy intake may be 
recalculated to promote weight maintenance.   If further, potentially undesirable weight loss 
continues, or if BMI is â‰¤ 18.5 kg/m2, the investigator should contact the Sponsor to discuss 
whether it is medically appropriate for the participant to continue  in the study . See SOM for 
more information related to assessing dietary intake and calculating nutrient needs.  
Participants  must fast for at least 8 hours prior to all visits  that include blood sampling  i.e., 
without food or liquids, except for water. Study medication and any medication which should be 
taken with or after a meal should be withheld on the day of the visit until blood samples have 
been obtained . 
For visits where PD samples are collected for analysis by the central lab,  if the participant is not 
fasting as required, the participant  should be called in for a new visit as soon as possible to have 
the fasting procedures done. Procedures requiring participants to fast include blood sampling of 
fasting plasma glucose (FPG), fasting serum insulin and lipid assessment s. 
Participants should  restrict alcohol consumption for the 24 hours  prior to study visits . 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 64 of 112 
5.3.2.  Activity   
Participants will be encouraged  to engage in at least 150 min utes of physical activity per week 
e.g., walking  or climbing stairs . The  device worn by participants  will be used to 
collect activity data.  
Additional details of the physical activity  program and the  device can be found in the 
SOM . 
5.3.3.  Other Restrictions   
Participant s should refrain from smoking for one hour prior  to study visits and during the study 
visits. 
Women of childbearing potential must  use an intrauterine device (IUD) , from at least 3 months 
before the baseline visit  through  at least 4 months after the last dose  of bimagrumab/placebo i.v. , 
and use an additional contraceptive (barrier) method  after the screening visit  through at least 4 
months after the last dose of bimagrumab/placebo . Additional information on h ighly effective 
contraception methods is provided in Section  10.4 Appendix 4. 
5.3.4.  Support During Treatment Withdrawal Period   
During the treatment withdrawal period, partic ipants will continue to have access to personnel 
who have experience in providing diet and exerci se counseling. Options for additional resources 
to help lifestyle management will also be available to participants during this time.  
5.4. Screen Failures   
A screen failure occurs when a participant who has consented to participate in the clinical study 
is not subsequently assigned to study interventio n, either due to a failure to meet the eligibility 
criteria  or by choosing not to proceed to enrollment . 
A minimal set of screen failure information is required to ensure transparent reporting of screen 
failure participants to meet the CONSORT publishing requirements and to respond to queries 
from regulatory autho rities. Minimal information includes demography, screen failure details, 
eligibility criteria, and any SAE.  
Individuals who do not meet the criteria for participation in this study may be rescreen ed once at 
the discretion of the Investigator . Rescreened  participants should be assigned a new screening  
number for every screening/rescreening event.   Individuals with laboratory  assessments that a re 
outside of the Week -6 to Day -1 window may be reassessed once within the same screening 
event (without requiring a new screening number ). 
6. STUDY INTERVENTION(S) AND CONCOMITANT THERAPY   
Study interventions are all pre -specified, investigational,  and non -investigational medicinal 
products, medical devices and other interventions (e.g., behavioral) intended to be administered 
to the study participants during the study conduct.  
A summary of study interventions administered in this study is found in Table  2. Treatment arms 
are listed in Table  3. 
$SSURYHGRQ$SU*07CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 65 of 112 
The semaglutide dosing regimen employed in this study follows the guidance provided in the 
package insert for WegovyÂ® . However, due to WegovyÂ® supply constraints, Ozempic Â® pens 
will be used in place of  WegovyÂ®  pens as needed . OzempicÂ® pens contain the same active 
ingredients as WegovyÂ® pens.  
Site staff will provide p articipants  with self -administration training specific to the type of 
semaglutide pen dispensed . 
Refer to the Ozempic Â® and WegovyÂ®  package insert s for additional information and 
instructions  on administration.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 66 of 112 
6.1. Study Intervention s Administered   
Table  2: Study Interventions Administered  
Intervention Label Low dose bimagrumab High dose 
bimagrumab Placebo (for 
bimagrumab) Low dose semaglutide a High dose semaglutide a,b 
Intervention Name  Bimagrumab Placebo Semaglutide 
Intervention 
Description Human monoclonal antibody to the activin 
receptor type II Placebo Glucagon-like peptide-1 (GLP-1) receptor agonist 
Type Biologic n/a Biologic 
Dose Formulation Liquid in a vial Autoinjector Pen 
Unit Dose Strength(s) Vial:  concentrate for solution for 
infusion contains  of bimagrumab in 
 (excluding 10% overfill)  n/a 0.25 mg, 0.5 mg, 1.0 mg 0.25 mg, 0.5 mg, 1.0  mg, 1.7 
mg, and 2.4 mg 
Core Treatment Dosage 
Level(s)  10 mg/kg at Weeks 1, 4, 
16, 28, and 40 30 mg/kg at Weeks 
1, 4, 16, 28 and 40 1 infusion at Weeks 1, 4, 
16, 28 and 40 Weeks 1 to 4:   0.25 mg 
Weeks 5 to 8:    0.5 mg 
Weeks 9 to 48:  1.0 mg Weeks 1 to 4:    0.25 mg 
Weeks 5 to 8:      0.5 mg 
Weeks 9 to 12:    1.0 mg 
Weeks 13 to 16:  1.7 mg 
Weeks 17 to 48:  2.4 mg 
Extension Treatment 
Dosage Level(s) 10 mg//kg at Weeks 52 
and 64 30 mg/kg at Weeks 
52 and 64 c1 infusion at Weeks 52 
and 64 Weeks 49 to 71 :  1.0 mg Weeks 49 to 71 :  2.4 mg 
Route of 
Administration i.v. s.c. 
Use Experimental Placebo Active comparator 
IMP and NIMP/AxMP IMP 
Sourcing Provided centrally by the Sponsor 
Packaging and 
Labeling  Study intervention will be provided as  3 vials per box. Each box and vial 
will be labeled as required per country requirement. Comparator will be provide d as either a single pen 
(OzempicÂ® ) or 4 pens per box (WegovyÂ®) , depending on the 
dose to be administered . Each box and pen will be labeled as 
required per country requirement. 
Current / Former 
Name(s) / Alias Bimagrumab Semaglutide (OzempicÂ®/WegovyÂ®) 
a Participants  who are unable to tolerate a weekly dose of 0.5 mg or hi gher may decrease in dose to the preceding dose level. 
b Semaglutide doses of 1.7 mg and 2.4 mg  may be substituted with 1. 5 mg and 2.5 mg, respectively, based on availability of semaglutide pens. 
c Placebo infusions to be  discontinued after the Week 48 da tabase lock and study unblinding. 
$SSURYHGRQ$SU*07CCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 67 of 112 
Table  3: Study Treatment  Arms  
Arm Title  Arm Type  Arm Description  Associated 
Intervention Labels  
Core: Bimagrumab 
placebo  
Extension: 30 mg/kg  
bimagrumab  Core: Placebo  
Extension: 
Experimental  Core Treatment Period : 
Participants will receive i.v. 
bimagrumab placebo at baseline, and 
at Weeks 4 , 16, 28 and 40  
Extension Treatment Period : 
Participants will receive  30 mg/kg  
i.v. bimagrumab at Weeks 52 and 64  Treatment Arm 1a 
Bimagrumab placebo 
+ 1.0 mg semaglutide  Placebo  + 
Comparator  All Treatment Periods: Participants 
will receive i.v. bimagrumab placebo 
at baseline, and at Weeks 4 , 16, 28, 
40, 52, and 64, and 1.0 mg s.c. 
semaglutide weekly per the dose 
escalation schedule  Treatment Arm 2a 
Bimagrumab placebo 
+ 2.4 mg semaglutide  Placebo + 
Comparator  All Treatment Periods: Participants 
will receive i.v. bimagrumab placebo 
at baseline, and at Weeks 4 , 16, 28, 
40, 52, and 64, and 2.4 mg s.c. 
semaglutide weekly  per the dose 
escalation schedule  Treatment Arm 3a 
Core: 10 mg/kg 
bimagrumab  
Extension: 30 mg/kg 
bimagrumab  Experimental  Core Treatment Period: 
Participants will receive 10 mg/kg 
i.v. bimagrumab at baseline, and at 
Weeks 4 , 16, 28 and 40  
Extension Treatment Period: 
Participants will receive 30 mg/kg 
i.v. bimagrumab at Weeks 52 and 64  Treatment Arm 4  
10 mg/kg 
bimagrumab + 1.0 
mg semaglutide  Experimental + 
Comparator  All Treatment Periods: Participants 
will receive 10 mg/kg i.v. 
bimagrumab at baseline, and at 
Weeks 4 , 16, 28, 40, 52, and 64, and 
1.0 mg s.c. semaglutide weekly per 
the dose escalation schedule  Treatment Arm 5  
10 mg/kg 
bimagrumab + 2.4 
mg semaglutide  Experimental + 
Comparator  All Treatment Periods: Participants 
will receive 10 mg/kg i.v. 
bimagrumab at baseline, and at 
Weeks 4 , 16. 28, 40, 52, and 64, and 
2.4 mg s.c. semaglutide weekly  per 
the dose escalation sch edule  Treatment Arm 6  
30 mg/kg 
bimagrumab  Experimental  All Treatment Periods: Participants 
will receive 30 mg/kg i.v. 
bimagrumab at baseline, and at 
Weeks 4 , 16, 28, 40, 52, and 64  Treatment Arm 7  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 68 of 112 
Arm Title Arm Type Arm Description Associated 
Intervention Labels 
30 mg/kg 
bimagrumab + 1.0 
mg semaglutide Experimental + 
Comparator All Treatment Periods: Participants 
will receive 30 mg/kg i.v. 
bimagrumab at baseline, and at 
Weeks 4, 16. 28, 40, 52, and 64, and 
1.0 mg s.c. semaglutide weekly per 
the dose escalation schedule Treatment Arm 8 
30 mg/kg 
bimagrumab + 2.4 
mg semaglutide Experimental + 
Comparator All Treatment Periods: Participants 
will receive 30 mg/kg i.v. 
bimagrumab at baseline, and at 
Weeks 4, 16, 28, 40, 52, and 64, and 
2.4 mg s.c. semaglutide per the dose 
escalation schedule Treatment Arm 9 
aPlacebo infusions to be discontinued after the 48 -week database lock and study unblinding .  
6.2. Preparation, Handling, Storage, and Accountability    
The Investigator  or designee must confirm appropriate conditions ( e.g., temperature) have been 
main tained during transit for all study intervention received, and any disc repancies reported and 
resolved before use of the study intervention.  
Only participants enrolled in the study may r eceive study intervention, and only authorized site 
staff may supply, prepare, or administer study intervention.  
All study intervention must be stored in a se cure, environmentally controlled, and monitored 
(manual or automated) area in accordance with the labeled storage conditions with access limited 
to the Investigator  and authorized site staff.  
The Investigator  and study pharmacist  are responsible for study intervention accountability, 
reconciliation, and record maintenance ( i.e., receipt, reconciliation, and final disposition 
records).  
Further guidance and information for  the final disposition of unused study interventions are 
provided in the pharmacy  manual . 
6.3. Assignment to Study Intervention   
Eligible participants will be randomly assigned to one of nine treatment arms using a centralized 
interactive  web randomization system (I WRS) . Before the study is initiated, directions for the 
log-in information  will be provided to each site.  
Randomization will be balanced in  a 1:1:1:1:1:1:1:1:1 ratio with  approximately  participants 
per treatment arm. Stratification across the treatment  arms will be based on gender.  
The randomization schedule will be generated as a randomized block design using SAS version 
9.4 or higher.  
The randomization number becomes definitive once a participant has been dosed and it may not 
be reassigned.  
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 69 of 112 
6.4. Blinding   
The study is triple blinded to the study participant , Investigator and Sponsor  with respect to 
bimagrumab and bimagrumab  placebo and open labe l with respect to semaglutide.   Blinding will 
remain intact at least until database is locked for the Week 48  primary analysis .  Additional 
details regarding blinding and unblinding will be described in the SAP and a separate blinding 
and unblinding plan.  
6.4.1.  Bimagrumab  and Placebo   
All treatment arms  are triple blinded  with regards to  bimagrumab and bimagrumab placebo  
(participants/ Investigator s, Sponsor ). The IWRS will be programmed with blind -breaking 
instructions. In case of an emergency, the Investigator  has the sole responsibility for determining 
if unblinding of a participantsâ€™ intervention assignment is warranted. Participant safety must 
always be the first consideration in making such a determination. If the Investigator  decides that 
unblinding is war ranted, the Investigator  may, at the Investigator â€™s discretion, contact the 
Sponsor  to discuss the situation prior to unblinding a participantâ€™s intervention assignment unless 
this could delay emergency treatment for the participant. If a participantâ€™s int ervention 
assignment is unblinded, the Sponsor  must be notified within 24  hours of this occurrence. The 
date and reason for the unblinding must be recorded.  
6.4.2.  Semaglutid e  
Because a  placebo of semaglutide is not available  for this study , the study cannot be double 
blinded to all semaglutide treatments. Therefore, participants assigned to a combination of 
semaglutide with bimagrumab or its placebo (approximately N= 330) will be aware o f their open 
label semaglutide dosage but blinded to the bimagrumab /placebo assignment and  dosage.  
Potential bias will be reduced through central randomization.  
6.4.3.  SAE and Unblinding   
Sponsor safety staff may unblind the intervention assignment for any participant with an SAE. If 
the SAE requires that an expedited regulatory report be sent to one or more regulatory agencies, 
a copy of the report, identifying the participantâ€™s interven tion assignment, may be sent to 
Investigator s in accordance with local regulations and/or Sponsor  policy.  
6.4.4.  Unblinded Personnel   
With the exception of any unblinded site staff identified below, all site staff (including study 
Investigator  and study nurse) will be blinded to study treatment throughout the study.  
Unblinded study personal will include:  
ï‚· Unblinded  site pharmacist  or pharmacy staff  
ï‚· Unblinded study monitor  
Bimagrumab and it s placebo will be supplied as bulk in boxes containing 3 vials per box . An 
unblinded pharmacist or other qualified trained personnel, who is independent of the study team, 
will be required  to prepare study drug  bags for infusion . They are the only site level personnel 
who will have access to t reatment assignments.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 70 of 112 
Appropriate measures must be taken by the unblinded pha rmacist to ensure that the treatment 
assignments are concealed from the rest of the site staff. Any potential visible difference in 
treatments will be concealed by the use of an opaque sleeve . 
6.5. Study Intervention Compliance   
When the individual dose for a participant is prepared, the preparation of the dose will be 
confirmed by a nother unblinded study staff  member.  
When participants are dosed at the site, they will receive study int ervention directly from the 
Investigator  or designee, under medical supervision. The date and time of each dose 
administered in the clinic will be recorded in the source documents. The dose of study 
intervention and study participant identification will be  confirmed at the time of dosing by a 
member of the study site staff other than the person administering the study intervention.  
In treatment arms receiving semaglutide,  when participants self -administer semaglutide  at home, 
compliance with study intervent ion will be assessed at each visit. Compliance will be assessed 
by direct questioning, checking of participant diary,  and return of all used and unused medication  
during the site visits and documented in the source documents and relevant form. Deviation(s) 
from the prescribed dosage regimen should be recorded.  
A record of the quantity of study interventions  dispensed to and administered to/by each 
participant must be maintained and reconciled with study intervention and compliance records. 
Intervention start and stop dates, including dates for intervention delays and/or dose reductions 
will also be recorded.  
6.6. Dose Modification   
6.6.1.  Bimagrumab   
No dose modification (up or down titration)  of bimagrumab  is allowed.   Interruption of dosing 
may be  allowed for safety reasons (see Section  7.1.1 ). 
6.6.2.  Semaglutide   
Semaglutide is initiate d at 0.25 mg once weekly for 4 weeks. Dose is increased i n 4-week 
intervals  until a dose of 2.4 mg is reached  for the 2.4 mg dose arm s and until 1.0 mg is reached 
for the 1.0 mg dose arm s. 
If participants  do not tolerate the maintenance 2.4 mg once -weekly dose, the dose can be 
temporarily  decreased to 1.7 mg once -weekly, for a maximum of 4 weeks. After 4 weeks, 
semaglutide  should be increased to the  maintenance  dose of  2.4 mg once weekly . 
If participants  do not tolerate the planned dose -escalation schedule , they  may drop back to the 
highest previously tolerated dose and  extend that dose  for an additional one week, and then  re-
attempt dose escalation at least once.  If the higher dose is not tolera ted, the participant can step 
down and remain on the lower , highest -tolerated  dose.   
 
 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 71 of 112 
Management of Participants with BMI â‰¤22 kg/m2  
If â€¦  And..  Then â€¦  
a participant has a  BMI 
â‰¤22 kg/m2 at any time 
during the study  1) the participant has completed 
dose escalation with 
semaglutide  
2) dietary modifications to slow 
weight loss have been attempted  the investigator should contact the sponsor 
to consider a dose reduction of 
semaglutide to the next  lowe r maintenance  
dose level.  
body weight reduction 
continues to decline after 
30 days despite a dose 
reduction to the next lower 
maintenance dose level  the investigator wants to consider 
discontinuing study intervention  the investigator should contact the sponsor 
for further discussio n. 
a participant has a 
BMI  â‰¤18.5   study intervention must be discontinued.  
Management of Participants with Perceived Excessive Body Weight Loss   
If BMI is not â‰¤22 kg/m2 but there are concerns that the degree of body weight reduction may 
lead to participant decision to discontinue from study intervention, the investigator  should 
contact the sponsor to consider dose reduction to the next lower maintenance dose level.  
6.7. Continued Access to Study Intervention after the End of Treatment   
No access to study medication will be provided after completion of the study  treatment period  or 
post-treatment follow -up period . 
6.8. Treatment of Overdose   
6.8.1.  Bimagrumab   
The Sponsor does not recommend specific treatment for an overdose of bimagrumab.  
6.8.2.  Semaglutide   
Overdose of s emaglutid e should follow the standard directions  as outlined in the package insert.  
6.9. Prior and Concomitant Therapy   
Any medication or vaccine (including over the counter  or prescription med icines,  recreational 
drugs,  vitamins, and/or herbal supplements) that the participant is receiving at the time of 
enrolment  or receives during the study must be recorded along with:  
ï‚· Reason for use  
ï‚· Dates of administration including start and end dates  
ï‚· Dosag e information including dose and frequency  
The medical monitor should be contacted if there are any questions regarding concomitant or 
prior  therapy.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 72 of 112 
6.9.1.  Prohibited Medicine   
The table below lists medications which are pr ohibited from use for the study  period.  
Table  4: Prohibited Medications  
Prohibited Medication  Prohibition 
Period  Action  
Anti-androgens  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
Gonadotropin releasing hormone (GnRH) 
analogues  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
Anabolic steroids ( testosterone, danazol, 
oxandr olone, stanozolol  etc.) except 
replacement doses in hypogonadal men . 
Hormone replacement therapy in women 
with the exception of low dose estrogen.  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
Recombinant human growth hormone 
(rhGH), hGH receptor antagonist (e.g. , 
pegvisomant), hGH releasing  hormone  
agonist  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
Oral beta-adrenergic  agonists  4 weeks prior to 
Day 1 to EoS  Report protocol deviation, if used 
>14 days discontinue the study  
Systemic glucocorticoid (dexamethasone, 
hydrocortisone, methyl prednisolone, 
prednisolone, prednisone, triamcinolone)  
at doses > 10 mg /d prednisone -equivalent  12 weeks prior 
to Day 1 to EoS  Short term courses of systemic 
glucocorticoid treatment up to 14 
days is allowed (maximum, 2 
courses per year).  Report 
protocol deviation, if used > 14 
days; discontinue the study  if >2 
courses of short -term steroid.  
Anti-obesity  medications,  dietary  
supplements,  dietary  interventions  other  
than described  in the protocol, or over the 
counter products  for weight  loss. 30 days  prior to 
Day 1 to EoS  Report protocol deviation, if used 
>30 days discontinue the study  
Any antidiabetic medication used to treat 
diabetes.  Note: Metformin or SGLT2 
inhibitors are  permitted if used for the 
treatment  of metabolic syndrome.  Insulin 
is allowed for up to one week at a time to 
correct for acute hyper glycemia.  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
Any product or medication known or 
suspected to  cause significant weight 
change  (e.g., mirtazapine ), in consultation 
with the medical monitor ), unless on 
stable dose for at least 12 weeks prior to 
Day 1 . 12 weeks prior 
to Day 1 to EoS  Report protocol deviation  (unless 
specific medication allowed by 
medical monitor ); if used > 30 
days, discontinue the study  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 73 of 112 
Prohibited Medication  Prohibition 
Period  Action  
Valproate  12 weeks prior 
to Day 1 to EoS  Report protocol deviation, if used 
>7 days discontinue the study  
6.9.2.  Prohibited Non-Pharmacological Concomitant Treatments   
Bariatric surgery  and use of Plenity Â® are prohibited for the study period . 
6.9.3.  Recommended Treatment  of Adverse Events   
Muscle symptoms  can be addressed with light self -massage of the involved area concentrating  
on improving circulation and relaxing muscle tissue. If excessive or prolonged soreness  presents, 
then acetaminophen can be used as needed.  
Acne  may be treated with a face wash containing 4 -10% benzoyl peroxide and over the  counter 
topical treatments. If needed, a prescription topical treatment ( e.g., antibiotic) or oral  antibiotic 
(e.g., minocycline 100 mg bid) may be reco mmended at the Investigator â€™s discretion.  Early 
intervention is recommended when acne presents.  
Diarrhea , nausea, vomiting, constipation  may be treated with over-the-counter  remedies. In 
cases of prolonged occurrence,  other treatments may be used at the Investigator â€™s discretion.  
7. DISCONTINUATION OF STUDY INTERVENTION , 
PARTICIPANT DISCONTINUATION  / WITHDRAWAL  AND 
STUDY STOPP ING / PAUSING   
7.1. Participant Discontinuation of Study Intervention   
In rare instances, it may be necessary for a part icipant to permanently discontinue study 
intervention. If study intervention is permanently discontinued  during one of the treatment 
periods , the End of Treatment (EOT)  visit should be conducted as soon as possible , followed by 
the End of Study  (EOS)  visit at least 12 weeks after last treatment with bimagrumab/placebo . 
Study  treatment  must  be discontinued  for an individual  participant  under  the following  
circumstances:  
ï‚· Withdrawal  of consent .ï€ 
ï‚· An infusion  reaction  that is considered  severe .ï€ 
ï‚· One or more symptomatic hypoglycemic events necessitating third party rescue and 
suspected to be related to study drug .ï€ 
ï‚· A serious  adverse  event (SAE)  thought to  be related  to study  drug.ï€ 
ï‚· Use of prohibited treatment fulfilling the criteria in Table  4.ï€ 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 74 of 112 
ï‚· Pregnancy: a positive pregnancy test after start of study treatment requires  immediate 
discontinuation of study treatment , even if confirmation testing is pending . In the 
event of pregnancy, report as described above.   
ï‚· Any protocol deviation  that results  in a significant risk  to the  participant â€™s safety .ï€ 
ï‚· Emergence of one or more adverse events that in the judgment of the Investigator , 
considering  the participant â€™s overall status, prevent the participant  from safely 
continuing in the   study . 
Investigational  treatment  may be discontinued  under  the following  circumstances:  
ï‚· Breaking  of the blind  (inadvertently  or for emergency  reasons)ï€ 
ï‚· Liver, pancreas, or muscle related adverse event  as described in Sections 10.6, 10.7, 
and 10.8.ï€ 
Participants  who discontinue study treatment should NOT be considered withdrawn from the 
study UNLESS they withdraw their consent. They should return approximately 12 weeks after 
their last dose of bimagrumab/place bo for the E nd of Study  visit as described above . If they fail 
to return for these assessments for unknown reasons, ever y effort should be made to contact them 
as specified in Section  7.3. 
7.1.1.  Liver , Pancreas, or Muscle  Related Events  Stopping Criteria   
Study treatment  may be interrupted or  discontinued if a participant meets one of the conditions 
for liver, pancreas or muscle related adverse events,  as out lined in the algorithm s in 
Section s 10.6, 10.7, and  10.8, Appendi ces 6, 7, and 8, or if the Investigator  believes it is in the 
best interest of the participant , even if the criteria are not met .  At the Week 4  and Week 64  
visits, participantsâ€™ safety lab results  must be available and reviewed against the guidance in 
Appendices 6, 7, and 8 in advance of dose administration  with bimagrumab/placebo . 
7.1.2.  Temporary Discontinuation   
No temporary discontinuation is allowed  except for management of adverse events, as described 
in Section 7.1.1 . Refer to Section 6.6.2  if the current semaglutide dose cannot be tolerated, and 
for management of  participants with BMI â‰¤22  kg/m2 or perceived excessive body weight loss.  
 
7.2. Participant Discontinuation/Withdrawal from the Study   
A participant may withdraw from the study at any time at the participantâ€™s own request for any 
reason (or without providing any reason).  
A participant may be withdrawn at any time at the discretion of the Investigator  for safety  or 
compliance reasons.  
At the time of discontinuing from the study, if during one of the treatment periods , an â€œend of 
treatment â€ visit should be conducted  as soon as possible,  as described in Section  7.1.  Please s ee 
SoA Section  1.3 for data to be collected at the time of study discontin uation and follow -up for 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 75 of 112 
any further evaluations nee ded for follow up of adverse events.   Participants should return at 
least 12 weeks after their last dose of bimagrumab/placebo for the End of Study visit . 
If the participant withdraws consent for disclosu re of future information, the Sponsor  may retain 
and continue to use any data collected before such a withdrawal of consent.  
If a participant withdraws from the study, the participant may request destruction of any samples 
taken and not tested, and the Investigator  must document this in the site study records.  
7.3. Lost to Follow -up  
A participant  will be considered lost to follow -up if the participant repeatedly fails to return for 
scheduled visits and is unable to be contacted by the study site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
ï‚· The site must attempt to contact the participant and reschedule the missed visit as 
soon as possible, counsel the participant on the importance of maintaining the 
assigned visit schedule and  ascertain whether the participant wishes to and/or shoul d 
continue in the study.  
ï‚· Before a participant is deemed lost to follow -up, the Investigator  or designee must 
make every effort to regain contact with the participant (where possible, 3 telephone 
calls, and if necessary, a certified letter to the participan tâ€™s last known mailing 
address or local equivalent methods). These contact attempts should be documented 
in the participantâ€™s medical record.  
ï‚· Should the participant continue to be unreachable, the participant will be considered 
"lost to follow -upâ€. 
7.4. Treatme nt Arm and Study Stopping/Pausing Rules   
The study will be paused and no further dosing and/or new recruitment will occur pending full 
safety review by the DMC, if any of the belo w criteria are met. After a safety review by the 
DMC, the DMC will recommend  to the sponsor either to continue the study, to stop an arm  or to 
stop the study . The study may resume following the safety review, if the DMC and Sponsor 
agree it is safe to proc eed and necessary approvals have been obtained from authorities according 
to local regulations.  
ï‚· Any death considered to be related to study treatment . 
ï‚· Two or more participants experience a TESAEs of a similar type (other than death, 
corresponding to NCI -CTCAE grade 3 or higher) considered to be related to blinded 
study treatment , unless expected per Reference Safety Information.  
ï‚· One or more participants develop a life -threatening (NCI -CTCAE grade 4) or fatal 
acute allergic reaction within 24 hours following study treatment administration (i.e., 
active drug /placebo ), unless clearly caused by exposure to a known allergen (e.g., 
peanut allergy).  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 76 of 112 
 Two or more participants are discontinued due to  a liver event  as defined in  
Section  10.6 Appendix 6.  
 Number and/or severity of AEs, abnormal safety monitoring t ests, or abnormal 
laboratory findings justify putting the study on hold . 
 The Sponsor unilaterally requests a stoppage.  
8. STUDY ASSESSMENTS AND PROCEDURES   
Study procedures and their timing are summarized in the SoA  Section  1.3. Protocol  waivers or 
exemptions are not allowed.  Visits should be performed as close to the plann ed timepoint as 
possible , with a visit window of +/- 7 days, with the following exceptions:  
 All required Screening assessments must be completed within Week -6 and Day -1.  
Any screening assessments that a re outside of this range may be repeated once  
witho ut screen failing.  
 For the baseline visit, DXA scans may be performed up to 14 days prior to the 
baseline visit.  For all other visits, the DXA assessment window is -2 weeks to +1 
week of the scheduled time.  
  (Week 4) and  (Week 64) dosing  should be per formed within a visit 
window of -2 to +14 days . 
Adherence to the study design requirements, including those specified in the SoA  Section  1.3, is 
essential and required for study conduct.  
All screening evaluations must be completed and reviewed to confirm that potential participants 
meet all eligibility criteria. The Investigator  will maintain a screening log to record details of all 
participants screened and to confirm eligibility or recor d reasons for screening failure, as 
applicable.  
":7+-,=:-;+76,=+<-,);8) :<7.<0-8):<1+18)6<J;:7=<16-+4161 +)45)6)/-5-6< (e.g., complete  
blood count)  and obtained before signing of the ICF may be utilized for screening or baseline 
purposes provided th e procedures met the protocol -specified criteria and were performed within 
the timeframe defined in the SoA  Section  1.3. 
In the event of a significan t study -continuity issue ( e.g., caused by a pandemic), alternate 
strategies for participant visits, assessments, medication distribution and monitoring may be 
implemented by the Sponsor  or the Investigator , as per local health authority/ethics requirements.  
Repeat or unscheduled samples may be taken for safety reasons or for technical issues with the 
samples.  
8.1. Administrative Procedures   
Demographic and baseline characteristic data will include  year of birth , sex, race, predominant 
ethnicity.  
Relevant medical history and current medical conditions will be recorded. Where possible, 
diagnoses but not symptoms will be recorded.  Investiga tors have the discretion to record 
$SSURYHGRQ$SU*07CCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 77 of 112 
abnormal test findings as medical history,  if in their  judgment, the  test abnormality  occurred 
prior  to the  informed consent  signature.  
Disease history  will include duration of obesity/overweight ( number of years).  Obesity -related 
comorbidities will be recorded on the Medical History form, along with assessment of  status of 
these at end of study . 
All current medications and significant non -drug therapies must be listed on the Concomitant 
medications  eCRF . 
Urine drug  screening will be  performed,  and the results kept as source data.  
Body height  will be measured as described in the SOM . 
8.2. Efficacy / Pharmacodynamics  Assessments   
Planned timepoints for all efficacy  and pharmacodynamic assessments are provided in the SoA  
Section  1.3. Additional d etails of the methods to perform  assessments are provided in the SOM.  
8.2.1.  Anthropometric Measurements   
8.2.1.1.  Body Weight   
Body weight will be measured in kilograms (kg) to the nearest 0.1 kg, in light indoor clothing, 
without shoes and on an empty bladder, using the scale provided by the Sponsor th roughout the 
trial. 
8.2.1.2.  Waist Circumference   
Waist circumference will be measured in standing position with a non -stretchable measuring tape 
and to  the nearest 0.1 centimeter (cm) .  The measurement should be taken with the participant  
standing  and with the waist area unclothed.  The tape should be positioned around the participant , 
parallel to the floor, with the lower edge of the tape at the level of the posterolateral  superior iliac 
crest bilaterally and the circumference measured at the end of a normal expiration.  
The same type of measuring tape should be used throughout the trial. The measuring tape will be 
provided by the Sponsor to ensure standardization.  
8.2.1.3.  Body Mass  Index   
BMI will be calculated in the electronic case report form (e CRF ) using the following formula:  
 BMI = Body weight (kg) / [Height (m)]2 
8.2.1.4.  Bioelectrical Impedance Analysis   
Bioelectrical impedance analysis (BIA) is a widely used method for estimating body 
composition. The technology is relatively simple, quick, and noninvasive. BIA is currently used 
in diverse settings, including private cliniciansâ€™ offices, health clubs, and hospitals, and across a 
spectrum of ages, body weights, and disease states. An estimate of total body water (TBW) is 
derived by measuring electrical impedance of body tissues, fr om which fat -free mass (FFM) , 
lean ( muscle ) mass,  and body fat (adiposity) are estimated.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 78 of 112 
8.2.2.  DXA  Scan   
Dual energy X -ray absorptiometry (DXA) will be used to assess changes in body composition,  
including total fat and lean body mass (FBM and LBM) , trunk fat mass , visceral adipose tissue  
(VAT) , subcutaneous adipose tissue (SAT),  and bone mineral density  (total body, lumbar spine, 
hip). 
Quality  assurance  is an important  issue  in the use of DXA  scans  to determine  body  composition. 
DXA instrument manufacturer and model should remain consistent,  and their  calibration should 
be monitored throughout the study. Use of a standardized scan acquisition  protocol and 
appropriate and unchanging scan acquisition and analysis software is essential to  achieve 
consistent results. Likewise, because of variability in interpretation of the scans, it is  important  to 
utilize  centralized  scan analysis  by experienced  staff.  
Data  collection  and processing  is explained  in the Imagi ng Manual  written and provided by 
the imaging CRO.  DXA scans will be sen t to the imaging CRO for central reading . Results  must 
remain blinded to Investigator  and participant  until database  lock, however medically significant 
incidental findings (e.g. , tumor) not related to the study analyses can be disclosed to the 
Investigator  as appropriate for the medical care of the participant . 
8.2.4.  Impact of Weight on Quality of Life -Lite Clinical Trial s Version   
The IWQOL -Lite CT is a 20-item modified survey instrument that is used to quantitatively 
);;-;;)616,1>1,=)4J;8-:+-8<176 of how their weight affects their day -to-day life  [34]. The LITE 
CT version  has been specifically  developed for clinical trials . The physical function score will 
also be evaluated.  This instrument is especially valuable to validate the effectiveness of the 
treatment for obesity using metrics that go beyond the physical measurements of weight loss.  
8.2.5.  Short  Form (SF -36) Health Survey   
SF-36 measures a participant J;7>-:)440-)4<0:-4)<-,9=)41<A7.41.-<1;) -item generic 
measure of health status that yields 2 summary scores for physical health and mental hea lth, and 
8 domain scores  [35]. The physical functioning score will also be evaluated.  
8.2.6.  Physical Activity Monitoring Via   
The Investigator  must encourage American Diabetes Association  walking guidelines  (at least 
150 minutes of physical activity  per week) . Daily steps and general activity levels will be 
monitored by a wrist worn   device provided to participants by the Sponsor . 
8.2.6.1.  Lipid Profile   
Blood  samples for total cholesterol, HDL  cholesterol , LDL  cholesterol , and triglycerides  will be 
collected under fasting conditions , unless specified otherwise . These parameters will be  
$SSURYHGRQ$SU*07CCI
CCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 79 of 112 
measured  by the local lab at screening  and by the central  laboratory  at Sponsor determined 
timepoints . 
8.2.6.2.  Glucose Metabolism Parameters: Hb A1c, Fasting Insulin and Glucose   
With the exception of the screening visit, s amples  for insulin  and glucose  will be collected  
under fasting conditions . Glucose will be  measured by the local lab for safety . HbA1c  and 
fasting insulin will be measured by the central laboratory , per the studyâ€™s Laboratory Manual,  at 
timepoints indicated in the SoA Section  1.3. 
The Homeostatic model assessment 2 â€“ insulin resistance index (HOMA -IR) and the quantitative 
insulin -sensitivity check index (QUICKI) are derived  insulin  resistance  index es that will be  
calculated  by data management . 
8.3. Safety Assessments   
Planned timepoints for all safety  assessments are provided in the SoA  Section  1.3. Details of the 
methods to perform assessment s are provided in the SOM.  
8.3.1.  Physical Examinations   
A complete physical examination  will be performed at all listed visits and will  include  the 
examination of general appearance, skin, neck (including thyroid), eyes, ears, nose, throat, lungs, 
heart, abdomen , back, lymph nodes, extremities , vascular , and neurological systems. If indicated 
based on medical history  and/or  symptoms, additional e xams may  be performed.  
Skin assessment should include findings of new , or worsening , and significant acne or skin 
lesions . 
For males, a bilateral assessment and measurement of gynecomastia (breast tissue diameter) will 
be made , if present . 
Investigator s should pay special attention to clinical signs related to previous serious illnesses  
and to those listed under â€œWarnings and precautionsâ€ for WegovyÂ®  or OzempicÂ® . 
8.3.2.  Vital Signs   
Temperature, pulse rate, and blood pressure will be recorded (before blood collection for 
laboratory tests).  
Blood pressure and pulse rate measurements will be assessed in a sitting position  with a 
completely automated device. Manual techniques will be used only if an automated device is not 
available  or not suitable for the participant . 
Blood pressure and pulse rate measurements should be preceded by at least 5 minutes of rest f or 
the participant in a quiet setting without distractions ( e.g., television, cell phones).  
If a b lood pressure measurement  is out of range, it  may be rep eated once, after the participant has 
rested for at least 5 minutes.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 80 of 112 
8.3.3.  Electrocardiograms   
A standard  12-lead ECG  will be performed with the participant in a supine position,  using an 
ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF 
intervals . Interpretation of the tracing must be made by a qualified physician and documented on 
the ECG and in the ECG section of the  eCRF . 
Each ECG trac ing should be labeled with the study  number, participant initials, participant 
number and date, and kept in the source documents  at the  study site. Clinically significant 
abnormalities should be recorded on the relevant medical  history  eCRF  page  prior  to informed  
consent  signature  and on the Adverse  Events  page  thereafter.  Clinically  significant  findings  must  
be discussed  with the Sponsor . 
The eCRF  will contain  the date and time of ECG , PR and RR  interval s, QT interval , QTcF , and 
QRS  duration . 
The Fridericia QT correction formula (QTcF) should be used for clinical decisions.  
Unless  auto calculated  by the ECG  machine,  the Investigator  must  calculate  QTcF.  See the Site 
Operations  Manual  for additional  details.  
Original  ECG  tracings,  appropriately  signed,  will be archived  at study  site. 
8.3.4.  Clinical Safety Laboratory Tests   
All protocol -required safety lab tests, as defined in Section  10.2 Appendix 2, must be conducted 
in accordance with the SoA  Section  1.3. 
The Investigat or must review the laboratory results, document this review, and record any 
clinically significant changes occurring during the study as an AE.  
Abnormal laboratory findings associated with the underlying disease are not considered 
clinically significant un less judged by the Investigator  to be more severe than expected for the 
participantâ€™s condition . 
All laboratory tests with values considered clinically significantly abnormal during participation 
in the study or until 30 days from the EOS visit  should be r epeated until the values return to 
normal or baseline or are no longer considered clinically significant by the Investigator  or 
medical monitor.  Additional guidance for the follow up of abnormal liver and pancreas tests , as 
well as elevated CK,  is provided in the safety monitoring section of this protocol and 
Sections  10.6, 10.7, and 10.8, Appendices 6 , 7, and 8. 
If clinically significant  values do not return to normal/baseline within a period  judged reasonable 
by the Investigator , the etiology should be identified, and the Sponsor  notified.  
If laboratory values from non -protocol -specified laboratory tests performed at the institutionâ€™s 
local laboratory require a change in participant management or are considered clinically 
significant by the Investigator  (e.g., SAE or AE or dose modification) , then the results must be 
recorded.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 81 of 112 
8.3.5.  Pregnancy Testing   
Serum pregnancy test is required for all female participants at screening  and for confirmation of 
any positive urine pregna ncy test . 
For all other visits, u rine dipstick pregnancy test ing will be required  for pre -menopausal female 
participants, unless serum is required based on local requirements. Women surgically sterilized  
(but pre -menopausal ) are still required to complete pregnancy tests. In case urine dipstick 
pregnancy test is positive, it must be co nfirmed with a serum pregnancy test prior to dosing . All 
positive urine test s will be followed up by a serum test . 
A negative test result is required prior to receiving any study medication.  
Additional serum or urine pregnancy tests may be performed, as determined necessary by the 
Investigator , or required by local regulation, to establish the absence of pregnancy at any time 
during the participantâ€™s participation in the study.  
8.3.6.  Hematology /Coag ulation   
Hemoglobin,  hematocrit, red blood cell count, RBC indices, white  blood  cell count  with 
differential  (e.g., neutrophils, basophils, eosinophils, monocytes, lymphocytes), e rythrocyte 
sedimentation  rate, platelet  count,  aPTT, and PT/INR will be measured.  
8.3.7.  Blood Chemistry   
Blood chemistry should be assessed after a fast of approximately 8 hours. Blood chemistry  will 
include  sodium,  potassium,  calcium,  magnesium,  bicarbonate/CO 2, chloride,  phosphate or 
phosphorus, creatinine, BUN or urea, glucose, uric acid, albumin, total protein, alkaline  
phosphatase, total and direct bilirubin, LDH, GGT, AST, ALT, amylase, lipase, and CK. 
If the total bilirubin  concentration  is increased  above 1.5 x ULN , direct  and indirect bilirubin 
should  be obtained . 
Additional  safety  labs may be performed  at the Investigator â€™s discretion  for any 
clinically/medically  significant abnormalities.  
8.3.8.  Urinalysis  and Urine Chemistry   
A midstream urine sample (approx. 30 mL) will be obtained in order to avoid contamination  with 
epithelial  cells and sediments  and to allow  proper  assessment.  Required  assessment s include  
occult blood, pH, specific gravity, ketones, glucose, protein, bilirubin, nitrite and  leukocytes.  A 
microscopic examination will be performed if blood or protein are abnormal.  The sample will 
also be used for measurement of urine microalbumin an d urine creatinine, for calculation of 
urine albumin:creatinine ratio (ACR).  
8.4. Adverse Events , Treatment Emergent Adverse Events,  Serious 
Adverse Events, and Other Safety Reporting   
The definitions  of AEs , TEAEs,  and SAEs  unsolicited and solicited adverse events can be found 
in Section  10.3 Appendix  3. 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 82 of 112 
The Investigator  and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE  or SAE and remain responsible for following 
up all AEs . This includes events reported by the participant (or, when appropriate, by a 
caregiver, surrogate, or the participantâ€™s legally authorized representative).  
The method of recording, evaluating, and assess ing causality of AEs  and SAEs  and the 
procedures for completing and transmitting SAE reports are provided in Section  10.3 
Appendix  3. 
8.4.1.  Time Period and  Frequency for Collecting AE , TEAE  and SAE Information   
All SAEs will be collected from the time of the signature of the informed consent until the EoS 
visit and  will be recorded in the database for all randomized participants .  Non-serious adverse 
events will be collected from the time of first dose of study medication(s)  until the EoS visit  
(treatment -emergent adverse events [TEAEs] ).  Non -serious medical condit ions identified during 
the screening period should be recorded as medical histor y. 
The Investigator will record and report a ll SAEs to the Sponsor or designee immediately and 
under no circumstance should this exceed 24 hours, as indicated in Section  10.3 Appendix 3. The 
Investigator  will submit any updated SAE data to the Sponsor  within 24 hours of it being 
available.  
Investigator s are not obligated to actively seek information on AEs or SAEs after conclusion of 
the study participation . However, if the Investigator  learns of any SAE, incl uding a death, at any 
time after a participant has been discharged from the study, and the Investigator  considers the 
event to be reasonably related to the study intervention or study participation, the Investigator  
must promptly notify the Sponsor . 
8.4.2.  Follow -up of AEs and SAEs   
After the initial AE/SAE report, the Investigator  is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs and AEs of special interest (as defined in 
Section  8.4.5 ) will be followed until resolution, stabilization, the event is otherwise explained, or 
the participant  is lost to follow -up (as defined in Section  7.3). Further information on follow -up 
procedures is provided in Section  10.3 Appendix 3. 
8.4.3.  Regulatory Reporting Requirements for SAEs   
Prompt not ification by the Investigator  to the Sponsor  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study 
intervention under clinical investigation are met.  
The Sponsor  has a leg al responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study intervention under clinical investigation. The 
Sponsor  will comply with country -specific regulatory requirements relating to safety re porting to 
the regulatory authority, institutional review boards (IRBs)/independent ethics committees 
(IECs) , and Investigator s. 
An Investigator  who receives an Investigator  Notification /Safety Report describing an SAE or 
other specific safety information ( e.g., summary or listing of SAEs) from the Sponsor  will 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 83 of 112 
review and then file it along with the IB/package insert and will notify the IRB/IEC, if 
appropriate according to local requirements.  
Investigator  Notification/S afety Reports must be prepared for suspected unexpected serious 
adverse reactions (SUSARs) according to local regulatory requirements and Sponsor  policy and 
forwarded to all participating Investigator s. 
8.4.4.  Pregnancy   
Details of all pregnancies in female participants , or in female partners of male participants,  
occurring in the study and until 4 months after  the last dose of study drug  (if the participant was 
on active drug ) will be collected  to determine the outcome of the pregnancy. The Investigator  
will collect the follow -up information on the participant  and the neonate and forward  the 
information  to the Sponsor . 
If a pregnancy is reported  or detected , the Investigator  will record  pregnancy information on the 
appropriate form and submit it to  the Sponsor  within 24 hours  of learning of the pregnancy.  
While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for med ical reasons will be reported as an AE or SAE.  
Abnormal pregnancy outcomes ( e.g., spontaneous abortion, fetal death, stillbirth, congenital 
anomalies, ectopic pregnancy) are considered SAEs and will be reported as such.  
Any post -study pregnancy -related SAE considered reasonably related to the study intervention 
by the Investigator  will be reported to the Sponsor  as described in Section  8.4.4 . While the 
Investigator  is not obligated to actively seek this information in former study participants , he or 
she may learn of an SAE through spontaneous reporting.  
Any female participant who becomes pregnant or has a positive pregnancy t est while 
participating in the study must discontinue study intervention  immediately . 
8.4.5.  Treatment Emergent  Adverse Events of Special Interest   
Adverse events of special interest (AESI) for bimagrumab are defined based on  an ongoing 
review of all safety data and include  (using CTCAE intensity grading) : 
ï‚· Muscle related events ( e.g., rhabdomyolysis, muscle spasm,  cramps , twitching , 
tightness ) [at lea st grade 3] 
ï‚· Skin lesions (e.g., acne, growths ) [at least grade 3] 
ï‚· Pancreatitis  
ï‚· Gastrointestin al events ( e.g., diarrhea , nausea ) [at least grade 3] 
ï‚· Malignancy   
8.5. Pharmacokinetics   
Serum bimagrumab and plasma semaglutide concentrations  (as applicable)  will be evaluated in 
samples collected from all participants according to the SoA  Section  1.3. 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 84 of 112 
Each serum /plasma  sample will be divided in to 2 aliquots (1  for analysis  and another for 
backup ). Samples collected for analyses of bimagrumab  concentration and semaglutide 
concentration may also be used to evaluate safety or efficacy aspects related to concerns arising 
during or after the study.  
Instructions for the collection and handling of  biological samples will be provided in the 
laboratory manual.   Post-bimagrumab  samples should be targeted for collection  15 minutes after 
the end of the post -infusion flush, but no later than 45 minutes after  the completion of the flush.  
Bimagrumab and serum concentration information will not be reported to investigative sites or 
blinded personnel until the study has been unblinded . 
Information on storage and future use of samples is detailed in Section  10.1.5.1 . 
8.6. Pharmacodynamics   
8.7. Genetics   
A 10 mL blood sample for DNA isolation will be collected at the baseline visit from participants 
who have consented to participate in the genetic analysis component of the study. Participation is 
optional. Participants who do not wish to participate in  genetic research may still participate in 
the study.  
$SSURYHGRQ$SU*07CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 85 of 112 
In the event of DNA extraction failure, a replacement genetic blood sample may be requested 
from the participant. Signed informed consent wi ll be required to obtain a replacement sample 
unless it was included in the orig inal consent.  
Instructions for the collection and handling of  biological samples will be provided in the 
laboratory manual.  
See Section  10.5 Appendi x 5 Genetics for information regarding genetic research . 
Information on storage and future use of samples is detailed in Section  10.1.5.1 . 
8.8. Immunogenicity Assessments   
Serum  samples from all participants collected according to the SoA will be screened for 
antibodies binding to bimagrumab  (anti-drug-antibodies, ADA)  and the titer of confirmed 
positive samples will be reported. Other analyses may be performed to evaluate the neutralizing 
activity or verify the stability of antibodies to bimagrumab  and/or further characterize the 
immunogenicity of bimagrumab . 
Instructions  for the collection and handling of biolog ical samples will be provided in the 
laboratory manual.  
Results will not be reported to investigative sites or blinded personnel until the study has been 
unblinded . 
Information on storage and future use of samples is detailed in Section  10.1.5.1 . 
9. STATISTICAL CONSIDERATIONS   
The statistical analysis plan (SAP) will be finalized prior to the primary  efficacy analysis  (e.g., 
when participants complete Week 48)  and it will include a more technical and detailed 
description of the endpoints to be summarized and the statistical analyses described in this 
section. This section is a summar y of the planned statistical analyse s of the key endpoints , 
subject to possible modifications in the final SAP . 
9.1. Statistical Analyses   
The primary objective is to assess the effect of varying doses of bimagrumab, semaglutide and 
bimagrumab in addition to semaglutide on body weight  after 48 weeks of treatment .  Change in 
body weight  is the primary outcome to be analyzed.  The proportion of participants in each 
treatment group who achieve  )?-1/0<47;;7. 7>-:<0-+7=:;-7.<:-)<5-6<?144 also be 
summarized and compared to control .  A viable treatment outcome will be one that shows either:  
 The difference in mean weight loss between the active -product and placebo -treated 
groups is at le ast % and the difference is  statistically significant,  
or 
 The proportion of participants  who lose greater than or equal to % of baseline body 
weight in the active -product group is at least %, is approximately  the proportion 
in the placebo -treate d group, and the difference between groups is statistically significant . 
$SSURYHGRQ$SU*07CCICCI
CCICCI
CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 86 of 112 
The FDA guidance for phase 3 clinical trials in weight management recommends that in general, 
a product can be considered effective for wei ght management if after 1 year of treatment either 
of the following occurs:  
 The difference in mean weight loss between the active -product and placebo -treated 
groups is at least  percent and the di fference is statistically significant  
or 
 The proportion of participant s who lose greater than or equal to  percent of baseline 
body weight in the active -product group is at least  percent, is approximately  
the proportion in the placebo -treated group, and the difference between groups is 
statistically significant.  
For phase 2 clinical trials,  the FDA guidance states that primary efficacy endpoints should 
include a comparison of the mean absolute or percent change in body weight between the active -
product and placebo -treated groups.  
All randomized participants who received at least one dose of study medication will be included 
in an intention -to-treat population (treatment policy strategy) . Baseline and efficacy results will 
be summarized by randomized treatment arm , with active treatment  arms compared to placebo , 
and combination treatment  arms  to each monotherapy of the same dose . 
The analyses to be performed will be similar to  the primary analysis described above.  Details of 
these analyses will be provided in the SAP.  
9.1.1.  Multiplicity Adjustment   
No multiplicity adjustment will be performed for this study . 
9.2. Analysis Sets   
For the purposes of statistical analysis and data summaries, the following analysis sets are 
defined:  
Analysis Set Description 
Full analysis set (FAS) 1. All participants who meet eligibility criteria, sign the informed 
consent and are randomized to a treatment arm, regardless of 
exposure to investigational products, are included in the FAS. 
Safety analysis set (SAF) 2. All participants who meet the definition of FAS and who are 
exposed to at least one dose of investigational products (including 
placebo) are included in the SAF. 
The FAS will be used to summarize demographi cs and baseline characteristics and analyze 
endpoints related to the efficacy objectives. Participant s will be grouped in summaries and 
included in the analyses according to the planned investigational inte rvention.  
The SAF will be used to summarize and analyz e the endpoints relate to safety and tolerability. 
Participant s will be grouped in summaries and included in the analyses according to the highest 
dose level of investigational products they actually re ceived.  
$SSURYHGRQ$SU*07CCI
CCI
CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 87 of 112 
9.3. Interim Analysis   
An interim analysis (IA)  will be conducted when approximately % of the participants 
complete the Week 24 visit. The interim analysis will evaluate efficacy as well as the safety 
profile of both the combination and monotherapy treatment arms, and may be used to help 
determine th e doses of bimagrumab to be used in future studies . 
9.4. Treatment Extension and Post-Treatment Follow -Up Period 
Analyses   
There will be no contemporaneous placebo /no treatment  group with data through the extension 
phase since all participant s originally enrolled into the placebo /no treatment  arm will be switched 
to 30 mg/kg bimagrumab.  Likewise, all participant s originally enrolled into the 10 mg/kg 
bimagrumab arm will switch to 30 mg/kg bimagrumab.  All other arms will remain unchanged.  
As a result, the maximum placebo response will be considered the response at the end of the core 
phase (48 weeks).  Analyses and summaries of treatment effect will continue to be based on the 
original randomization assignments. Analy ses and summaries of treatment effect at 72 weeks 
will be provided .  
After 72 weeks, all participants  remaining in the study will be withdrawn from treatment and 
followed for an additional 24 weeks.  Analyses  and summaries of withdrawal effect will be 
provided .  
Details of analysis methods will be presented i n an SAP for the extension phase.  
9.5. Sample Size Determination   
 participants will be randomized to 1 of 9 treatment groups. The sample size 
calculation is based on the primary efficacy estimand for weight.   Based on the FDA guidance on 
treatment for weight m anagement, the minimum meaningful treatment effect for weight loss is 
5% of baseline body weight over 1 year of treatment.   Assuming the minimum treatment effect 
of % weight loss (approximately 5 kg) with a standard deviation (SD) of , for a minimum 
effect size of   [2, 3] , a sample size of  participants per treatment arm will have 
approximately % statistical power to detect a treatment difference between any active group 
and placebo /no treatment  using a 2 -sided t-test at alpha .   Assum ing a % dropout rate, 
enrollment will target  participant s per treatment arm.  
Sample size was estimated using a t-test for 2 means  in NQuery Advisor V9.1 
(www.statsols.com).  [4, 5] . 
  
$SSURYHGRQ$SU*07CCICCI
CCI
CCICCICCI
CCICCI
CCICCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 88 of 112 
10. SUPPORTING DOCUMENTATION AND OPERA TIONAL 
CONSIDERATIONS    
10.1. APPENDIX  1: Regulatory, Ethical, and Study Oversight 
Considerations   
10.1.1.  Regulatory and Ethical Considerations   
This study will be conducted in accordance with the protocol and with the following:  
ï‚· Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) international ethical guidelines  
ï‚· Applicable ICH Good Clinic al Practice (GCP) guidelines  
ï‚· Applicable laws and regulations  
The protocol, protocol amendments, ICF, Investigator â€™s brochure, and other relevant documents 
(e.g., advertisements) must be submitted to an IRB/EC by the Investigator  and reviewed and 
approved b y the IRB/IEC before the study is initiated.  
Any amendments to the protocol will require IRB/EC approval before implementation of 
changes made to the study design, except for changes necessary to eliminate an immediate 
hazard to study participants.  
Protoco ls and any substantial amendments to the protocol will require health authority approval 
prior to initiation except for changes necessary to eliminate an immediate hazard to study 
participants.  
The Investigator  will be responsible for the following, as app licable:  
ï‚· Providing written summaries of the status of the study to the IRB/EC annually or 
more frequently in accordance with the requirements, policies, and procedures 
established by the IRB/EC . 
ï‚· Notifying the IRB/EC of SAEs or other significant safety find ings as required by 
IRB/EC procedures . 
ï‚· Providing oversight of the conduct of the study at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/EC, and all other applicable local 
regulations . 
10.1.2.  Financial Disclosure   
Investigator s and sub -Investigator s will provide the Sponsor  with sufficient, accurate financial 
information as requested to allow the Sponsor  to submit complete and accurate financial 
certification or  disclosure statements to the appropriate regulatory authorities. Investigator s are 
responsible for providing information on financial interests during  the study and for 1 year after 
completion of the study.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 89 of 112 
10.1.3.  Informed Consent Process   
The Investigator  or the Investigator â€™s representative will explain the nature of the study, 
including the risks and benefits, to the potential participant and answer all questio ns regarding 
the study.  
Potential participants must be informed that their participation is voluntary. They will be 
required to sign a statement of informed consent that meets the requirements of 21 CFR 50, local 
regulations, ICH guidelines, privacy,  and d ata protection requirements, where applicable, and the 
IRB/IEC or study center.  
The medical record must include a statement that written informed consent was obtained before 
the participant was enrolled in the study and the date the written consent was obt ained. The 
authorized person obtaining the informed consent must also sign the ICF.  
Participants must be reconsented to the most current version of the ICF(s) during their  
participation in the study.  
A copy of the ICF(s) must be provided to the participant . Participants who are rescreened are 
required to sign a new ICF.  
10.1.4.  Recruitment Strategy   
Recruitment into the study will be via the clinical Investigator  sitesâ€™  patient database, new 
referrals. Advertisements for the study may also be used, following EC/IRB approval.  
10.1.5.  Data Protection   
Participants will be assigned a unique identifier by t he Sponsor . Any participant records or 
datasets that are transferred to the Sponsor  will contain the identifier only; participant names or 
any information which would make the participant identifiable will not be transferred.  
The participant must be inform ed that their personal study -related data will be used by the 
Sponsor  in accordance with local data protection law. The level of disclosure must also be 
explained to the participant who will be required to give consent for their data to be used as 
describe d in the informed consent . 
The participant must be informed that their medical records may be examined by Clinical 
Quality Assurance auditors or other authorized personnel appointed by the Sponsor , and by 
inspectors from regulatory authorities.  
The contrac t between Sponsor /designee  and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and respective 
communication and cooperation of the parties.  
Information technology systems used to c ollect, process, and store study -related data are secured 
by technical and organizational security measures designed to protect such data against 
accidental or unlawful loss, alteration, or unauthorized disclosure or access.  
10.1.5.1.  Future Use of Stored Specimens and Data   
Any residual samples remaining after the protocol -defined analysis has been performed may be 
used for additional exploratory analysis  of similar kind . For example, samples analyzed for 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 90 of 112 
enzyme or hormone levels may indicate a need for further isozyme  or related hormone analys es 
to better understand the results. These results may be included in the clinical study report.  
Future use may also include , but is  not limited to , using residual samples for analytical purposes 
(e.g., to cross check between different sites and/or for stability assessment). Given the 
exploratory nature of the work, the analytical method used for those assessments may not be 
validated.  As such, the results from this exploratory analysis will not be included in the clinical 
study report.  
The Sponsor  may store samples for up to 15 years after the end of the study to achieve study 
7*2-+<1>-;,,1<176)44A?1<08):<1+18)6<;J+76;-6<;)584 es may be used for further research by 
the Sponsor or others such as universities or other companies to contribute to the development of 
related or new treatments or research methods.  
During the conduct of the study, an individual participant can choose to  withdraw consent to 
have biological specimens stored for futur e research. However, withdrawal of consent regarding  
biosample storage may not be possible after the study is completed.  
10.1.6.  Data Safety Committee   
Participant safety will be continuously monitored by th e site Investigator  and medical monitor , 
which includes safety signal detection at any time during the study.  
In addition, an early aggregated safety data review will be performed  by the DMC , the goal of 
which is to ensure no emerging safety trends . An initial safety review for this study is planned 
for the first  % of participants who are dosed and have provided safety data for  at least  days 
after administration of the first dose.  Enrollment will not be  paused during the review . 
Thereafter, the DMC will meet periodically , with ad hoc meeting s as necessary.  
The committee will consist of at least 2 i ndependent clinicians, knowledgeable in bariatric 
treatment, and 1 biostatistician. Prior to initiati ng enrollment, a DMC charter will be drafted and 
approved by the committee members. The primary role of the DMC i s to advise on study 
conduct that will ensure participant safety. Th is may include recommendations to discontinue a 
specific  treatment arm that appears to be showing characteristics of intolerance , or the study as a 
whole .  Unblinded data may be provided t o the DMC in accordance with the DMC charter . 
Although the DMC may make recommendations to the Sponsor about changes in the conduct  of 
the study, final decisions will be made by the Sponsor . In the case of early termination,  
consultation  with Health Authorities may  be required.  
Members of the DMC will not share any unblinded or semi -blinded information with anyone  
outside  of the DMC.  Particularly,  the Sponsor  blinded team members will remain  fully  blinded  
to any results  throughout the study unless the  DMC recommends changes in the conduct of the 
study (for  example,  early  termination  due to negative  safety  findings).  
An independent statistical reporting team not involved in the conduct of the studies will  prepare  
the information  for the DMC  according  to the specifications  from  the DMC  statistician.  The 
main tasks may  include:  
 Generation of blinded and/or unblinded outputs for the DMC, including tables, 
figures, and listings, as   required.
$SSURYHGRQ$SU*07CCI CCI
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 91 of 112 
ï‚· Preparation  of any other  reports  requested  by the DMC  during  the closed  session.ï€ 
ï‚· Review  of the data reports  before  sending  to the DMC.ï€ 
10.1.7.  Site Monitoring   
Before an investigational site can enroll participants into the study, the Sponsor  or designee will 
visit the investigational study site to:  
ï‚· Determine the adequacy of the facilities . 
ï‚· Discuss with the Investigator (s) and other personnel their responsibilities regarding  
protocol adherence  and applicable regulations . This will be documented in a Clinical 
Study Agreement between the Sponsor /designee and the Investigator . 
ï‚· Sites which have been qualified for a previous Sponsor  study within the past 2 years 
or sites participating in low -risk st udies, do not need an onsite visit and may be 
qualified remotely.  
During the study, the Sponsor or designee will have regular contacts with the investigational site, 
for the following:  
ï‚· Provide information and support to the Investigator (s). 
ï‚· Confirm that fa cilities remain acceptable . 
ï‚· Confirm that the investigational team is adhering to the protocol and that data are 
being accurately recorded in the case report forms . 
ï‚· Perform source data verification. This includes a comparison of the data in the case 
report forms with the participantâ€™s medical records at the hospital or practice, and 
other records relevant to the study. This will require direct access to all original 
records for each participant (e.g. , clinic charts).  
ï‚· Record and report any protocol deviations  not previously sent to the 
Sponsor/designee.  
ï‚· Confirm AEs and SAEs have been properly documented on  eCRF s and confirm any 
SAEs have been forwarded to the Sponsor/ designee  and those SAEs that met criteria 
for reporting have been forwarded to the IRB.  
The mo nitor will be available between visits if the Investigator (s) or other staff needs 
information or advice.  
10.1.8.  Clinical Monitoring   
Clinical site monitoring is conducted to ensure that  the rights and well -being of trial participants 
are protected, that the reported trial data are accurate, complete, and verifiable, and that the 
conduct of the trial is in compliance with the currently approved protocol/amendment(s), with 
International Co nference on Harmoni zation  Good Clinical Practice (ICH GCP), and with 
applicable regulatory requirement(s).  
Monitoring for this study will be performed by the CRO.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 92 of 112 
Details of clinical site monitoring are documented in the Clinical Monitoring Plan (CMP). The 
CMP describes in detail who will conduct the monitoring, at what frequency monitoring will be 
done, at what level of detail monitoring will be performed, and the distribution of monitoring 
reports.  
Independent audits may be conducted by Sponsor/designee  to ensure monitoring practices are 
performed consistently across all participating sites and that monitors are following the CMP . 
10.1.9.  Audits and Inspections   
Authorized representatives of the Sponsor, a regulatory authority, an Independent Ethics 
Committee or an Institutional Review Board may visit the site to perform audits or inspections, 
including source data verification.  
The purpose of a sponsor audit or inspection is to systematically and independently examine all 
study -related activities and documents to determine whether these activities were conducted, and 
data were reco rded, analyzed, and accurately reported according to the protocol, Good Clinical 
Practice guidelines of the International Conference on Harmonization, and any applicable 
regulatory requirements. The Investigator should contact the Sponsor immediately if co ntacted 
by a regulatory agency about an inspection.  
10.1.10.  Data Quality Assurance   
ï‚· All participant data relating to the study will be recorded on printed or electronic  
eCRF s unless trans mitted to the Sponsor  or designee electronically ( e.g., laboratory 
data). The Investigator  is responsible for verifying that data entries are accurate and 
correct by physically or electronically signing the  eCRF . 
ï‚· Guidance on completion of  eCRF s will be pro vided.  
ï‚· The Investigator  must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source documents.  
ï‚· Monitoring details describing strategy, including definition of study critical data 
items  and processes ( e.g., risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk -based monitoring), 
methods, responsibilities, and requirements, including handling of noncompliance 
issues and moni toring techniques (central, remote, or on -site monitoring) are provided 
in the monitoring plan . 
ï‚· The Sponsor  or designee is responsible for the data management of this study, 
including quality checking of the data.  
ï‚· The Sponsor  assumes accountability for actions delegated to other individuals ( e.g., 
contract research organizations).  
ï‚· Records and documents, includi ng signed ICFs, pertaining to the conduct of this 
study must be retained by the Investigator  for 20 years after study completion unless 
local regulations or institutional policies require a longer retention period. No records 
may be destroyed during the re tention period without the written approval of the 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 93 of 112 
Sponsor . No records may be transferred to another location or party without written 
notification to the Sponsor . 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 94 of 112 
10.1.11.  Data Handling and Recordkeeping   
Source Document s 
Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data collected. Source documents are filed at the Investigator â€™s site.  
Data reported on the  eCRF  or entered in  the eCRF that are transcribed from source documents 
must be consistent with the source documents or the discrepancies must be explained. The 
Investigator  may need to request previous medical records or transfer records, depending on the 
study. Also, curre nt medical records must be available.  
Definition of what constitutes source data,  and its origin can be found in monitoring guidelines . 
The Investigator  must maintain accurate documentation (source data) that supports the 
information entered in to the eCRF . 
The Sponsor  or designee will perform monitoring to confirm that data entered into the  eCRF  by 
authorized site personnel are accurate, complete, and verifiable from source documents; that the 
safety and rights of participants are being protected; and that the study is being conducted in 
accordance with the currently approved protocol and any other study agreements, ICH GCP, and 
all applicable regulatory requirements.  
The Investigator /study personnel will allow the Sponsor  (or designee) and appropriate regul atory 
authorities access to these records . 
Data Collection and Electronic Case Report Form (eCRF) Completion  
The Investigator , or designee, will enter data from the clinicâ€™s medical records and study source 
worksheets into an online electronic data capture  (EDC) system. All study personnel will be 
trained and receive a password protected login. Sponsor designated monitors will perform 
clinical monitoring, including verification of eCRFs and the source documentation.  
Data entry should occur in a timely manne r for accuracy, but especially for complying with 
regulations if an unanticipated or serious adverse event occurs (within 24 hours). If delays in 
entry occur frequently, a formal corrective plan will be established.  
Inspection of Records  
Spon sor/designee  will be allowed to conduct site visits to the investigation facilities for the 
purpose of monitoring any aspect of the study. The Investigator  agrees to allow the monitor to 
inspect participant  charts and study source documents, and other records relative to study 
conduct.  
Retention of Records  
The Principal Investigator  must maintain all documentation relating to the study for a period of 
up to 20 years after the end of the study. If it becomes necessary for the Sponsor or the 
Regulatory Authority to review any documentation relating to the study, the Investigator  must 
permit access to such records.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 95 of 112 
10.1.12.   Study and Site Start and Closure   
Study Start  
The study start date is  defined as the date when the first participant signs the informed consent . 
Study/Site Termination  
The Sponsor  or designee reserves the right to close the study site or terminate the study at any 
time for any reason at the sole discretion of the Sponsor . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been co llected and a study -site closure visit has been performed.  
The Investigator  may initiate study -site closure at any time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.  
Reasons for the early closure of a study site by the Sponsor  or Investigator  may include but are 
not limited to:  
For study termination:  
ï‚· Discontinuation of further study intervention development . 
For site termination:  
ï‚· Failure of the Investigator  to comply w ith the protocol, the requirements of the 
IRB/IEC or local health authorities, the Sponsor â€™s procedures, or GCP guidelines . 
ï‚· Inadequate or no recruitment (evaluated after a reasonable amount of time) of 
participants by the Investigator . 
ï‚· Total number of part icipants included earlier than expected . 
If the study is prematurely terminated or suspended, the Sponsor  shall promptly inform the 
Investigator s, the IECs/IRBs, the regulatory authorities, and any CRO (s) used in the study of the 
reason for termination or suspension, as specified by the applicable regulatory requirements. The 
Investigator  shall promptly inform the participant and should ensure  appropriate participant 
therapy and/or follow -up. 
10.1.13.  Publicatio n Policy   
The results of this study are expected to be published or presented at scientific meetings  and in 
clinical study registries . 
The Sponsor  will comply with the requirement s for publication of study results. In accordance 
with standard editorial and ethical practice, the Sponsor  will generally support publication of 
multicenter studies only in their entirety and not as individual site data. In this case, a 
coordinating Inves tigator  will be designated by mutual agreement.  
Authorship will be determined by mutual agreement and in line with the International  Committee 
of Medical Journal Editors authorship requirements.  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 96 of 112 
10.2. APPENDIX 2: Clinical Laboratory Tests   
The tests detailed in Table  5 will be performe d by the safety lab (local or central, depending on 
region) . 
Protocol -specific requirements for inclusion or exclusion of participants are detailed in Section  5 
of the protocol.  
Additional tests may be performed at any time during the study as determined necessary by the 
Investigator  or required by local regulations . 
Table  5: Safety Laboratory Tests   
Laboratory Tests  Parameters  
Hematology  ï‚· Hemoglobin  
ï‚· Hematocrit  
ï‚· Red blood cell (RBC) count  
ï‚· RBC indices  
ï€­ Mean corpuscular volume (MCV)  
ï€­ Mean corpuscular hemoglobin (MCH)  
ï€­ Mean corpuscular hemoglobin concentration (MCHC)  
ï€­ Reticulocytes (% and absolute)  
ï‚· White blood cell (WBC) count with differential (% and absolute)  
ï‚· Neutrophils  
ï€­ Lymphocytes  
ï€­ Monocytes  
ï€­ Eosinophils  
ï€­ Basophils  
ï‚· Erythrocyte sedimentation rate  
ï‚· Platelet count  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 97 of 112 
Laboratory Tests  Parameters  
Clinical chemistrya ï‚· Sodium  
ï‚· Potassium  
ï‚· Chloride  
ï‚· Bicarbonate (CO2)  
ï‚· Phosphate  
ï‚· Magnesium  
ï‚· Calcium  
ï‚· Albumin  
ï‚· Total protein  
ï‚· Uric acid  
ï‚· Urea/Blood urea nitrogen (BUN)  
ï‚· Creatinine  
ï‚· Glucose  
ï‚· Creatine kinase (CK)  
ï‚· Lipase  
ï‚· Amylase  
ï‚· Liver function tests  
ï€­ AST / SGOT  
ï€­ ALT/ SGPT  
ï€­ LDH  
ï€­ GGT  
ï€­ Alkaline phosphatase  
ï‚· Total  and direct bilirubin  
Urinalysis and urine 
chemistry  ï‚· pH, specific gravity, glucose, protein, bilirubin, nitrite, and leukocytes, 
blood, ketones by dipstick  
ï‚· Microscopic examination (if blood or protein is abnormal)  
ï‚· Microalbumin, urine creatinine, albumin creatine ratio  (calculated)  
Pregnancy testing  ï‚· Serum (for all women at screening and to confirm a positive urine test)  
ï‚· Rapid urine human chorionic gonadotropin (hCG) pregnancy test (for 
all other visits)  
Coagulation 
parameters  ï‚· aPTT, PT/INR  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 98 of 112 
Laboratory Tests  Parameters  
Screening only tests  ï‚· Total cholesterol  
ï‚· Triglycerides  
ï‚· HDL cholesterol  
ï‚· LDL cholesterol  
ï‚· HbA1C  
ï‚· Follicle -stimulating hormone (FSH) for post -menopausal women  
ï‚· Urine drug screen (to include at minimum: amphetamines, 
barbiturates, cocaine, opiates, cannabinoids and benzodiazepines)  
ï‚· Thyroid -stimulating hormone (TSH), conducted unless a n ormal value 
is documented within 6 months prior to screening  
ï‚· HIV antibody, HBsAg, HCVAb  
a Details of liver , pancreas , and CK  chemistry stopping criteria and required actions and follow -up are given in 
Section s 10.6, 10.7, and 10.8 (Appendi ces 6, 7, and 8 ), respectively . 
Investigator s must document their review of each laboratory safety report.  
The tests detailed in  Table  6 will be performed by the central lab . A list of potential biomarkers 
to be analyzed by the central lab  may include, but is not limited to, those in Table  6.  These 
results may not be reported to the Investigator until the end of the study.  
Table  6: Other Laboratory Tests (Central Lab)  
Laboratory Tests  Parameters  
Adipokines  ï‚· Leptin  
ï‚· Adiponectin  
ï‚· Adips in 
Fasting lipid  profile  ï‚· Total cholesterol  
ï‚· HDL  cholesterol  
ï‚· LDL cholesterol  
ï‚· Triglycerides  
Inflammation 
biomarkers  ï‚· IL-6 
ï‚· IL-18 
ï‚· hsCRP  
ï‚· NGAL  
Endocrine biomarkers  ï‚· FSH 
ï‚· Estradiol  
ï‚· Free testosterone  
ï‚· Insulin  
ï‚· HbA1c  
ï‚· Serum CTX  
ï‚· BSAP  
ï‚· P1NP  
TGF -Î² superfamily 
biomarkers  ï‚· Activin s (TBD)  
ï‚· GDF s (TBD)  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 99 of 112 
Immunogenicity  ï‚· Anti-drug antibodies (ADA) to bimagrumab  
Safety biomarkers  ï‚· ALP isoenzymes  
ï‚· Amylase  isoenzymes  
ï‚· Lipase isoenzymes  
ï‚· 5â€™NT  
ï‚· miR-122 
ï‚· CCK18  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 100 of 112 
10.3. APPENDIX 3: AEs and SAEs: Definitions and Procedures for 
Recording, Evaluating, Follow -up, and Reporting   
10.3.1.  Definition of AE   
AE Definition  
ï‚· An AE is any untoward medical occurrence in a clinical study participant, temporally 
associated with the use of study intervention, whether or not considered related to the 
study intervention.  
ï‚· NOTE: An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study intervention.  
Definition of Unsolicited and Solicited AE  
ï‚· An unsolicited AE is an AE that was no t solicited using a participant diary and that is 
communicated by a participant who has signed the informed consent. Unsolicited 
AEs include serious and nonserious AEs.  
ï‚· Potential unsolicited AEs may be medically attended ( i.e., symptoms or illnesses 
requir ing a hospitalization, emergency room visit, or visit to/by a healthcare 
provider). The participant will be instructed to contact the site as soon as possible to 
report medically attended event(s), as well as any events that, though not medically 
attended,  are of participant concern. Detailed information about reported unsolicited 
AEs will be collected by qualified site personnel and documented in the participantâ€™s 
records.  
ï‚· Unsolicited AEs that are not medically attended nor perceived as a concern by the 
participant will be collected during an interview with the participant and by review of 
available medical records at the next visit.  
ï‚· Solicited AEs are predefined local (at the injection site ) and systemic events for 
which the participant is specifically ques tioned, and which are noted by the 
participant in their diary.  
Events Meeting the AE Definition  
ï‚· Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or 
other safety assessments ( e.g., ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinically significant in the 
medical and scientific judgment of the Investigator  (i.e., not related to progression of 
underlying disease, or more se vere than expected for the participantâ€™s condition)  
ï‚· Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition  
ï‚· New condition detected or diagnosed after study intervention ad ministration even 
though it may have been present before the start of the study  
ï‚· Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 101 of 112 
ï‚· Signs, symptoms, or the clinical sequelae of a suspected overdose of either study 
intervention or  a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -harming 
intent. Such overdoses should be reported regardless of sequelae.  
Events not Meeting the AE Definiti on 
ï‚· Any abnormal laboratory findings or other abnormal safety assessments that are 
associated with the underlying disease, unless judged by the Investigator  to be more 
severe than expected for the participantâ€™s condition  
ï‚· The disease/disorder being studied o r expected progression, signs, or symptoms of the 
disease/disorder being studied, unless more severe than expected for the participantâ€™s 
condition  
ï‚· Medical or surgical procedure ( e.g., endoscopy, appendectomy): the condition that 
leads to the procedure is t he AE  
ï‚· Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospital)  
ï‚· Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.  
10.3.2.  Definition of SAE   
An SAE is defined as any untoward medical occurrence that, at any dose, meets one or more of 
the criteria listed:  
a. Results in death  
b. Is life threatening  
The term life threatening  in the definition of serious  refers to an event in which the 
participant was at risk of death at the time of the event. It does not refer to an event, 
which hypothetically might have caused death, if it were more sever e. 
c. Requires inpatient hospitalization or prolongation of existing hospitalization  
ï€­ In general, hospitalization signifies that the participant has been admitted (usually 
involving at least an overnight stay) at the hospital or emergency ward for 
observation and/or treatment that would not have been appropriate in the 
physicianâ€™s office or outpatient setting. Complications that occur during 
hospitalization are AEs. If a complication prolongs hospitalization or fulfills any 
other serious criteria, the event is serious. When in doubt as to whether 
hospitalization occurred or was necessary, the AE should be considered serious.  
ï€­ Hospitalization for elective treatment of a pre -existing condition that did not 
worsen from baseline is not considered an AE.  
d. Results in pe rsistent or significant disability/incapacity  
ï€­ The term disability means a substantial disruption of a personâ€™s ability to conduct 
normal life functions.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 102 of 112 
ï€­ This definition is not intended to include experiences of relatively minor medical 
significance such as  uncomplicated headache, nausea, vomiting, diarrhea, 
influenza, and accidental trauma ( e.g., sprained ankle) that may interfere with or 
prevent everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect  
f. Is a suspected transmission of any infectious agent via an authorized medicinal 
product  
g. Other situations:  
ï€­ Medical or scientific judgment should be exercised by the Investigator  in deciding 
whether SAE reporting is appropriate in other situations such as im portant 
medical events that that may not be immediately life -threatening or result in death 
or hospitalization but may jeopardize the participant or may require medical or 
surgical intervention to prevent one of the other outcomes listed in the above 
defin ition. These events should usually be considered serious.  
ï€­ Examples of such events include invasive or malignant cancers, intensive 
treatment in an emergency room or at home for allergic bronchospasm, blood 
dyscrasias, convulsions not resulting in hospitali zation, or development of 
intervention dependency or intervention abuse.  All malignancies must be reported 
as SAEs.  
10.3.3.  Recording and Follow -Up of AE and/or SAE   
AE and SAE Recording  
ï‚· When an AE/SAE occurs, it is the responsibility of the Investigator  to review all 
documentation ( e.g., hospital progress notes, laboratory reports, and diagnostics 
reports) related to the event.  
ï‚· The Investigator  will then record all relevant AE/SAE informa tion. 
ï‚· It is not acceptable for the Investigator  to send photocopies of the participantâ€™s 
medical records in lieu of completion of the required form.  
ï‚· There may be instances when copies of medical records for certain cases are 
requested by the Sponsor/design ee. In this case, all participant identifiers, except for  
the participant number, will be redacted on the copies of the medical records before 
submission.  
ï‚· The Investigator  will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual signs/symptoms) will be documented as the AE/SAE.  
Assessment of Intensity  
The Investigator  will make an assessment of intensity based on the CTCAE grades [36] for each 
AE and SAE reported during the study . 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 103 of 112 
Assessment of Causality  
ï‚· The Investigator  is obligated to assess the relationship between study intervention and 
each occurrence of each AE/SAE. The Investigator  will use clinical judgment to 
determine the relationship.  
ï‚· A reasonable possibility  of a relationship conveys that there are facts, evid ence, 
and/or arguments to suggest a causal relationship, rather than a relationship cannot be 
ruled out.  
ï‚· Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to st udy intervention 
administration, will be considered and investigated.  
ï‚· For causality assessment, the Investigator  will also consult the IB and/or product 
information, for marketed products.  
ï‚· The Investigator  must review and provide an assessment of causality  for each 
AE/SAE and document this in the medical notes. There may be situations in which an 
SAE has occurred,  and the Investigator  has minimal information to include in the 
initial report. However, it is very important that the Investigator  always assess  
causality for every event before the initial transmission of the SAE data.  
ï‚· The Investigator  may change their opinion of causality considering  follow -up 
information and send an SAE follow -up report with the updated causality assessment.  
ï‚· The causality assess ment is one of the criteria used when determining regulatory 
reporting requirements.  
Follow -up of AEs and SAEs  
ï‚· The Investigator  is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by the 
Sponsor to elucidate the nature and/or causality of the AE or SAE as fully as possible. 
This may include additional laboratory tests or investigations, histopathological 
examinations, or consultation with other health care professionals.  
ï‚· If a participant dies during participation in the study or during a recognized follow -up 
period, the Investigator  will provide Sponsor/designee with a copy of any postmortem 
findings including histopathology.  
ï‚· New or updated information will be recorded in t he originally submitted documents.  
ï‚· The Investigator  will submit any updated SAE data to Sponsor/designee  within 24 
hours of receipt of the information.  
10.3.4.  Reporting of SAEs   
SAE Reporting to Sponsor/designee via an Electronic Data Collection Tool  
ï‚· The primary mechanism for reporting an SAE to Sponsor/designee  will be the 
electronic data collection to ol. 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 104 of 112 
ï‚· If the electronic system is unavailable, then the site will use the paper SAE data 
collection tool (see next section) to report the event within 24 hours.  
ï‚· The site will enter the SAE data into the electronic system as soon as it becomes 
available.  
ï‚· After the study is completed at a given site, the electronic data collection tool will be 
taken offline to prevent the entry of new data or changes to existing data.  
ï‚· If a site receives a report of a new SAE from a study participant or receives updated 
data on a previously reported SAE after the electronic data collection tool has been 
taken offline, then the site can report this information on a paper SAE form (see next 
section) or to the Sponsor/designee  by telephone.  
ï‚· Contacts for SAE reporting can be found in  the SOM . 
SAE Reporting to Sponsor/designee via Paper Data Collection Tool  
ï‚· Facsimile transmission of the SAE paper data collection tool is the preferred method 
to transmit this information to the  Sponsor/designee . 
ï‚· In rare circumstances and in the absence of facsimile equipment, notification by 
telephone either verbally (less preferred) or by cell phone photo (more preferred)  is 
acceptable with a copy of the SAE data collection tool sent by overnight mail or 
courier service.  
ï‚· Initial notification via telephone does not replace the need for the Investigator  to 
complete and sign the SAE data collection tool within the designated reporting 
timeframes.  
ï‚· Contacts for SAE reporting can be found in SOM . 
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 105 of 112 
10.4. APPENDIX  4: Contracep tive Guidance   
In order to prevent pregnancy, female participants must satisfy one of the following  criteria : 
ï‚· Be post-menopausal, defined as having had â‰¥12 months of natural (spon taneous) 
amenorrhea with an appropriate clinical/hormonal profile  (e.g., FSH > 40 IU/L) 
ï‚· Have undergone surgical sterilization (surgical bilateral oophorectomy with or 
without hysterectomy), total hysterectomy or tubal ligation at least six weeks before 
taking study treatment. In case of oophorectomy alone, only when the reproductive 
status of the woman has been confirmed by follow up hormone level assessment.  
ï‚· All other female participants must meet both of the following criteria:  
ï€­ Two negative preg nancy tests (1 at screening and 1 at randomization)  
ï€­ Use of an intrauterine device, from at least 3 months prior to the baseline visit  
  through at least 4 months after the last dose of bimagrumab/placebo i.v.  
ï€­ Use of a n additional contraceptive ( barrier ) method from screening through at 
least 4 months after the last dose of bimagrumab/placebo i.v.  to further reduce  the 
risk of unintended pregnancy.  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 106 of 112 
10.5. APPENDIX 5: Genetics   
10.5.1.  Optional Consent   
The study includes an optional DNA component which requires a separate informed consent 
signature if the participant  agrees to participate.  
Genetic variation may impact a participantâ€™s response to study intervention, susceptibility to, and 
severity and pro gression of disease. Variable response to study intervention may be due to 
genetic determinants that impact drug absorption, distribution, metabolism, and excretion; 
mechanism of action of the drug; disease etiology; and/or molecular subtype of the disease  being 
treated. Therefore, where local regulations and IRB/IEC allow, a blood sample will be collected 
for DNA analysis from consenting participants.  
10.5.2.  Use/Analysis of DNA  
As techn ology changes over time, the most appropriate technology will be used at the time the 
exploratory DNA research is performed. This may include the study of the entire genome.  
In addition, recent advances in genotyping technologies have made genome -wide appr oaches 
possible. Genome -wide approaches may also be undertaken within the restricted scope described 
below.  
Exploratory DNA research studies are planned as a part of this study with the objectives of 
identifying genetic factors which may  
ï‚· be related to obes ity 
ï‚· predict response to treatment with bimagrumab  
ï‚· predict relative susceptibility to drug -drug interactions  
ï‚· predict genetic predisposition to side effects  
Additional analyses may be conducted if it is hypothesized that this may help further understand 
the clinical data.  
The samples may be analyzed as part of a multi -study assessment of genetic factors involved in 
the response to bimagrumab  or study interventions of this class to understand the study disease 
or related conditions.  
The results of genetic analyses may be reported in the clinical study report (CSR) or in a separate 
study summary.  
10.5.3.  Storage of Genetic Samples   
The Sponsor  will store the DNA samples in a secu re storage space with adequate measures to 
protect confidentiality.  
The samples will be retained while research on study interventions of this class or 
obesity/overweight  continues but no longer than  10 years or other period as per local 
requirements.  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 107 of 112 
10.6. APPENDIX 6: Liver Safety: Suggested Actions and Follow -up 
Assessments   
Table  7: Liver Event  and Laboratory Trigger Definitions  
Definition  Thresholds  
Potential Hyâ€™s law case  ï‚· ALT or AST >3x ULN and total bilirubin >2x ULN 
without notable increase in ALP to >2x ULN)  
If ALT, AST, and total bilirubin normal 
at baseline  ï‚· ALT or AST >8 x ULN  
ï‚· ALT  or AST >5x ULN and â‰¤8x ULN  
ï‚· ALT  or AST >3x ULN and â‰¤5x ULN  
ï‚· ALP >2 x ULN (in the absence of known bone 
pathology)  
ï‚· Total bilirubin >3 x ULN (in the absence of known 
Gilbert syndrome)  
ALT or AST elevation with 
coagulopathy  ï‚· ALT or AST >3x ULN and PT/INR >1.5 (in the 
absence of anti-coagulation)  
ALT or AST elevation accompanied by 
symptoms  ï‚· ALT or AST >3x ULN accompanied by (general) 
malaise, fatigue, abdominal pain, nausea, or vomiting, 
or rash, or eosinophilia  
Isolated ALP elevation  ï‚· ALP >2x ULN ( unless attributable to bone -specific 
ALP)   
Others  ï‚· Any clinical event of jaundice  
ï‚· Any AE potentially indicative of liver toxicity  
Table  8: Actions Required  for Liver Events  and Laboratory Triggers   
Criteria  Actions required  
Potential Hyâ€™s law case  
ALT or AST elevation with coagulopathy  
ALT or AST elevation accompanied by 
symptoms  
Isolated ALT or AST elevation >8x ULN  
Jaundice ï‚· If possible Hyâ€™s law, report to sponsor within 24 h  
ï‚· Discontinue study treatment  
ï‚· Hospitalize if clinically appropriate  
ï‚· Establish causality  
Isolated ALT or AST elevation  >5x ULN 
and â‰¤8 x ULN  ï‚· If confirmed, consider interruption or discontinuation 
of study drug s 
ï‚· If elevation persists for more than 2 weeks, 
discontinue study drug s 
ï‚· Follow -up for symptoms  
ï‚· Establish causality  
Isolated ALT or AST elevation  >3x ULN 
and â‰¤5x ULN  ï‚· Monitor liver chemistry at least 2 times weekly  
ï‚· If confirmed, consider interruption or discontinuation 
of study drug s 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 108 of 112 
Criteria  Actions required  
ï‚· Follow -up for symptoms  
Isolated ALP elevation  ï‚· Repeat liver chemistry test within 48 â€“72 hours  
ï‚· If elevation is confirmed, measure fractional ALP; if 
>50% of it is liver origin, establish hepatic causal ity 
Any AE potentially indicative of liver 
toxicity  ï‚· Consider study treatment interruption or 
discontinuation  
ï‚· Hospitalize if clinically appropriate  
Table  9: Follow Up Requirements  for Liver Laboratory Triggers  - Isolated 
Hyperbilirubinemia  
Criteria  Actions required  
Total biliru bin (isolated)   
>1.5â€“3x ULN  ï‚· Maintain treatment  
ï‚· Repeat LFTs within 48 -72 hours  
ï‚· Monitor LFTs weekly until resolution to â‰¤ Grade 1 or 
to baseline  
>3-10x ULN (in the absence of known 
Gilbert syndrome)  ï‚· Interrupt treatment  
ï‚· Repeat LFT within 48 -72 hours  
ï‚· Monitor LFTs weekly until resolution to â‰¤ Grade 1 or 
to baseline (ALT, AST, total bilirubin, Alb, PT/INR, 
ALP and GGT)  
ï‚· Test for hemolysis (e.g. , reticulocytes , haptoglobin, 
unconjugated [indirect] bilirubin)  
ï‚· Hospitalize if clinically appropriate  
ï‚· Establish causality  
>10x ULN  ï‚· Discontinue the study treatment immediately  
ï‚· Hospitalize the participant  
ï‚· Establish causality  
Any AE potentially indicative of a liver 
toxicity ï‚· Consider study treatment interruption or 
discontinuation  
ï‚· Hospitalization if clinically appropriate  
ï‚· Establish causality  
In all instances, record the AE and contributing factors (e.g. , concomitant medications, medical 
history, laboratory results ) in the appropriate  eCRF . 
Based on investigatorâ€™s discretion, investigation(s) for contributing factors for the liver event can 
include  serology tests, imaging, and pathology assessments, hepatologistâ€™s consultancy,  
obtaining more detailed history of symptoms and prior or concurren t diseases, history of 
concomitant drug use, exclusion of underlying liver disease.  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 109 of 112 
10.7. APPENDIX 7 : Lipase and Amylase Safety   
To ensure participant  safety and enhance reliability i n determining the potential for pancreatic  
events with bimagrumab, a standardized process for identification, monitoring and evaluation  of 
pancreatic  events  should be followed  (Table  10). 
Table  10: Safety Monitoring Guidance  for Amylase  and Lipase Elevations  
Event  Follow  up monitoring  
Lipase  and/or  amylase  
>2x and â‰¤3x ULN  ï‚· If asymptomatic,  re-check enzymes (amylase, lipase)  and additional follow  
up at discretion  of Investigator.  
ï‚· If clinical symptoms are present  (e.g., abdominal pain, nausea, diarrhea) 
and suggest ive of  pancreatic involvement, re -check enzymes  (amylase, 
lipase) and inflammatory markers ( e.g., C-reactive  protein) and consider 
pancreatic imaging ( e.g., contrast -enhanced  CT or MRI /MRCP ) to evaluate 
for presence of  pancreatitis.  
ï‚· If serum lipase is >2x ULN and >1.5x baseline  at or prior to Visit 4 , 
interrupt stud y treatments and consult with medical monitor . 
Lipase  and/or  amylase  
>3x and â‰¤5X ULN  ï‚· If at or prior to Visit 4, interrupt study treatments and consult with medical 
monitor . 
ï‚· Re-check enzymes  (amylase, lipase) and inflammatory markers (C -reactive 
protein) independent of presence of clinical symptoms , until enzyme  levels 
return to <2x ULN . 
ï‚· Assess participant for clinical symptoms  (e.g., abdominal pain, nausea, 
diarrhea) . 
ï‚· Conduct pancreatic imaging ( e.g., CECT or MRI /MRCP ) to evaluate for 
presence of pancreatitis . 
ï‚· If clinical symptoms and/or pancreatic imaging indicative of pancreatitis , 
discontinue  study treatments . 
>5x ULN or 
confirmed  diagnosis 
of pancreatitis ï‚· Discontinue study treatment s. 
ï‚· Hospitalize if clinically appropriate.  
ï‚· Establish causality . 
Medically  significant  pancreatic  events  which  are considered  as serious  adverse  events  (SAEs)  
should  follow  the standard  procedures  for SAE  reporting  as described  in Section  8.4. 
Every pancreatic event reported as an SAE should include a causality assessment  of the event , 
considering  alternative  causes (e.g.,  gallstones,  co-medication).  
An investigation of the pancreas needs to be followed up until resolution. A gastroenterology  
consult can be included at the Investigatorâ€™s discr etion. All follow -up information, and the  
procedures  performed,  should  be recorded  in the appropriate  eCRF s. 
An independent adjudication  committee may be formed to adjudicate suspected cases of acute 
pancreatitis and other major adverse events in a blinded  manner.   Any completed adjudications 
will be utilized in safety analyses.  
 
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 110 of 112 
10.8. APPENDIX 8: Creatine Kinase  Safety   
To ensure participant  safety and enhance reliability in determining the potential for 
rhabdomyolysis , a standardized process for identification, monitoring and evaluation of serum 
CK should be followed ( Table  11). 
Table  11: Safety Monitoring Guidance for Creatine Kinase Elevations  
Event  Follow up monitoring  
Creatine kinase (CK) 
>5x ULN  and â‰¤10x 
ULN  ï‚· Inquire about recent intensive muscular exertion or injury, infection, body 
temperature changes, medications such as statins  
ï‚· Assess participant  for clinical symptoms (e.g., myalgia, weakness, dark 
urine ). 
ï‚· Re-check  CK and check serum troponin  I/T, creatinine, sodium, potassium, 
calcium, phosphate, and urine myoglobin  
ï‚· If symptoms and/or lab tests indicative of rhabdomyolysis, discontinue 
study treatments.  
Creatine kinase (CK) 
>10x ULN  or 
rhabdomyolysis is 
confirmed  ï‚· In addition to above actions:  
o Interrup t study drugs and consult with the medical monitor  
o Discontinue study  if rhabdomyolysis is confirmed  
o Hospitalize if clinically appropriate.  
o Establish causality  
  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 111 of 112 
11. REFERENCES   
1. NICE. Obesity: identification and classification of overweight and obesity (update) . 
2022; Available from: https: //www .nice.org.uk/guidance/indevelopment/gid -ng10284.  
2. Jastreboff, A.M., et al., Tirzepatide Once Weekly for the Treatment of Obesity.  N Engl J 
Med, 2022. 387(3): p. 205 -216. 
3. Wildman, R.P., Healthy obesity.  Curr Opin Clin Nutr Metab Care, 2009. 12(4): p. 438 -
43. 
4. Zhong, P., et al., Efficacy and safety of once -weekly semaglutide in adults with 
overweight or obesity: a meta -analysis.  Endocrine, 2022. 75(3): p. 718 -724. 
5. Heymsfield, S.B., et al., Effect of Bimagrumab vs Placebo on Body Fat Mass Among 
Adults With Type 2 Diabetes and Obesity: A Phase 2 Randomized Clinical Trial.  JAMA 
Netw Open, 2021. 4(1): p. e2033457.  
6. WHO, World Health Organization: Obesity and overweight.  2021.  
7. Ritchie, H.a.R., M. Obes ity. 2017; Available from: https: //ourworldindata.org/obesity.  
8. Kushner, R.F., Weight Loss Strategies for Treatment of Obesity: Lifestyle Management 
and Pharmacotherapy.  Prog Cardiovasc Dis, 2018. 61(2): p. 246 -252. 
9. Ahima, R.S., Adipose tissue as an endocrine organ.  Obesity (Silver Spring), 2006. 14 
Suppl 5 : p. 242S -249S.  
10. Janssen, I., P.T. Katzmarzyk, and R. Ross, Waist circumference and not body mass index 
explains obesity -related health risk.  Am J Clin Nutr, 2004. 79(3): p. 379 -84. 
11. Pischon, T., et al., General and abdominal adiposity and risk of death in Europe.  N Engl 
J Med, 2008. 359(20): p. 2105 -20. 
12. De Lorenzo, A., et al., Adiposity rather than BMI determines metabolic risk.  Int J 
Cardiol, 2013. 166(1): p. 111 -7. 
13. Romero -Corral, A.,  et al., Accuracy of Body Mass Index to Diagnose Obesity in the US 
Adult Population.  Int J Obes (Lond), 2008. 32(6): p. 959 -66. 
14. Shah, N.R. and E.R. Braverman, Measuring adiposity in patients: the utility of body mass 
index (BMI), percent body fat, and leptin.  PLoS One, 2012. 7(4): p. e33308.  
15. Heymsfield, S.B., et al., Weight loss composition is one -fourth fat -free mass: a critical 
review and critique of this widely cited rule.  Obesity Reviews, 2014. 15(4): p. 310 -321. 
16. Phillips, S.M. and M.B. Zeme l, Effect of protein, dairy components and energy balance 
in optimizing body composition.  Nestle Nutr Inst Workshop Ser, 2011. 69: p. 97 -108; 
discussion 108 -13. 
17. Ravussin, E., et al., Reduced rate of energy expenditure as a risk factor for body -weight 
gain.  N Engl J Med, 1988. 318(8): p. 467 -72. 
18. Tsai, A.G. and T.A. Wadden, Systematic review: an evaluation of major commercial 
weight loss programs in the United States.  Ann Intern Med, 2005. 142(1): p. 56 -66. 
19. Heymsfield, S.B., B. Bourgeois, and D.M. Thomas, Why is it Difficult to Lose and 
Maintain Large Amounts of Weight with Lifestyle and Pharmacologic Treatments?  
Obesity (Silver Spring), 2017. 25(12): p. 2017.  
20. Jo, E., et al., Resistance training during a 12-week protein supplemented VLCD treatment 
enhances weight -loss outcomes in obese patients.  Clin Nutr, 2019. 38(1): p. 372 -382. 
21. Chmelo, E.A., et al., Legacy effects of short -term intentional weight loss on total body 
and thigh composition in overweigh t and obese older adults.  Nutr Diabetes, 2016. 6(4): 
p. e203.  
Approved on 09 Apr 2024 GMT
Protocol No. VER201 -PH2-031 
Version No. 5.0 
 
Confidential & Proprietary  
Page 112 of 112 
22. Koncarevic, A., et al., A novel therapeutic approach to treating obesity through 
modulation of TGFbeta signaling.  Endocrinology, 2012. 153(7): p. 3133 -46. 
23. Lee, S.J., et al., Regulation o f muscle mass by follistatin and activins.  Mol Endocrinol, 
2010. 24(10): p. 1998 -2008.  
24. Lee, S.J., et al., Regulation of muscle growth by multiple ligands signaling through 
activin type II receptors.  Proc Natl Acad Sci U S A, 2005. 102(50): p. 18117 -22. 
25. Trendelenburg, A.U., et al., TAK-1/p38/nNFkappaB signaling inhibits myoblast 
differentiation by increasing levels of Activin A.  Skelet Muscle, 2012. 2(1): p. 3.  
26. Emdin, C.A., et al., DNA Sequence Variation in ACVR1C Encoding the Activin Receptor -
Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes.  
Diabetes, 2019. 68(1): p. 226 -234. 
27. Kelly, A., Trauma -Informed Mindfulness -Based Stress Reduction: A Promising New 
Model for Working with Survivors of Interpersonal Viole nce. Smith College Studies in 
Social Work, 2015. 85(2): p. 194 -219. 
28. Tomlinson, B., et al., Selective beta -adrenoceptor partial agonist effects of pindolol and 
xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy 
subjects.  Br J Clin Pharmacol, 1990. 30(5): p. 665 -72. 
29. Albanese, C.V., E. Diessel, and H.K. Genant, Clinical applications of body composition 
measurements using DXA.  J Clin Densitom, 2003. 6(2): p. 75 -85. 
30. Wilding, J.P.H., et al., Once -Weekly Semaglutide in A dults with Overweight or Obesity.  
New England Journal of Medicine, 2021. 384(11): p. 989 -1002.  
31. USDHHS, 2008 Physical Activity Guidelines for Americans.  2008.  
32. FDA, FDA Draft Guidance: Developing Products for Weight Management - Revision 1 . 
2007.  
33. Garvey, W.T., et al., Two-year effects of semaglutide in adults with overweight or 
obesity: the STEP 5 trial.  Nat Med, 2022. 28(10): p. 2083 -2091.  
34. Kolotkin, R.L., et al., Development of a clinical trials version of the Impact of Weight on 
Quality of Life -Lite questionnaire (IWQOL -Lite Clinical Trials Version): results from two 
qualitative studies.  Clin Obes, 2017. 7(5): p. 290 -299. 
35. Ware, J.E., Jr. and C.D. Sherbourne, The MOS 36 -item short -form health survey (SF -36). 
I. Conceptual framewor k and item selection.  Med Care, 1992. 30(6): p. 473 -83. 
36. USDHHS, Common Terminology Criteria for Adverse Events (CTCAE).  2017.  
 
Approved on 09 Apr 2024 GMT
6LJQDWXUH3DJHIRU99&/,1Y
6LJQDWXUH3DJHIRU99&/,1Y$SSURYDO
$SU*07
$SSURYDO
DQ
$SU*07
$SSURYHGRQ$SU*07PPD
PPD